SEARCH

Search Details

TERAKAWA Tomoaki
University Hospital /
Associate Professor

Researcher basic information

■ Research Areas
  • Life sciences / Urology

Research activity information

■ Paper
  • Kotaro Suzuki, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    Feb. 2025, Clinical Genitourinary Cancer
    Scientific journal

  • Takuto Hara, Jun Teishima, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Hideaki Miyake
    Jan. 2025, International Journal of Urology
    Scientific journal

  • Jun Teishima, Naoto Wakita, Yukari Bando, Yasuyoshi Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Kei Matsushita, Yuzo Nakano, Hiroaki Kitatsuji, Hideaki Miyake
    Jan. 2025, International Journal of Urology
    Scientific journal

  • Takuto Hara, Hideto Ueki, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Jun Teishima, Hideaki Miyake
    Elsevier BV, Jan. 2025, Urologic Oncology: Seminars and Original Investigations, 43(1) (1), 63.e19 - 63.e27
    Scientific journal

  • Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Akihisa Yao, Jun Teishima, Hideaki Miyake
    Dec. 2024, International Journal of Clinical Oncology
    Scientific journal

  • Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Munenori Uemura, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Jun Teishima, Yuzo Nakano, Raizo Yamaguchi, Hideaki Miyake
    Dec. 2024, Cancers
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takuto Hara, Jun Teishima, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Yuzo Nakano, Hideaki Miyake
    Elsevier BV, Dec. 2024, Clinical Genitourinary Cancer, 22(6) (6), 102236 - 102236
    Scientific journal

  • Takuto Hara, Kotaro Suzuki, Yasuyoshi Okamura, Hideto Ueki, Yukari Bando, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake
    Elsevier BV, Nov. 2024, Urologic Oncology: Seminars and Original Investigations
    Scientific journal

  • Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    Oct. 2024, International Journal of Urology
    Scientific journal

  • Kotaro Suzuki, Yusuke Shiraishi, Junya Furukawa, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    Oct. 2024, Clinical Genitourinary Cancer
    Scientific journal

  • Taisuke Tobe, Tomoaki Terakawa, Hideto Ueki, Takuto Hara, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    ABSTRACT Background This study aimed to investigate the perioperative outcomes of robot‐assisted laparoscopic pyeloplasty (RLP) using the recently launched hinotori surgical robot system. Methods This retrospective study compared the perioperative outcomes of 11 consecutive patients who underwent RLP with the hinotori surgical robot system from October 2022 to March 2024 (hinotori group) and 30 consecutive patients who underwent RLP with the da Vinci system from March 2019 to September 2022 (da Vinci group). Results The patient characteristics of the groups were similar. The median operative times in the hinotori and da Vinci groups were 236.0 and 231.5 min, respectively (p = 0.480). The success rates were 100.0% and 96.7%, respectively (p = 1.000). Clavien‐Dindo grade ≥ 3 complications occurred in one patient (9.1%) in the hinotori group and one patient (3.3%) in the da Vinci group (p = 0.470). Conclusions The perioperative outcomes in the hinotori group were not inferior to those in the da Vinci group.
    Wiley, Sep. 2024, The International Journal of Medical Robotics and Computer Assisted Surgery, 20(5) (5)
    Scientific journal

  • Hideto Ueki, Naoe Jimbo, Tomoaki Terakawa, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    BACKGROUND: The diagnosis of treatment-related neuroendocrine prostate cancer (t-NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of patients with t-NEPC to better understand their prognosis and diagnostic utility. METHODS: This retrospective study reviewed the records of patients diagnosed with t-NEPC at Kobe University Hospital between October 2018 and December 2022. Clinical data, including age, serum neuroendocrine marker levels, and treatment history, were collected. IHC was performed for conventional neuroendocrine markers (synaptophysin, chromogranin A, and CD56) and RB1 and p53 expression. Next-generation sequencing (NGS) was conducted using FoundationOne® CDx to identify mutations in RB1 and TP53. RESULTS: This study included 20 patients with t-NEPC. The median time from ADT initiation to development was 42.8 months. IHC revealed RB1 loss in 75% of cases and p53 abnormalities in 75% of cases. NGS identified RB1 mutations in 55% and TP53 mutations in 75% of cases. The concordance between NGS and IHC results was high, with 70% (14/20) agreement for RB1/RB1 and 80% (16/20) for p53/TP53. The immunostaining and genomic analysis of RB1/RB1 and p53/TP53 showed abnormal findings for the four negative cases for conventional neuroendocrine markers. CONCLUSIONS: This study indicated high concordance between IHC and NGS findings for RB1/RB1 and p53/TP53 in t-NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t-NEPC.
    Sep. 2024, The Prostate, English, International magazine
    Scientific journal

  • Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Yoji Hyodo, Jun Teishima, Yuzo Nakano, Ryosuke Kuroda, Hideaki Miyake
    Springer Science and Business Media LLC, Sep. 2024, Journal of Bone and Mineral Metabolism, 42(6) (6), 668 - 674
    Scientific journal

  • Kotaro Suzuki, Kazuki Murata, Naoto Wakita, Tomoaki Terakawa, Takaaki Nakanishi, Takuto Hara, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    Jul. 2024, International Cancer Conference Journal
    Scientific journal

  • NAOTO WAKITA, TAKUTO HARA, KOTARO SUZUKI, TOMOAKI TERAKAWA, JUN TEISHIMA, YUZO NAKANO, HIDEAKI MIYAKE
    Anticancer Research USA Inc., May 2024, Anticancer Research, 44(6) (6), 2627 - 2635
    Scientific journal

  • Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
    INTRODUCTION: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC). METHODS: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared. RESULTS: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups. CONCLUSIONS: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.
    May 2024, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 18(5) (5), E162-E166, English, International magazine
    Scientific journal

  • Taisuke Tobe, Tomoaki Terakawa, Yoshiko Ueno, Keitaro Sofue, Takuto Hara, Junya Furukawa, Jun Teishima, Yuzo Nakano, Kenichi Harada, Masato Fujisawa
    INTRODUCTION: Leiomyosarcoma of the inferior vena cava is associated with poor prognosis. Complete resection is the only curative treatment. We present a patient with this disease in whom cine magnetic resonance imaging was valuable in selecting the surgical strategy and mitigating invasiveness. CASE PRESENTATION: A 68-year-old woman presented with right-sided abdominal pain. Computed tomography revealed an 86 mm tumor in the right retroperitoneal space that extended into the inferior vena cava and reached superiorly to the right atrium. Percutaneous needle biopsy confirmed leiomyosarcoma. Cine magnetic resonance imaging demonstrated no adhesions between the tumor and the upper segment of inferior vena cava wall, nor with the right atrial wall, indicating resectability. Radical tumor resection was successfully performed without requiring thoracotomy. CONCLUSION: Cine magnetic resonance imaging appears to be useful in inferior vena cava leiomyosarcoma for evaluating adhesions between the tumor and vessel wall.
    Jan. 2024, IJU case reports, 7(1) (1), 30 - 33, English, International magazine
    Scientific journal

  • Takuto Hara, Junya Furukawa, Takahiro Tsutiya, Takayuki Kodama, Keiichiro Uehara, Tomoaki Terakawa, Kenichi Harada, Jun Teishima, Yuzo Nakano, Masato Fujisawa
    INTRODUCTION: Renal cell carcinoma with an inferior vena cava tumor thrombus is a challenging disease that requires a multimodal treatment approach. Pembrolizumab plus lenvatinib has displayed promising efficacy in metastatic renal cell carcinoma. CASE PRESENTATION: A 61-year-old man was diagnosed with metastatic renal cell carcinoma and a tumor thrombus adhering to the inferior vena cava wall by cine magnetic resonance imaging. After 6 months of pembrolizumab and lenvatinib therapy, tumor shrinkage was detected, excluding the advanced portion of the inferior vena cava thrombus, and nephrectomy and thrombectomy were performed. Adhesion of the tumor thrombus to the inferior vena cava wall was observed during surgery. Resection produced a remarkable pathological complete response with no viable cells in the resected specimens, including the thrombus site. CONCLUSION: This case highlights the potential of pembrolizumab plus lenvatinib for treating advanced renal cell carcinoma with an inferior vena cava thrombus and the utility of cine magnetic resonance imaging for evaluating thrombus adhesion to the inferior vena cava.
    Jan. 2024, IJU case reports, 7(1) (1), 60 - 63, English, International magazine
    Link to Kobe Univ. Repository (Kernel)

  • Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
    The present study aimed to clarify the relationship between the therapeutic outcome of combination regimens, including immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs), and cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). The present study retrospectively assessed the association between treatment efficacy and prognosis with or without CN, and the timing of CN in 151 patients treated with combination regimens for mRCC who were categorized as intermediate/poor risk. The first-line regimens included the ICI-ICI and ICI-TKI regimens in 98 and 53 cases, respectively. In patients with recurrence after radical surgery (n=66), the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 33.6 months and not reached (NR) (P=0.4032), respectively, and the 50% OS times were 53.7 months and NR (P=0.6886), respectively. Among the 38 patients with metastasis from the initial diagnosis who underwent upfront CN, the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 10.5 and 8.2 months (P=0.5806), respectively, and the 50% OS times were NR and 15.8 months (P=0.0587), respectively. Among the 51 patients who did not receive upfront CN, the 50% PFS time of the ICI-TKI group was significantly higher than that in the ICI-ICI group (4.1 months and NR, respectively; P=0.0210), and the 50% OS times were 29.8 months and NR (P=0.7343), respectively. In conclusion, according to the analysis of real-world data, good therapeutic efficacy can be achieved with any regimen in patients with recurrence after radical surgery. In addition, improved results could be achieved through treatment with ICI-TKI in patients without upfront CN.
    Nov. 2023, Oncology letters, 26(5) (5), 470 - 470, English, International magazine
    Scientific journal

  • Hideto Ueki, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Junya Furukawa, Yuzo Nakano, Masato Fujisawa
    INTRODUCTION: The performance of robot-assisted laparoscopic pyeloplasty has recently been increasing in frequency. However, patients with duplicated renal pelvises and ureters can present challenges. CASE PRESENTATION: A 71-year-old woman presented with flank pain and was diagnosed with ureteropelvic junction obstruction with an incomplete duplicated collecting system. Preoperative imaging did not reveal the details of the stenosis. Therefore, three reconstructive procedures were prepared: The Anderson-Hynes procedure, end-to-side pyeloureterostomy, and upper pole ureter to lower pole pyeloplasty with the Anderson-Hynes procedure for the lower pole. These procedures were determined by the length of the intact ureter and the presence of crossed vessels. During the surgery, the crossing vein was severed, allowing successful reconstruction with Anderson-Hynes anastomosis. CONCLUSION: Preoperative evaluation and preparation of multiple surgical techniques are crucial in robot-assisted laparoscopic pyeloplasty for incomplete duplicated collecting systems.
    Nov. 2023, IJU case reports, 6(6) (6), 357 - 361, English, International magazine

  • Taisuke Tobe, Tomoaki Terakawa, Takuto Hara, Hideto Ueki, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Yuzo Nakano, Kenichi Harada, Masato Fujisawa
    Oct. 2023, Clinical genitourinary cancer, 21(5) (5), 613.e1-613.e6, English, International magazine

  • Takuto Hara, Junya Furukawa, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    OBJECTIVES: The efficacy of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs) has been suggested in the real-world setting. We retrospectively examined the efficacy of CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC. METHODS: Synchronous mRCC patients who received nivolumab plus ipilimumab at Kobe University Hospital or five affiliated hospitals between October 2018 and December 2021 were included in this study. We compared the outcomes of objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) between patients with CN prior to systemic therapy and without CN. In addition, patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. RESULTS: Twenty-one patients received CN prior to nivolumab plus ipilimumab (Prior CN) and 33 received nivolumab plus ipilimumab alone (Without CN). PFS of the Prior CN group was 10.8 months (95%CI 5.5-NR) and 3.4 months (95%CI 2.0-5.9) for the Without CN group (p = 0.0158). OS of Prior CN was 38.4 months (95%CI NR-NR) and 12.6 months (95%CI 4.2-30.8) for Without CN (p = 0.0024). Univariate and multivariate analyses identified prior CN as a significant prognostic indicator for PFS and OS. Moreover, propensity score matching analysis showed significant improvements in PFS and OS in Prior CN. CONCLUSIONS: Patients who underwent CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC had a better prognosis than patients treated with nivolumab plus ipilimumab alone. These results suggest the efficacy of prior CN for synchronous mRCC with ICI combination therapy.
    Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 746 - 752, English, International magazine
    Scientific journal

  • Takuto Hara, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    BACKGROUND: The objective of this study was to evaluate the background and treatment course of patients with metastatic prostate cancer (PC), with a particular focus on radiographic progression in the absence of prostate-specific antigen (PSA) progression. METHODS: The study population consisted of 229 patients with metastatic hormone-sensitive PC (HSPC), who received prostate biopsy and androgen deprivation therapy at Kobe University Hospital between January 2008 and June 2022. Clinical characteristics were retrospectively evaluated using medical records. PSA progression-free status was defined as ≤1.05 times greater than that from 3 months before. Multivariate analyses were performed using the Cox proportional hazards regression model to identify parameters associated with time to progression on imaging without PSA elevation. RESULTS: A total of 227 patients with metastatic HSPC without neuroendocrine PC were identified. The median follow-up period was 38.0 months, with a median overall survival of 94.9 months. Six patients exhibited disease progression on imaging without PSA elevation during HSPC treatment, three during first-line castration-resistant PC (CRPC) treatment, and two during late-line CRPC treatment. The rate of disease progression without PSA elevation at 3 years after treatment initiation was 7.4%. Multivariate analysis revealed that organ metastases and upfront treatment with docetaxel or androgen receptor axis-targeted therapy were independent prognostic factors for imaging progression without PSA elevation. CONCLUSIONS: Disease progression on imaging without PSA elevation occurred not only during HSPC treatment and first-line CRPC treatment, but also during late-line CRPC treatment. Patients with visceral metastases or those treated with upfront androgen receptor axis-targeted or docetaxel may be more prone to such progression.
    Sep. 2023, The Prostate, 83(13) (13), 1270 - 1278, English, International magazine
    Scientific journal

  • Takuto Hara, Junya Furukawa, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Kenichi Harada, Satoru Takahashi, Yuzo Nakano, Masato Fujisawa
    OBJECTIVES: We investigated poor prognosticators in advanced or unresectable urothelial carcinoma, focusing on renal parenchymal invasion (RPI). METHODS: This study included 48 bladder cancer (BC) and 67 upper tract urothelial carcinoma (UTUC) patients treated with pembrolizumab from December 2017 to September 2022 at Kobe University Hospital. Medical records were retrospectively reviewed for clinical characteristics, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Multivariate analyses were performed using the Cox proportional hazard regression model to identify parameters associated with either PFS or OS. RESULTS: Of 67 UTUC patients, 23 had RPI and 41 patients did not, while 3 cases could not be evaluated. Patients with RPI were predominantly elderly and had liver metastases. ORR for patients with RPI was 8.7%, while it was 19.5% for those without RPI. PFS was significantly shorter for patients with RPI compared with those without RPI. Patients with RPI had significantly shorter OS than those without RPI. On multivariate analysis, performance status (PS) ≥ 2, neutrophil-lymphocyte ratio (NLR) ≥ 3, C-reactive protein ≥0.3 mg/dL and RPI were independent prognostic factors for PFS. PS ≥ 2, NLR ≥ 3, visceral metastasis and RPI were independent prognostic factors for OS. UTUC patient OS was significantly shorter than BC patient OS, while no significant difference in PFS or OS was observed between BC patients and UTUC patients without RPI. CONCLUSIONS: RPI was a poor prognostic factor in advanced urothelial carcinoma treated with pembrolizumab, possibly resulting in a poorer prognosis for UTUC compared with BC.
    Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 779 - 786, English, International magazine
    Scientific journal

  • Ken-Ichi Harada, Ryo Sato, Yukari Bando, Asuka Sano, Yuto Matsushita, Keita Tamura, Tomoaki Terakawa, Junya Furukawa, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
    OBJECTIVES: The objective of this study was to assess the clinical outcomes following combined treatment with pembrolizumab and axitinib as first-line therapy for patients with advanced RCC. METHODS: This study retrospectively included 47 consecutive Japanese patients who were diagnosed with advanced RCC and subsequently received pembrolizumab and axitinib between February 2020 and January 2022. Efficacy and safety of this combined therapy in these patients were comprehensively investigated. RESULTS: The 47 included patients were classified into the following 3 groups by the IMDC system: favorable, 7 (14.9%); intermediate, 24 (51.1%) and poor, 16 (34.0%). Responses to this combined therapy in the 47 patients were as follows: CR, 8 (17.0%); PR, 20 (42.6%); SD, 16 (34.0%) and PD, 3 (6.4%); thus, the ORR was 59.6%. During the observation period, disease progression and death occurred in 19 (40.4%) and 9 (19.1%) patients, respectively, and the median PFS and OS were 18 months and not reached, respectively. Univariate analyses identified the following significant predictors for poor prognostic outcomes: lack of nephrectomy, liver metastasis, bone metastasis, elevated CRP and IMDC poor risk for PFS; and lack of nephrectomy, non-CCC and elevated CRP for OS. AEs and those corresponding to grade ≥ 3 occurred in all (100%) and 30 (63.8%) patients, respectively. CONCLUSIONS: To our knowledge, this is the first study focusing on real-world outcomes following pembrolizumab and axitinib for treatment-naïve advanced Japanese RCC patients, which showed the efficacy and safety of this combined therapy being similar or even superior to those in clinical trial.
    Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 772 - 777, English, International magazine
    Scientific journal

  • Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Toshiro Shirakawa
    Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 antibodies compared to the mice treated by the antibodies alone. This result suggests that B. longum 420 oral cancer vaccine as an adjunct to ICIs could provide a novel treatment option for RCC patients. Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs.
    Jun. 2023, Scientific reports, 13(1) (1), 9994 - 9994, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Junichiro Hirata, Naoe Jimbo, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    OBJECTIVE: This study retrospectively reviewed the clinical characteristics and treatment outcomes of patients with histologically diagnosed treatment-related pure small-cell neuroendocrine prostate cancer. METHODS: We retrospectively evaluated data for 13 patients with treatment-related neuroendocrine prostate cancer who were diagnosed between May 2015 and February 2022. Standardized systemic therapies of etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan were selected as sequential treatments. Cancer-specific survival and progression-free survival were evaluated as the primary endpoint. The Cox proportional hazards model was used to evaluate the relationships between treatment regimens, clinical variables, cancer-specific survival and progression-free survival. RESULTS: The median cancer-specific survival after diagnosis for all patients was 22.4 months (range 1.3-33.4 months). The median progression-free survival was 9.3 months after first-line etoposide plus cisplatin (or carboplatin) treatment (n = 13); 4.2 months after second-line amrubicin treatment (n = 4); and >15 months after third-line nogitecan treatment (n = 2). The median progression-free survival after first-line chemotherapy of the liver metastasis (-) group was 10.2 months, and that of the (+) group was 5.3 months (P = 0.015, hazard ratio = 11.6, 95% confidence interval = 1.01 - 133.7). No clinicopathological parameters were identified as significant independent predictors of cancer-specific survival in univariate analysis. CONCLUSION: Sequential chemotherapy with etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan may be helpful for patients with treatment-related pure small-cell neuroendocrine prostate cancer. Early biopsy of metastases and initiation of effective therapy is essential for patients with progressive castration-resistant prostate cancer and low prostate-specific antigen.
    Jun. 2023, Japanese journal of clinical oncology, 53(6) (6), 522 - 529, English, International magazine
    Scientific journal

  • Hideaki Miyake, Yasumasa Kakei, Yuzo Nakano, Tomoaki Terakawa, Keiko Miyakoda, Kenichi Harada, Masato Fujisawa
    INTRODUCTION: This is a multicentre, open-label, single-arm clinical trial to evaluate the efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer. METHODS AND ANALYSIS: The trial will be performed at 4 university hospitals and 14 city hospitals in Japan. The target number of patients will be 110. The patients will be orally administered 240 mg apalutamide once daily during the treatment period. The primary outcome is the prostate-specific antigen (PSA) response rate. PSA response is defined as ≥50% decline from baseline at 12 weeks. Secondary outcomes are time to PSA progression, progression-free survival, overall survival, progression-free survival during second therapy, ≥50% decline in PSA from baseline at 24 and 48 weeks, ≥90% decline in PSA from baseline or lower PSA detection sensitivity after the initial dose at 12, 24 and 48 weeks, PSA maximal changes, accumulated PSA response from screening to 24 and 48 weeks, and grade 3 or 4 adverse events according to the Common Terminology Criteria for Adverse Events version 4.0. ETHICS AND DISSEMINATION: This study has been approved by the Certified Research Review Board of Kobe University (No. CRB5180009). All participants will be required to provide written informed consent. Findings will be disseminated through scientific and professional conferences and peer-reviewed journal publications. The datasets generated during the study will be available from the corresponding author on reasonable request. TRIAL REGISTRATION NUMBER: jRCTs051220077.
    Mar. 2023, BMJ Open, 13(3) (3), e070173, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoto Wakita, Nobuyuki Hinata, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa
    BACKGROUND/AIM: Increasing availability of effective treatment options for metastatic renal cell carcinoma (mRCC) has highlighted the importance of identifying predictors of treatment response. Although PD-L1 expression in renal cancer has been reported as a predictor of treatment response and prognosis, its assessment by immunohistochemistry is invasive and difficult to perform repeatedly. Soluble PD-L1 (sPD-L1) has recently been proposed as a predictive biomarker for several tumour types. Therefore, we evaluated sPD-L1 levels in patients with mRCC treated with nivolumab and investigated its association with treatment response. PATIENTS AND METHODS: We performed a prospective single-arm study in patients with mRCC treated with nivolumab as second line or later therapy. We measured serum sPD-L1 before and during treatment, classified patients based on baseline values (sPDL1 ≥0.23 ng/ml vs. <0.23 ng/ml) and compared outcomes between the two groups. RESULTS: A total of 43 patients with mRCC were included in this study, with 17 (39.5%) classified as low sPD-L1 and 26 (60.5%) as high sPD-L1. The International Metastatic RCC Database Consortium risk score was significantly poorer in the high sPD-L1 group. The objective response rate was significantly higher (41.2% vs. 7.7%) and overall survival significantly longer (p=0.0323) in the low group compared to the high group. There were no significant differences in progression-free survival between the two groups. CONCLUSION: Our study findings indicate that sPD-L1 might be a predictor of treatment response to nivolumab in patients with mRCC.
    Feb. 2023, Anticancer research, 43(2) (2), 841 - 847, English, International magazine
    Scientific journal

  • Yukari Bando, Junya Furukawa, Takuto Hara, Yasuyoshi Okamura, Tomoaki Terakawa, Yuzo Nakano, Masato Fujisawa
    Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.
    2023, Urologia internationalis, 107(3) (3), 321 - 326, English, International magazine
    Scientific journal

  • 悪性パラガングリオーマ多発骨転移に対し,集学的治療を行った1例
    楠瀬 正史, 鈴木 光太郎, 寺川 智章, 千葉 公嗣, 古川 順也, 原田 健一, 重村 克己, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Dec. 2022, 泌尿器科紀要, 68(12) (12), 397 - 397, Japanese

  • 前立腺神経内分泌癌に対しEP療法後にアムルビシンが奏功した1例
    坪谷 一樹, 寺川 智章, 古川 順也, 原田 健一, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    泌尿器科紀要刊行会, Aug. 2022, 泌尿器科紀要, 68(8) (8), 285 - 285, Japanese

  • Hideto Ueki, Takuto Hara, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    PURPOSE: Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab. MATERIALS AND METHODS: This study evaluated 96 patients with RCC who received nivolumab. The SMI and PMI were calculated for each patient and normalized for stature by use of the following formulas: SMI (cm²/m²)=([skeletal muscle cross-sectional area at the level of L3]/[height]²) and PMI (cm²/m²) = ([left-right sum of the psoas muscle areas at the level of L3]/[height]²). The relationship of the clinical variables with progression-free survival and overall survival (OS) was examined using a Cox proportional hazards model. RESULTS: According to the SMI-based definition of sarcopenia, 74.0% of patients had sarcopenia. However, according to the PMI-based definition of sarcopenia, only 34.3% of patients were diagnosed with sarcopenia. Multivariate analysis identified sarcopenia based on PMI (hazard ratio [HR], 3.85; 95% confidence interval [CI], 2.04-7.26; p<0.001) and International Metastatic RCC Database Consortium poor risk status (HR, 1.90; 95% CI, 1.03-3.50; p=0.041) as significant and independent prognostic factors of OS. CONCLUSIONS: PMI-based sarcopenia is a significant prognostic factor for OS in patients with RCC who receive nivolumab therapy.
    Jul. 2022, Investigative and clinical urology, 63(4) (4), 415 - 424, English, International magazine
    Scientific journal

  • Hideto Ueki, Tomoaki Terakawa, Yoshiko Ueno, Keitaro Sofue, Shintaro Horii, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Takamichi Murakami, Masato Fujisawa
    OBJECTIVE: In renal cell carcinoma with inferior vena cava (IVC) thrombus, adhesion to, or invasion into, the IVC wall will often increase the level of surgical difficulty and even necessitate resection of the IVC. It will generally be difficult to perform an accurate preoperative assessment using the standard imaging modalities of contrast-enhanced computed tomography and standard magnetic resonance imaging (MRI). Cine MRI is an MRI sequence that captures motion to produce detailed information on both the anatomy and the dynamic motion. In the present study, we evaluated the accuracy of preoperative cine MRI for determining the need for IVC wall resection, with validation of the imaging findings according to the intraoperative findings. METHODS: A total of 15 patients who had undergone radical nephrectomy and tumor thrombectomy from May 2018 to April 2020 met the inclusion criteria. The primary outcome of interest was the need for IVC resection because of adhesion or invasion of a venous tumor thrombus. Cine MRI was used to evaluate the blood flow between the tumor thrombus and the IVC wall and the presence of tumor thrombus mobility during free respiration. The sensitivity and specificity were calculated for preoperative cine MRI for determining the need for IVC wall resection. The Fisher exact test was used to determine the association between intraoperative IVC wall resection and the cine MRI findings. Furthermore, receiver operating characteristic curves and the area under the curve were used to compare the accuracy of conventional MRI and cine MRI. RESULTS: Of the 15 patients, 8 (53.3%) had undergone IVC resection. We found that the absence of both dynamic blood flow and tumor thrombus mobility on cine MRI could reliably predict for IVC resection with 100% (95% confidence interval, 51.8%-100%) sensitivity and 85.7% (95% confidence interval, 42.1%-1.00%) specificity. The area under the receiver operating characteristic curve was 0.821 for conventional MRI and 0.929 for cine MRI. CONCLUSIONS: In the preoperative setting, cine MRI could be a helpful examination modality to predict for the need for IVC wall resection for patients with renal cell carcinoma with venous tumor thrombus.
    Mar. 2022, Journal of vascular surgery. Venous and lymphatic disorders, 10(4) (4), 908 - 915, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yukari Bando, Junya Furukawa, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Yuzo Nakano, Masato Fujisawa
    BACKGROUND/AIM: The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. PATIENTS AND METHODS: We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. RESULTS: Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). CONCLUSION: Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.
    Feb. 2022, Anticancer research, 42(2) (2), 973 - 979, English, International magazine
    Scientific journal

  • 副腎癌術後、再発を繰り返すも長期生存を得た1例
    植松 陸, 寺川 智章, 古川 順也, 原田 健一, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jan. 2022, 泌尿器科紀要, 68(1) (1), 23 - 23, Japanese

  • Umar Iqbal, Zhe Jing, Youssef Ahmed, Ahmed S Elsayed, Craig Rogers, Ronald Boris, James Porter, Mohammad Allaf, Ketan Badani, Michael Stifelman, Jihad Kaouk, Tomoaki Terakawa, Nobuyuki Hinata, Ahmed A Aboumohamed, Eric Kauffman, Qiang Li, Ronney Abaza, Khurshid A Guru, Ahmed A Hussein, Daniel Eun
    Objective: To develop a structured and objective scoring tool for assessment of robot-assisted partial nephrectomy (RAPN): Scoring for Partial Nephrectomy (SPaN). Materials and Methods: Content development: RAPN was deconstructed into 6 domains by a multi-institutional panel of 10 expert robotic surgeons. Performance on each domain was represented on a Likert scale of 1 to 5, with specific descriptions of anchors 1, 3, and 5. Content validation: The Delphi methodology was utilized to achieve consensus about the description of each anchor for each domain in terms of appropriateness of the skill assessed, objectiveness, clarity, and unambiguous wording. The content validity index (CVI) of ≥0.75 was set as cutoff for consensus. Reliability: 15 de-identified videos of RAPN were utilized to determine the inter-rater reliability using linearly weighted percent agreement, and Construct validation of SPaN was described in terms of median scores and odds ratios. Results: The expert panel reached consensus (CVI ≥0.75) after 2 rounds. Consensus was achieved for 36 (67%) statements in the first round and 18 (33%) after the second round. The final six-domain SPaN included Exposure of the kidney; Identification and dissection of the ureter and gonadal vessels; Dissection of the hilum; Tumor localization and exposure; Clamping and tumor resection; and Renorrhaphy. The linearly weighted percent agreement was >0.75 for all domains. There was no difference between median scores for any domain between attendings and trainees. Conclusion: Despite the lack of significant construct validity, SPaN is a structured, reliable, and procedure-specific tool that can objectively assesses technical proficiency for RAPN.
    Dec. 2021, Journal of endourology, 36(5) (5), 647 - 653, English, International magazine
    Scientific journal

  • RENAL nephrometry score 10以上の高難度症例に対するロボット支援腎部分切除術の治療成績検討
    脇田 直人, 板東 由加里, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2021, 日本内視鏡外科学会雑誌, 26(7) (7), MO234 - 2, Japanese

  • ロボット支援腎部分切除術の今後の展開:腎機能温存最大化を目指して 腎動脈阻血と選択的腎動脈阻血
    寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, SY34 - 1, Japanese

  • 下大静脈塞栓を有する腎癌症例に対する術前アベルマブ、アキシチニブ併用療法の有用性に関する検討
    寺川 智章, 佐野 貴紀, 脇田 直人, 白石 祐介, 岡村 泰義, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, OP79 - 07, Japanese

  • ニボルマブを使用した腎細胞癌患者の予後と骨格筋量との関連についての検討
    植木 秀登, 原田 健一, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP02 - 09, Japanese

  • 当院における進行性腎癌に対するカボザンチニブの初期投与経験
    佐野 貴紀, 白石 祐介, 脇田 直人, 岡村 泰義, 坂本 茉莉子, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP03 - 04, Japanese

  • 神戸大学における転移性腎癌に対するアキシチニブrechallengeの治療成績
    白石 祐介, 原田 健一, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克己, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP03 - 10, Japanese

  • 神戸大学における転移性腎細胞癌に対するイピリムマブ・ニボルマブ併用療法の治療成績
    古川 順也, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP04 - 04, Japanese

  • ペムブロリズマブを使用した進行性尿路上皮癌患者の予後予測因子についての免疫組織学的検討
    植木 秀登, 日向 信之, 北川 孝一, 岡村 泰義, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 中野 雄造, 白川 利朗, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP26 - 02, Japanese

  • ホルモン治療に伴う前立腺癌者の骨密度および骨代謝マーカーの推移についての前向き観察研究
    原 琢人, 岡村 泰義, 坂東 由加里, 福田 輝雄, 西本 華子, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 新倉 隆宏, 中野 雄造, 黒田 良祐, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP36 - 01, Japanese

  • 転移性腎癌における単発転移に対するmetastasectomyの有用性の臨床的検討
    鈴木 光太郎, 佐野 貴紀, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP55 - 06, Japanese

  • 術前cine MRIによる腎癌血栓の下大静脈壁への癒着評価の有効性(The efficacy of pre-operative cine MRI to evaluate the adhesion of renal cancer thrombus to the wall of inferior vena cava)
    植木 秀登, 寺川 智章, 上野 嘉子, 祖父江 慶太郎, 岡村 泰義, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 166 - 166, English

  • 転移性腎細胞癌に対するイピリムマブ・ニボルマブ併用療法における初回投与時期の検討
    原田 健一, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 199 - 199, Japanese

  • Takuto Hara, Tomoaki Terakawa, Toshiki Hyodo, Naoe Jinbo, Yuzo Nakano, Masato Fujisawa
    A 79-year-old female was diagnosed with a right renal tumor with a level II tumor thrombus of the vena cava. presurgical therapy was initiated with a combination of avelumab and axitinib for 3 monthes. Then, she underwent nephrectomy and thrombectomy. Histologically, the primary tumor and tumor thrombus had no viable cells, indicating that pathological complete response was achieved with presurgical tyrosine kinase inhibitor/Immuno-oncology combination therapy. An immunohistological xamination showed very strong staining for tumor-infiltrating lymphocytes in the embolized area of the tumor, with CD8 predominating over CD4.
    Nov. 2021, Urology case reports, 39, 101800 - 101800, English, International magazine
    Link to Kobe Univ. Repository (Kernel)

  • The efficacy of pre-operative cine MRI to evaluate the adhesion of renal cancer thrombus to the wall of inferior vena cava(和訳中)
    植木 秀登, 寺川 智章, 上野 嘉子, 祖父江 慶太郎, 岡村 泰義, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 166 - 166, English

  • H Ueki, N Hinata, K Kitagawa, T Hara, T Terakawa, J Furukawa, K Harada, Y Nakano, M Komatsu, M Fujisawa, T Shirakawa
    OBJECTIVES: Recently, the standard of care for advanced urothelial cancer (UC) has been changed by developing immune-checkpoint inhibitors (ICIs). However, its response rate is limited to 20-30%. The identification of biomarkers to predict the therapeutic effects of ICIs is urgently needed. The present study explored the association between immunohistochemical biomarkers and clinical outcomes in UC patients treated with pembrolizumab. PATIENTS AND METHODS: A total of 85 patients with UC who received pembrolizumab after chemotherapy from January 2018 to May 2020 were retrospectively reviewed. Tumor tissues were obtained for immunohistochemical study from 47 out of 85 patients. The protein expressions of PD-L1, WT1, Nectin-4, CD4, CD8, Foxp3, and CD68 in tumor cells and/or tumor infiltrating lymphocytes were immunohistochemically examined. The associations between protein expressions and overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) were statistically analyzed. RESULTS: Patients with positive PD-L1 in tumor cells showed significantly worse OS (Log-rank test: HR 5.146, p = 0.001, Cox regression analysis: HR 4.331, p = 0.014) and PFS (Log-rank test: HR 3.31. p = 0.022), along with significantly lower DCR (14.3%) compared to the PD-L1 negative patients (67.5%). In addition, patients with strong expression of Nectin-4 in tumor cells showed significantly higher DCR (100%) than the other patients (50%). CONCLUSION: PD-L1 expression in tumor cells was associated with poor prognosis (OS and PFS) and low DCR. Interestingly, the strong expression of Nectin-4 was correlated with high DCR. PD-L1 and Nectin-4 expression in tumor cells could be prognostic biomarkers useful for pembrolizumab in patients with advanced UC.
    Oct. 2021, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, English, International magazine
    Scientific journal

  • 進行性尿路上皮癌に対するPembrolizumab投与後のPaclitaxel/Carboplatin療法の成績
    古川 順也, 板東 由加里, 岡村 泰義, 原 琢人, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, O22 - 5, English

  • 神戸大学における転移性腎癌に対するアキシチニブrechallengeの治療成績
    白石 祐介, 原田 健一, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 重村 克己, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, O23 - 3, English

  • 非淡明型腎細胞癌に対するニボルマブ・イピリムマブ併用療法の成績
    板東 由加里, 植木 秀登, 佐野 貴紀, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, P27 - 1, English

  • 去勢抵抗性前立腺癌に対するカバジタキセルの治療効果と安全性の検討
    脇田 直人, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, P29 - 6, English

  • Naoto Wakita, Nobuyuki Hinata, Kotaro Suzuki, Yukari Bando, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa
    Wiley, Jul. 2021, International Journal of Urology
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    BACKGROUND: Patients with solitary metastasis of renal cell carcinoma (RCC) have shown to be ideal candidates for surgical metastasectomy (SM). However, whether SM will show more benefit than systemic therapy remains unclear. METHODS: We included 73 patients treated for solitary metastasis after nephrectomy at our institute from April 2008 to December 2018. We compared the clinical outcomes between the SM (n = 29) and no-SM (n = 44) group which were treated with only systemic therapy. RESULTS: Eleven of 29 patients in the SM group received presurgical targeted therapy (PTT). Although 13 of 29 patients in the SM group showed recurrence during the study period, a Cox proportional hazards model showed that SM was significantly associated with a favorable overall survival (hazard ratio: 0.18; p = 0.007). Patients receiving PTT prior to SM showed a longer recurrence-free survival after SM in comparison to those who underwent SM without PTT (median: not reached vs. 27.7 months; p = 0.009). CONCLUSIONS: If resection is feasible, SM may be beneficial for patients with solitary metastasis of RCC, and we showed the possibility that PTT prior to SM may be effective for avoiding recurrence after SM. Further large-scale prospective studies are needed to clarify the ideal treatment strategy for metastatic RCC.
    Jun. 2021, Urologia internationalis, 106(4) (4), 1 - 7, English, International magazine
    Scientific journal

  • Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Kenichi Harada, Masato Fujisawa
    Wiley, Jun. 2021, International Journal of Urology
    Scientific journal

  • 腎癌単発転移に対するMetastasec-tomyの有用性の臨床的検討
    鈴木 光太郎, 佐野 貴紀, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 252 - 252, Japanese

  • 肉腫様腎癌多発骨転移に対し免疫併用療法を施行しCRが得られた1例
    福永 博之, 鈴木 光太郎, 岡田 桂輔, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 重村 克己, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 253 - 253, Japanese

  • Presurgical therapyによって腎静脈内まで腫瘍塞栓が縮小し腹腔鏡下に摘除し得た腎癌下大静脈腫瘍塞栓の1例
    寺川 智章, 前田 光毅, 脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 253 - 253, Japanese

  • 進行性尿路上皮癌に対するPembrolizumab治療における好中球/リンパ球比の意義
    古川 順也, 脇田 直人, 坂本 茉利子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 256 - 256, Japanese

  • 前立腺小細胞癌に対する2nd line化学療法としてのアムルビシンの使用経験
    前田 光毅, 寺川 智章, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 板東 由香里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 265 - 265, Japanese

  • Kotaro Suzuki, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Masato Fujisawa
    BACKGROUND: Although bone metastasis beyond the vertebrae and pelvis has been a key factor in prognostic models of metastatic hormone-sensitive prostate cancer (mHSPC), the clinical significance of it is still unclear. The present study evaluated the prognostic impact of the volume of bone metastasis beyond the vertebrae and pelvis on the outcomes of mHSPC and created an ideal risk classification based on it. METHODS: We retrospectively reviewed 197 patients with mHSPC who were treated with combined androgen blockade as the initial treatment between June 2003 and October 2019. We calculated the bone scan index (BSI), including the BSI beyond the vertebrae and pelvis (bBSI), using BONENAVI, and investigated the association between the BSI and the overall survival (OS) of mHSPC. RESULTS: According to the CHAARTED criteria, 91 and 106 patients were classified into the low- and high-volume groups, respectively. Of the 79 patients who did not have visceral metastasis in the high-volume group, those with a bBSI ≤ 0.27 (n = 16) showed a favorable OS, as did those in the low-volume group. The modified CHAARTED high-volume group (presence of visceral metastases or 4 bone lesions with a bBSI > 0.27) showed a significantly shorter OS than others, with a hazard ratio (HR) of 4.69 (p < 0.001), which was higher than that observed with the original CHAARTED criteria (HR = 4.33). CONCLUSIONS: Our data suggested that considering the volume of bone metastasis beyond the vertebrae and pelvis may help to improve the accuracy of risk classification. Further large-scale prospective studies are needed to validate our findings.
    May 2021, International journal of clinical oncology, 26(8) (8), 1533 - 1540, English, Domestic magazine
    Scientific journal

  • Yukari Bando, Junya Furukawa, Tomoaki Terakawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    OBJECTIVE: The purpose of this study was to assess the therapeutic efficacy of molecular targeted therapies following nivolumab in metastatic renal cell carcinoma and to examine the relationship between therapeutic efficacy and the specific molecular targeted therapy used. METHODS: We retrospectively reviewed the medical records of 115 metastatic renal cell carcinoma patients who were treated with nivolumab at our institution and five affiliated hospitals. Among them, 52 patients who received subsequent molecular targeted therapy following nivolumab were selected to survey treatment outcomes. Progression-free survival and overall survival were estimated with Kaplan-Meier curves, and differences were analyzed by the log-rank test. RESULTS: Among the 52 eligible patients, 40 (76.9%) were treated with tyrosine kinase inhibitors and 12 (23.1%) were treated with mammalian target of rapamycin inhibitor. The median time to treatment failure and progression-free survival of subsequent molecular targeted therapy were 5.6 and 8.0 months, respectively. The median overall survival from the initiation of first-line therapy was not reached. The disease control rate of subsequent molecular targeted therapy was 69.2% (partial response: 25.0%, stable disease: 44.2%). The median progression-free survival of subsequent tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor were 9.2 and 8.0 months, respectively (P = 0.37). The progression-free survival of patients whose best response to prior nivolumab was either progressive disease or stable disease/partial response were 6.3 and 11.3 months, respectively (P = 0.36). CONCLUSIONS: Molecular targeted therapies following nivolumab had comparatively better therapeutic efficacy, which was confirmed regardless of the type of molecular targeted agent used.
    May 2021, Japanese journal of clinical oncology, 51(8) (8), 1313 - 1318, English, International magazine
    Scientific journal

  • 植木 秀登, 原田 健一, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    日本老年泌尿器科学会, Apr. 2021, 日本老年泌尿器科学会誌, 34(1) (1), 123 - 123, Japanese

  • Nobuyuki Hinata, Ahmed A Hussein, Yukari Bando, Tomoaki Terakawa, Gen Murakami, Masahito Yamamoto, Shin-Ichi Abe, Khurshid Guru, Masato Fujisawa
    OBJECTIVE: To understand the structures around the vesicourethral junction and to improve functional outcomes after nerve-sparing radical cystectomy with orthotopic urinary diversion for female patients, we histologically elucidated the fibromuscular construction and nerve distribution around the vesicourethral junction. METHODS: Pelvic specimens containing all the pelvic viscera were obtained from 33 donated female cadavers. Macroslices that included the urethra, the anterior wall of the vagina, and the inferomedial edge of the levator ani muscle were made and performed elastica Masson and immunohistochemical staining. The intraoperative findings were collected in 3 female patients undergoing nerve-sparing radical cystectomy. RESULTS: In 18 out of the 33 cadavers, smooth muscle mass occupied a space between the urethra and the inferomedial edge of the levator ani muscle and covered the inferior margin of the bladder detrusor. We termed this mass the hiatal smooth muscle. The detrusor nerves entered the bladder, and the cavernous and sphincter nerves ran between the hiatal smooth muscle and vesicourethral junction. The boundary between hiatal smooth muscle and urethral smooth muscle was easily distinguished intraoperatively during dissection of the vesicourethral junction. CONCLUSION: We found that more than half of elderly women have hiatal smooth muscle between the urethra and inferior edge of the levator ani. Autonomic nerve fibers innervating the urethral sphincter, run between the hiatal smooth muscle and vesicourethral junction in female cadavers with hiatal smooth muscle. When performing female radical cystectomy before neobladder reconstruction, nerve sparing can be reliably performed using the hiatal smooth muscle as a landmark.
    Mar. 2021, Urology, 149, 161 - 167, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 当院における非転移性去勢抵抗性前立腺癌に対する治療成績の検討
    寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1149 - 1149, Japanese

  • 進行性腎細胞癌患者におけるニボルマブ関連続発性副腎不全の臨床的検討
    鈴木 光太郎, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1193 - 1193, Japanese

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌12例の臨床的検討
    寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1320 - 1320, Japanese

  • 神戸大学における転移性腎癌に対するアキシチニブrechallengeの治療成績
    原田 健一, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1417 - 1417, Japanese

  • ニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
    白石 祐介, 坂東 由加里, 寺川 智章, 古川 順也, 重村 克己, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1418 - 1418, Japanese

  • 神戸大学における転移性腎癌に対するイピリムマブ・ニボルマブ併用療法の初期経験
    原田 健一, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1594 - 1594, Japanese

  • 初診時にリンパ節転移を認めた上部尿路癌に対する集学的治療の検討
    脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1707 - 1707, Japanese

  • 当院における精巣腫瘍の臨床的検討
    岡村 泰義, 白石 祐介, 脇田 直人, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1718 - 1718, Japanese

  • 当科におけるクッシング症候群に対する腹腔鏡下副腎摘除術の手術成績と治療アウトカムに関する検討
    坂本 茉莉子, 白石 祐介, 脇田 直人, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1745 - 1745, Japanese

  • 血清中可溶性PD-L1蛋白高値の根治切除不能または転移性の腎細胞癌におけるニボルマブの治療効果予測効果についての研究
    板東 由加里, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1798 - 1798, Japanese

  • 尿路上皮癌に対するPembrolizumabの治療効果についての検討
    原 琢人, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1843 - 1843, Japanese

  • 当院における非転移性去勢抵抗性前立腺癌に対する治療成績の検討
    寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1149 - 1149, Japanese

  • 進行性腎細胞癌患者におけるニボルマブ関連続発性副腎不全の臨床的検討
    鈴木 光太郎, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1193 - 1193, Japanese

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌12例の臨床的検討
    寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1320 - 1320, Japanese

  • ニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
    白石 祐介, 坂東 由加里, 寺川 智章, 古川 順也, 重村 克己, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1418 - 1418, Japanese

  • 神戸大学における転移性腎癌に対するイピリムマブ・ニボルマブ併用療法の初期経験
    原田 健一, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1594 - 1594, Japanese

  • 初診時にリンパ節転移を認めた上部尿路癌に対する集学的治療の検討
    脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1707 - 1707, Japanese

  • 当院における精巣腫瘍の臨床的検討
    岡村 泰義, 白石 祐介, 脇田 直人, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1718 - 1718, Japanese

  • 当科におけるクッシング症候群に対する腹腔鏡下副腎摘除術の手術成績と治療アウトカムに関する検討
    坂本 茉莉子, 白石 祐介, 脇田 直人, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1745 - 1745, Japanese

  • 血清中可溶性PD-L1蛋白高値の根治切除不能または転移性の腎細胞癌におけるニボルマブの治療効果予測効果についての研究
    板東 由加里, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1798 - 1798, Japanese

  • 尿路上皮癌に対するPembrolizumabの治療効果についての検討
    原 琢人, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1843 - 1843, Japanese

  • 馬蹄鉄腎に発生した腎細胞癌に対する後腹膜鏡下腎摘除術
    古川 順也, 寺川 智章, 千葉 公嗣, 重村 克巳, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2020, 日本泌尿器内視鏡学会総会, 34回, V - 3, Japanese

  • 当院におけるロボット支援根治的膀胱全摘除術の成績
    日向 信之, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 322, Japanese

  • 非転移性去勢抵抗性前立腺癌に対するエンザルタミドとアビラテロンの治療効果
    脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 358, Japanese

  • ニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
    白石 祐介, 坂東 由加里, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克己, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 305, Japanese

  • 原 琢人, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2020, 西日本泌尿器科, 82(増刊) (増刊), 164 - 164, Japanese

  • ニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
    白石 祐介, 坂東 由加里, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克己, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 305, Japanese

  • 当院におけるロボット支援根治的膀胱全摘除術の成績
    日向 信之, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 322, Japanese

  • 非転移性去勢抵抗性前立腺癌に対するエンザルタミドとアビラテロンの治療効果
    脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 358, Japanese

  • 副腎皮質癌11例の臨床的検討
    原 琢人, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本内分泌外科学会, Aug. 2020, 日本内分泌外科学会雑誌, 37(Suppl.1) (Suppl.1), S111 - S111, Japanese

  • Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    BACKGROUND: Sequential treatment starting with target therapy is still the standard care for metastatic renal cell carcinoma (mRCC), even in the era of immune checkpoint inhibitors. Our objective was to compare the clinical outcomes between axitinib and nivolumab as second-line therapy following prior targeted therapy in mRCC patients. METHODS: We identified 41 patients treated with axitinib and 39 patients treated with nivolumab as a second-line regimen after targeted therapy, and retrospectively compared the treatment efficacy and safety in these patients. RESULTS: The clinical benefit rate of axitinib was significantly higher than that of nivolumab (82.9% versus 56.4%; p = 0.014) and patients who received axitinib tended to show longer progression-free survival (PFS) than those who received nivolumab (10.3 months versus 7.3 months; p = 0.067). There was no difference in the overall survival (OS) of the two groups (both not reached; p = 0.581). The incidence of grade ≥ 3 adverse events (AEs) was similar between the two groups, but one patient in the nivolumab group died due to an immune-related AE. In addition, a Cox proportional hazards model showed that the pre-treatment KPS, the baseline neutrophil-to-lymphocyte ratio (NLR), and an objective response in second-line therapy were significantly associated with PFS, while the pre-treatment KPS, the number of metastatic organs, and an objective response in second-line therapy significantly contributed to the predicted OS. CONCLUSIONS: Although the prognosis did not differ markedly between the two groups, axitinib resulted in a better tumor response rate. Further randomized prospective studies are needed for the ideal order of this sequential treatment.
    Jun. 2020, International journal of clinical oncology, 25(9) (9), 1678 - 1686, English, Domestic magazine
    [Refereed]
    Scientific journal

  • 原 琢人, 白石 祐介, 脇田 直人, 坂本 茉莉子, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    医学図書出版(株), Jun. 2020, 泌尿器外科, 33(臨増) (臨増), 910 - 910, Japanese

  • Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Jun. 2020, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(9) (9), 1678 - 1686, English
    [Refereed]
    Scientific journal

  • KOTARO SUZUKI, TOMOAKI TERAKAWA, NAOE JIMBO, RENA INABA, YUZO NAKANO, MASATO FUJISAWA
    Anticancer Research USA Inc., Jun. 2020, Anticancer Research, 40(6) (6), 3519 - 3526
    [Refereed]
    Scientific journal

  • 乳頭状腎細胞癌肺転移に対してイピリムマブ・ニボルマブ併用療法が奏功した1例
    京野 成紀, 原 琢人, 千葉 公嗣, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 重村 克己, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Mar. 2020, 泌尿器科紀要, 66(3) (3), 97 - 97, Japanese

  • 下大静脈平滑筋肉腫の1例
    坂本 裕章, 福田 輝雄, 寺川 智章, 古川 順也, 原田 健一, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人, 稲葉 礼奈, 神澤 真紀, 浦瀬 靖代, 上野 嘉子
    泌尿器科紀要刊行会, Mar. 2020, 泌尿器科紀要, 66(3) (3), 100 - 100, Japanese

  • Yukari Bando, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    BACKGROUND: The optimal extent of lymph node dissection in radical prostatectomy has not been determined. Lymph nodes in the fossa of Marcille, which is an important pelvic lymphatic pathway and candidate for additional dissection, have not been evaluated at the molecular level. Here, we assessed by molecular analysis the presence of occult positive lymph nodes in the fossa of Marcille in patients with clinically localized high-risk prostate cancer. METHODS: Fifty-two patients with clinically localized high-risk prostate cancer underwent pelvic lymph node dissection accompanied by robot-assisted radical prostatectomy. All nodal packets were dissected separately and grouped into right and left obturator, external and internal iliac regions (including common iliac region to ureter crossing), and fossa of Marcille. All lymph nodes were bisected and evaluated by histopathological or molecular analysis using a quantitative reverse transcription-polymerase chain reaction. The number of positive lymph nodes in the fossa of Marcille and the difference in detection rate were investigated using histopathological and molecular analyses. Perioperative complication rate and predictive factors for biochemical recurrence were evaluated. RESULTS: In the molecular analysis, there were seven positive lymph nodes in the fossa of Marcille in three patients, which were coexistent with positive nodes in other regions. The detection rate of positive lymph nodes was significantly higher using molecular than histopathological analysis (P < .01). Perioperative complication rate within 90 days after the operation was 25.0% and no Clavien-Dindo grade ≥3 complication was confirmed. Detection of metastasis by histopathological and molecular analysis was a significant factor related to biochemical recurrence in the Cox proportional hazards regression model. CONCLUSIONS: No case of positive lymph nodes in the fossa of Marcille that had skipped over other regions was confirmed. Additional lymph node dissection of fossa of Marcille did not lead to complete resection of molecularly positive lymph nodes.
    Mar. 2020, The Prostate, 80(4) (4), 345 - 351, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 定型化した生体ドナー腎採取術を学ぶ 神戸大学での単孔式腹腔鏡下ドナー腎採取術
    石村 武志, 遠藤 貴人, 西岡 遵, 横山 直己, 小田 晃廉, 小川 悟史, 寺川 智章, 千葉 公嗣, 古川 順也, 原田 健一, 重村 克巳, 藤澤 正人
    (一社)日本臨床腎移植学会, Feb. 2020, 日本臨床腎移植学会プログラム・抄録集, 53回, 123 - 123, Japanese

  • 下大静脈腫瘍塞栓を伴う腎癌症例におけるCineMRIの有用性
    田 寛之, 寺川 智章, 上野 嘉子, 高橋 哲, 古川 順也, 原田 健一, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Feb. 2020, 泌尿器科紀要, 66(2) (2), 60 - 60, Japanese

  • サブクリニカルクッシング症候群を合併した原発性アルドステロン症の1例
    高瀬 雄太, 岡田 桂輔, 堀部 祐輝, 寺川 智章, 古川 順也, 原田 健一, 松下 経, 石村 武志, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Feb. 2020, 泌尿器科紀要, 66(2) (2), 63 - 63, Japanese

  • Kotaro Suzuki, Tomoaki Terakawa, Shiro Kimbara, Masanori Toyoda, Naoe Jimbo, Yuzo Nakano, Hironobu Minami, Masato Fujisawa
    Jan. 2020, Clinical genitourinary cancer, English, International magazine
    [Refereed]

  • 下大静脈塞栓を有する腎癌患者に対する術前分子標的治療薬投与の有用性に関する検討
    寺川 智章, 岡村 泰義, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    (一社)腎癌研究会, 2020, 腎癌研究会会報, (50) (50), 16 - 16, Japanese

  • IO時代の腎癌治療の実臨床 神戸大学における進行性腎癌に対するニボルマブの臨床的検討
    原田 健一, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    (一社)腎癌研究会, 2020, 腎癌研究会会報, (50) (50), 44 - 44, Japanese

  • Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    BACKGROUND: Association between systemic inflammation and clinical outcome of immune checkpoint inhibitors (ICIs) has received focus. Our objective was to evaluate the utility of the neutrophil-to-lymphocyte ratio (NLR) in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab as well as the prognostic impact of the C-reactive protein (CRP) level. MATERIALS AND METHODS: Sixty-five mRCC patients treated with nivolumab were enrolled. We retrospectively investigated several factors, including the NLR and the CRP level, for their association with progression-free survival (PFS) and overall survival (OS). In addition, we evaluated their impact on the objective response. RESULTS: The CRP level was confirmed to be positively correlated with the NLR in a correlation analysis. An NLR ≥ 5 was significantly associated with a worse PFS (hazard ratio [HR]: 4.54, 95% confidence interval [CI] 1.93-10.7; p < 0.001), and an NLR ≥ 5 and a CRP ≥ 2.1 mg/dL were identified as a significant factors predicting worse OS with HRs of 4.88 (95% CI 1.35-17.7; p < 0.016) and 3.89 (95% CI 1.01-15.0; p = 0.049), respectively. In addition, patients with a ≥ 25% decrease in the NLR and CRP level showed a significantly better response to nivolumab than those without a ≥ 25% decrease in the NLR and CRP level, with odds ratios of 9.54 (95% CI 2.09-49.8, p = 0.001) and 4.36 (95% CI 1.03-18.9, p = 0.032), respectively. CONCLUSION: Both the NLR and CRP levels were significantly associated with the clinical outcome of nivolumab in mRCC patients. The potential prognostic impact of those markers needs to be further prospectively investigated.
    Jan. 2020, International journal of clinical oncology, 25(1) (1), 135 - 144, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Adrenal insufficiency is an extremely rare event in patients treated nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, and its detailed clinical characteristics remain unclear. The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal cell carcinoma (mRCC). A total of 49 consecutive patients with mRCC or unresectable renal cell carcinoma were treated with nivolumab at Kobe University Hospital between December 2016 and August 2018. Adrenal insufficiency occurred in 5 (10.2%) of these patients. We retrospectively collected the data of these 5 patients, including their clinical characteristics, clinical and laboratory findings of adrenal insufficiency, and the clinical outcome of nivolumab treatment. All cases were diagnosed with secondary adrenal insufficiency due to isolated hyposecretion of adrenocorticotropic hormone. Eosinophilia at the onset of symptoms was observed in 4 patients. No patients showed signs of hypophysitis on brain magnetic resonance imaging and the secretion of other pituitary hormones were normal in all cases. The conditions of all patients were improved by hydrocortisone replacement therapy at a physiological dose. Notably, all 5 patients showed a partial response to nivolumab and remained stable after the cessation of nivolumab. In conclusion, we described, for the first time, a case series of nivolumab-induced adrenal insufficiency in patients with mRCC. Our findings may be useful for the accurate diagnosis and the prompt treatment of this condition. In addition, there is a possibility that adrenal insufficiency may be associated with a favorable response to nivolumab in patients with mRCC.
    Jan. 2020, Journal of immunotherapy (Hagerstown, Md. : 1997), 43(1) (1), 38 - 42, English, International magazine
    [Refereed]
    Scientific journal

  • 神経温存ロボット支援腹腔鏡下前立腺全摘除術後における性機能の検討
    中野 雄造, 寺川 智章, 千葉 公嗣, 古川 順也, 重村 克巳, 原田 健一, 石村 武志, 日向 信之, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2019, 日本内視鏡外科学会雑誌, 24(7) (7), MO093 - 3, Japanese

  • 当院におけるアミノレブリン酸塩酸塩を併用した経尿道的膀胱腫瘍切除術の臨床検討
    大西 篤史, 寺川 智章, 千葉 公嗣, 古川 順也, 原田 健一, 重村 克巳, 日向 信之, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2019, 日本内視鏡外科学会雑誌, 24(7) (7), MO339 - 4, Japanese

  • Presurgical therapyにて病理学的に完全奏功を得た腎癌下大静脈腫瘍栓の1例
    戸邉 泰将, 寺川 智章, 松下 経, 古川 順也, 原田 健一, 石村 武志, 重村 克己, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Nov. 2019, 泌尿器科紀要, 65(11) (11), 486 - 486, Japanese

  • Okamura Y, Terakawa T, Sakamoto M, Bando Y, Suzuki K, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M
    UNLABELLED: Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. MATERIALS AND METHODS: We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. RESULTS: Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). CONCLUSION: Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.
    Nov. 2019, In vivo (Athens, Greece), 33(6) (6), 2013 - 2019, English, International magazine
    [Refereed]
    Scientific journal

  • Kotaro Suzuki, Tomoaki Terakawa, Katsumi Shigemura, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no longer recommended in the clinical guidelines of prostate cancer in light of the new hormonal and cytotoxic agents available, this therapy has proven beneficial for some patients with castration-resistant prostate cancer (CRPC). The objective of this study was to identify favorable subgroups for alternative anti-androgen therapy among CRPC patients. Eighty-eight consecutive CRPC patients treated with alternative anti-androgen therapy were included in this study. All patients were treated with bicalutamide in the initial maximum androgen blockade (MAB) and switched to flutamide in the subsequent alternative anti-androgen therapy, combined with a luteinizing hormone-releasing hormone analogue. Several clinical and pathological factors for predicting the prostate-specific antigen (PSA) decline and PSA progression-free survival (PSA-PFS) of alternative anti-androgen therapy were investigated. Of all patients, 45 (51.1%) patients showed ≥50% PSA decline. The median PSA-PFS was 7.5 months [95% confidence interval (CI), 5.7-10.3]. Notably, 15 (17.0%) patients had a PSA-PFS over 2 years. A multivariate analysis showed that ≥3 bone metastatic lesions and a duration <12 months of initial MAB were significant factors shortening the duration of PSA-PFS, with hazard ratios of 2.11 (95% CI, 1.23-3.62; P=0.007) and 2.08 (95% CI, 1.20-3.57; P=0.008), respectively. Patients without any of these factors had a median PSA-PFS of 22.8 months (95% CI, 6.7-48.8). The overall survival in patients with a ≥7.5-month PSA-PFS receiving alternative anti-androgen therapy was significantly longer than that of patients with a <7.5-month PSA-PFS (109.1 vs. 40.8 months; P<0.001). In conclusion, a longer duration of initial MAB and the absence of severe bone metastasis may predict a favorable response to alternative anti-androgen therapies in CRPC patients. Alternative anti-androgen therapy may still be beneficial for these patients, but this needs to be investigated further.
    Nov. 2019, Molecular and clinical oncology, 11(5) (5), 523 - 530, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 原田 健一, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 151 - 151, Japanese

  • 坂本 裕章, 福田 輝雄, 寺川 智章, 古川 順也, 原田 健一, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 152 - 152, Japanese

  • 桂 大希, 原田 健一, 岡田 桂輔, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 169 - 169, Japanese

  • 京野 成紀, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 175 - 175, Japanese

  • 転移性腎癌におけるニボルマブ関連副腎不全の臨床的検討
    鈴木 光太郎, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P35 - 7, English

  • 当院における進行性腎細胞癌に対するニボルマブの治療成績
    坂本 茉莉子, 白石 祐介, 脇田 直人, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P36 - 4, English

  • 転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
    白石 祐介, 古川 順也, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 重村 克己, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P40 - 2, English

  • 進行性腎細胞癌に対する一次治療におけるパゾパニブの有効性と安全性
    脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P40 - 6, English

  • 当院でのアラグリオを使用したTURBTの検討
    原 琢人, 脇田 直人, 白石 祐介, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P41 - 1, English

  • 腎癌下大静脈腫瘍塞栓に対して術前分子標的薬投与を行った際の手術成績の比較検討
    岡村 泰義, 寺川 智章, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P41 - 7, English

  • ロボット支援根治的前立腺全摘除術における拡大リンパ節郭清の検討
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P94 - 2, English

  • IO時代の腎癌治療の実臨床 神戸大学における進行性腎癌に対するニボルマブの臨床的検討
    原田 健一, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    (一社)腎癌研究会, Jul. 2019, 腎癌研究会会報, (49) (49), 30 - 30, Japanese

  • 下大静脈塞栓を有する腎癌患者に対する術前分子標的治療薬投与の有用性に関する検討
    寺川 智章, 岡村 泰義, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 山口 雷蔵, 藤澤 正人
    (一社)腎癌研究会, Jul. 2019, 腎癌研究会会報, (49) (49), 38 - 38, Japanese

  • 当院で経験した膀胱異物の3例
    高瀬 雄太, 小田 晃廉, 寺川 智章, 古川 順也, 原田 健一, 松下 経, 石村 武志, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, Jun. 2019, 泌尿器科紀要, 65(6) (6), 239 - 239, Japanese

  • Yasuyoshi Okamura, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Ichiro Nakamura, Takaaki Inoue, Takayoshi Ogawa, Masato Fujisawa
    BACKGROUND: Nomograms have been developed for the prediction of progression-free survival (PFS) and liver toxicity in patients with advanced renal cell carcinoma (RCC) who are treated with pazopanib. The objectives of this study were to review clinical outcomes, to perform an external validation of these nomograms and to develop a new nomogram in Japanese patients. METHODS: A retrospective chart review of 150 Japanese patients with advanced RCC who received pazopanib at Kobe University Hospital and affiliated hospitals from March 2014 to June 2017 was performed. We evaluated the clinical efficacy and safety of pazopanib using logistic regression analysis to analyze the prognostic factors for overall survival (OS) and PFS. For nomogram validation, concordance index (C-index) and calibration were used. RESULTS: The median PFS and OS in this study was 13.1 and 37.4 months, respectively. Multivariate analyses identified prognostic factors for OS (number of metastasis, white blood cell (WBC) count and lactate dehydrogenase) and PFS (number of metastasis, WBC count). The C-index of nomograms for 12-month PFS was 0.598. The C-index of nomograms for liver toxicity was 0.558. A new Nomogram for predicting 12-month PFS for patients who received pazopanib was developed and performed internal validation. The C-index of the nomogram was 0.768. CONCLUSION: The clinical effect and safety of pazopanib reported in this study was similar to previous studies. This study suggests careful application of nomograms to Japanese patients treated with pazopanib. We have developed a new nomogram for predicting 12-month PFS with pazopanib therapy from Japanese patients.
    Jun. 2019, International journal of clinical oncology, 24(6) (6), 698 - 705, English, Domestic magazine
    [Refereed]
    Scientific journal

  • 岡村 泰義, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 重村 克己, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    日本老年泌尿器科学会, May 2019, 日本老年泌尿器科学会誌, 32(1) (1), 187 - 187, Japanese

  • Zaeem Lone, Shelby Hall, Tomoaki Terakawa, Youssef E Ahmed, Ahmed S Elsayed, Naif Aldhaam, Paul R May, Austin Miller, Zhe Jing, Luciano Nunez Bragayrac, Hijab Khan, Jared Cohen, Adam Cole, Omer Rana, Renuka Kanapan, Christian Prechtl, Ahmed A Hussein, Khurshid A Guru
    Introduction: There is paucity of literature about the validation of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) surgical risk calculator for prediction of outcomes after robot-assisted radical cystectomy (RARC). We sought to evaluate the accuracy of the ACS NSQIP surgical risk calculator in the patients who underwent RARC at our institute. Methods: We retrospectively reviewed our prospectively maintained database for patients who underwent RARC between 2005 and 2017. Accuracy of the ACS NSQIP surgical risk calculator was assessed, by comparing the rate of actual complication events after surgery with the receiver operating characteristics curve analysis by calculating the fractional area under the curve (AUC) and the Brier score (BS). We utilized the code number 51595 and 51596 in the ACS NSQIP calculator for the patients undergoing radical cystectomy and reconstructed with the ileal conduit and neobladder, respectively. Results: A total of 462 patients were included in this study: 99 (22%) had diabetes, 302 (66%) had hypertension requiring medication, and 241 (52%) were classified as high American Society of Anesthesiologists (≥3) class. The actual observed rates of any complication and serious complications were 48% and 11%, vs 29% and 25% predicted by the ACS NSQIP, respectively. The actual mean length of hospital stay (10.6 ± 7.8 days) was longer compared with the predicted length (8.5 ± 1.6 days). AUC values were low and the BSs were high for any complication (AUC: 0.50 and BS: 0.29), serious complication (AUC: 0.53 and BS: 0.12), urinary tract infection (AUC: 0.61 and BS: 0.14), renal insufficiency (AUC: 0.64 and BS: 0.08), return to operation room (AUC: 0.58 and BS: 0.07), and early readmission (AUC: 0.55 and BS: 0.11, respectively). Conclusions: The ACS NSQIP calculator demonstrated low accuracy in predicting postoperative outcomes after RARC. These findings highlight the need for development of procedure- and technique-specific RARC calculators.
    May 2019, Journal of endourology, 33(5) (5), 383 - 388, English, International magazine
    [Refereed]

  • 淡明細胞型腎細胞癌に対するfirst-line Sunitinibの治療成績
    古川 順也, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 141, Japanese

  • 神戸大学における進行性腎癌に対する2nd lineアキシチニブの治療成績
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 146, Japanese

  • 神戸大学における進行性腎癌に対するニボルマブの臨床的検討
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 459, Japanese

  • ハイリスク前立腺癌に対するロボット根治的前立腺全摘除術の治療成績
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP2 - 097, Japanese

  • 転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の臨床的検討
    坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 069, Japanese

  • ニボルマブ関連内分泌異常に対する当科での取り組み
    原 琢人, 坂本 茉莉子, 坂東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 148, Japanese

  • 腎癌下大静脈腫瘍塞栓を有する患者に対して術前分子標的薬投与を行った際の手術成績の比較検討
    岡村 泰義, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 185, Japanese

  • Yusuke Shiraishi, Tomoaki Terakawa, Naoe Jimbo, Katsumi Shigemura, Nobuyuki Hinata, Masato Fujisawa
    Feb. 2019, International journal of urology : official journal of the Japanese Urological Association, 26(2) (2), 313 - 314, English, International magazine
    [Refereed]
    Scientific journal

  • 膀胱ヘルニアを合併した前立腺癌に対しロボット支援下前立腺全摘除術を施行した1例
    寺川 智章, 千葉 公嗣, 原田 健一, 重村 克己, 石村 武志, 日向 信之, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2018, 日本内視鏡外科学会雑誌, 23(7) (7), DP137 - 8, Japanese

  • High Expression of SLCO2B1 is Associated with Prostate Cancer Recurrence after Radical Prostatectomy
    Tomoaki Terakawa, Eriko Katsuta, Kazuaki Takabe, Yukari Bando, Takuto Hara, Koutarou Suzuki, Hiroyuki Momozono, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuuzou Nakano, Masato Fujisawa
    Oct. 2018, INTERNATIONAL JOURNAL OF UROLOGY, 25, 337 - 337, English
    [Refereed]

  • Kotaro Suzuki, Mariko Sakamoto, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    BACKGROUND/AIM: There is no definitive biomarker that predicts the effectiveness of abiraterone acetate. The objective of this study was to investigate whether dehydroepiandrosterone sulfate (DHEA-S) predicts the effectiveness of abiraterone acetate. MATERIALS AND METHODS: This study included a total of 28 consecutive patients. The optimal cutoff value of DHEA-S for predicting the PSA response was calculated by receiver operating characteristic (ROC) analysis. The Cox proportional hazards model was performed to determine the predictive factors for the susceptibility to abiraterone acetate. RESULTS: Serum DHEA-S at baseline intercorrelated with the PSA response (correlation coefficient: -0.516). The optimal cutoff value of serum DHEA-S at baseline was 47.4 ug/dl in predicting >50% PSA decline. Serum PSA and serum DHEA-S at baseline were identified as significant factors for predicting PSA progression-free survival (p=0.010 and p=0.003, respectively). CONCLUSION: Serum DHEA-S at baseline may be a biomarker for predicting the prognosis of CRPC patients treated with abiraterone acetate.
    Oct. 2018, Anticancer research, 38(10) (10), 5929 - 5935, English, International magazine
    [Refereed]
    Scientific journal

  • Tomoaki Terakawa, Ahmed A Hussein, Yukari Bando, Khurshid A Guru, Junya Furukawa, Katsumi Shigemura, Kenichi Harada, Nobuyuki Hinata, Yuzou Nakano, Masato Fujisawa
    The aim of this study was to investigate the clinical benefit of presurgical therapy with pazopanib in renal cell carcinoma (RCC) patients with a tumor thrombus extending to a high level in the vena cava. A retrospective review was performed for seven consecutive patients with RCC and tumor thrombus involving the vena cava above the hepatic vein (level 3-4, Mayo Clinic classification) treated with pazopanib without initial cytoreductive nephrectomy at our institution. The effect of pazopanib was assessed in terms of the primary site response, thrombus diameter, and height (before and after treatment) on computed tomography or MRI. The tumor thrombus level before the induction of pazopanib was 3 in one patient and 4 in the remaining six patients. After pazopanib, shrinkage of the primary site and thrombus diameter and length were observed in all patients except one (with a rhabdoid tumor). The mean decreases of primary tumor diameter, tumor thrombus diameter, and length were 14, 9, and 31 mm, respectively. The tumor thrombus level decreased in three (43%) patients and remained stable in the remaining patient. Our findings suggest that presurgical treatment with pazopanib may shrink the tumor thrombus and decrease the surgical invasiveness in RCC patients with a high-level tumor thrombus.
    Jul. 2018, Anti-cancer drugs, 29(6) (6), 565 - 571, English, International magazine
    [Refereed]
    Scientific journal

  • Michelle Whittum, Ahmed Aly Hussein, Youssef E Ahmed, Hijab Khan, Collin Krasowski, Neil B Huben, Paul R May, Tomoaki Terakawa, Qiang Li, Khurshid A Guru
    INTRODUCTION: We aimed to investigate patient and disease variables associated with gynecological organ invasion in females with bladder cancer at the time of robot-assisted radical cystectomy (RARC). METHODS: We conducted a retrospective review of female patients who underwent robot-assisted anterior pelvic exenteration (RAAE) between 2005 and 2016. Patients were divided into two groups: those with gynecological organ involvement at RAAE and those without. Data were reviewed for perioperative and pathological outcomes. Kaplan-Meier method was used to depict survival outcomes. Multivariable stepwise regression analysis was performed to identify predictors of gynecological organ involvement. RESULTS: A total of 118 female patients were identified; 17 (14%) showed evidence of gynecological organ invasion at RAAE. Patients with gynecological organ invasion had more lymphovascular invasion at transurethral resection of bladder tumour (TURBT) (82% vs. 46%; p=0.006), trigonal tumours at TURBT (59% vs. 18%; p=0.001), multifocal disease (65% vs. 33%; p=0.01), pN+ (71% vs. 22%; p<0.001), positive surgical margins (24% vs. 4%; p=0.02), and they less commonly demonstrated pure urothelial carcinoma at TURBT (18% vs. 66%; p<0.001). On multivariate analysis, significant predictors of gynecological organ invasion were pN positive disease (odds ratio [OR] 6.48; 95% confidence interval [CI] 1.64-25.51; p=0.008), trigonal tumour location (OR 5.72; 95% CI 1.39-23.61; p=0.02), and presence of variant histology (OR18.52; 95% CI 3.32-103.4; p=0.001). CONCLUSIONS: Patients with trigonal tumours, variant histology, and nodal involvement are more likely to have gynecological organs invasion at RAAE. This information may help improve counselling of patients and better identify candidates for gynecological organ-sparing cystectomy.
    May 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, English, International magazine
    [Refereed]

  • Tomoaki Terakawa, Eriko Katsuta, Li Yan, Nitesh Turaga, Kerry-Ann McDonald, Masato Fujisawa, Khurshid A Guru, Kazuaki Takabe
    Solute carrier organic anion (SLCO) gene families encode organic anion transport proteins, which are transporters that up-take a number of substrates including androgens. Among them, high expression of SLCO2B1 is known to associate with the resistance to androgen deprivation therapy in prostate cancer (PCa). We hypothesized that high expression of SLCO genes enhances PCa progression by promoting the influx of androgen. Here, we demonstrated the impact of the expression levels of SLCO2B1 on prognosis in localized PCa after radical prostatectomy (RP) utilizing 494 PCa cases in The Cancer Genome Atlas (TCGA). SLCO2B1 high expression group showed significantly worse Disease-free survival (DFS) after RP (p = 0.001). The expression level of SLCO2B1 was significantly higher in advanced characteristics including Gleason Score (GS ≤ 6 vs GS = 7; p = 0.047, GS = 7 vs GS ≥ 8; p = 0.002), pathological primary tumor (pT2 vs pT3/4; p < 0.001), and surgical margin status (positive vs negative; p = 0.013), respectively. There was a significant difference in DFS between these two groups only in GS ≥ 8 patients (p = 0.006). Multivariate analysis demonstrated that only SLCO2B1 expression level was an independent predictor for DFS after RP in GS ≥ 8. SLCO2B1 high expressed tumors in GS ≥ 8 not only enriched epithelial mesenchymal transition (EMT) related gene set, (p = 0.027), as well as Hedgehog (p < 0.001), IL-6/JAK/STAT3 (p < 0.001), and K-ras signaling gene sets (p < 0.001), which are known to promote EMT, but also showed higher expression of EMT related genes, including N-cadherin (p = 0.024), SNAIL (p = 0.001), SLUG (p = 0.001), ZEB-1 (p < 0.001) and Vimentin (p < 0.001). In conclusion, PCa with high expression of SLCO2B1 demonstrated worse DFS, which might be due to accelerated EMT.
    Mar. 2018, Oncotarget, 9(18) (18), 14207 - 14218, English, International magazine
    [Refereed]
    Scientific journal

  • Kenichi Harada, Yusuke Shiraishi, Kohtaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Takeshi Ishimura, Katsumi Shigemura, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    To investigate the efficacy and safety of first-line Pazopanib advanced or metastatic renal cell carcinoma (RCC): a single-institution study. (Patients and methods) We gathered 23 RCC patients treated between April 2014 and February 2018 in our institution and examined the treatments outcome and adverse events (AEs). (Results) Their risk criteria were categorized as follows: Favorable (n=2), Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion (IMDC). Median progression free survival (PFS) was 8.6 months and median overall survival (OS) was unreached. Best response (BR) of Pazopanib was partial response (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting (n=1) and bowel bleeding (n=1). (Conclusion) The fist-line pazopanib demonstrated good clinical benefit with well-tolerance.
    2018, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 109(4) (4), 216 - 219, Japanese, Domestic magazine
    [Refereed]

  • Yukari Bando, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
    The purpose of this study was to evaluate the efficacy of cabazitaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) after sequential therapy with docetaxel (DTX) and single or dual regimens of novel androgen receptor-axis-targeted (ARAT) agents. We retrospectively reviewed 84 consecutive patients treated with cabazitaxel at Kobe University Hospital and related hospitals from September 2014 to September 2016. The association of each prognostic parameter with progression-free survival (PFS) was evaluated, including the sequence of therapy. Patients were divided according to their treatment after receiving cabazitaxel as follows: group 1 (after DTX and single regimen of novel ARAT agent) and group 2 (after DTX and dual novel ARAT agents). Median PFS for cabazitaxel treatment was 10.3 months (range 4.5-14.2 months). Prostate-specific antigen (PSA) response rates (≥30%) were 46.8 and 46.1% in group 1 and group 2, respectively [p = 0.96, hazard ratio (HR) 1.02, 95% confidence interval (CI) 0.57-1.80]. PSA response rates (≥50%) were 43.8 and 26.9% in patients of group 1 and group 2, respectively (p = 0.18, HR 1.54, 95% CI 0.78-3.04). Univariate analysis revealed that PFS for cabazitaxel treatment was significantly associated with baseline alkaline phosphatase, bone metastasis, and prior sequential therapy. Multivariate analysis revealed that bone metastasis and prior sequential therapy were independently associated with PFS. Prior sequential therapy with single regimen or dual regimens of novel ARAT agents was independently associated with PFS of patients with mCRPC treated with cabazitaxel. The effect of cabazitaxel after the administration of DTX and single novel ARAT agent was more sustained.
    Aug. 2017, Medical oncology (Northwood, London, England), 34(9) (9), 163 - 163, English, International magazine
    [Refereed]
    Scientific journal

  • Nobuyuki Hinata, Ahmed Aly Hussein, Tomoaki Terakawa, Yukari Bando, Gen Murakami, Khurshid Guru, Masato Fujisawa
    Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E1092 - E1092, English
    [Refereed]

  • Nobuyuki Hinata, Ahmed Aly Hussein, Tomoaki Terakawa, Yukari Bando, Gen Murakami, Khurshid Guru, Masato Fujisawa
    Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E530 - E530, English
    [Refereed]

  • Nobuyuki Hinata, Yukari Bando, Akira Miyazaki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa
    Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E917 - E917, English
    [Refereed]

  • Hideaki Miyake, Takuto Hara, Tomoaki Terakawa, Seiichiro Ozono, Masato Fujisawa
    BACKGROUND: The objective of the present study was to comprehensively compare the clinical outcomes between abiraterone acetate (AA) and enzalutamide (Enz) in Japanese patients with docetaxel-naive metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The present study retrospectively included 280 consecutive mCRPC patients, consisting of 113 and 167 who had received AA and Enz, respectively, without previous treatment with docetaxel. RESULTS: Of the several baseline characteristics examined, some parameters, including performance status (PS), prostate-specific antigen (PSA) value, and incidence of lymph node metastasis, significantly favored the Enz over the AA group. The PSA response rate in the Enz group was significantly greater than that in the AA group, and the PSA progression-free survival in the Enz group was significantly superior to that in the AA group. Multivariate analyses of several parameters identified the following independent predictors of PSA progression-free survival: duration of androgen deprivation therapy and PS for the AA group, age and PS for the Enz group, and PS but not the introduced agent (ie, AA vs. Enz) for the overall patients. The common adverse events observed in the present series were fatigue (19.4%) and liver toxicity (11.5%) in the AA group and fatigue (32.3%) and appetite loss (19.2%) in the Enz group. In addition, the proportion of patients with adverse events grade ≥ 3 in the Enz group (11.4%) was significantly greater than that in the AA group (4.4%). CONCLUSION: Both AA and Enz were effective and tolerable for patients with docetaxel-naive mCRPC in the routine clinical setting.
    Apr. 2017, Clinical genitourinary cancer, 15(2) (2), 313 - 319, English, International magazine
    [Refereed]

  • The effects of paclitaxel and carboplatin as a second-line chemotherapy against advanced urothelial carcinoma after failure of first-line gemcitabine and cisplatin therapy
    Tomoaki Terakawa, Masato Fujisawa, Takaaki Inoue, Yuzo Nakano, Nobuyuki Hinata, Kenichi Harada, Junya Furukawa, Masayuki Nishikawa, Akira Miyazaki, Satoshi Imai, Hiroyuki Momozono
    Jul. 2016, INTERNATIONAL JOURNAL OF UROLOGY, 23, 40 - 40, English
    [Refereed]

  • Interposition of novel nerve-regeneration conduit after non nerve-sparing radical prostatectomy: Short-term results from a prospective trial
    Nobuyuki Hinata, Masato Fujisawa, Yuzo Nakano, Kei Matsushita, Takeshi Ishimura, Kenichi Harada, Junya Furukawa, Tomoaki Terakawa, Koji Chiba
    Jul. 2016, INTERNATIONAL JOURNAL OF UROLOGY, 23, 78 - 78, English
    [Refereed]

  • [Ligand-independent activation of androgen receptor].
    Tomoaki Terakawa, Hideaki Miyake, Masato Fujisawa
    May 2016, Nihon rinsho. Japanese journal of clinical medicine, 74 Suppl 3, 106 - 10, Japanese, Domestic magazine
    [Refereed]

  • Junya Furukawa, Masatomo Nishikawa, Tomoaki Terakawa, Koji Chiba, Katsumi Shigemura, Ken-ichi Harada, Nobuyuki Hinata, Takeshi Ishimura, Kei Matsushita, Yuzo Nakano, Hideaki Miyake, Kazushi Tanaka, Masato Fujisawa
    Apr. 2016, JOURNAL OF UROLOGY, 195(4) (4), E566 - E566, English
    [Refereed]

  • Tomoaki Terakawa, Hideaki Miyake, Naoki Yokoyama, Akira Miyazaki, Hiroyuki Tanaka, Takaaki Inoue, Masato Fujisawa
    OBJECTIVE: The objective was to investigate the efficacy and tolerability of combined therapy with paclitaxel and carboplatin (TC) in patients with advanced urothelial carcinoma after the failure of first-line chemotherapy with gemcitabine and cisplatin (GC). PATIENTS AND METHODS: This was a retrospective study including a total of 16 patients with advanced urothelial carcinoma who showed evidence of progressive and/or recurrent disease after first-line therapy with GC and subsequently received second-line chemotherapy consisting of paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5). TC therapy was repeated every 3 weeks and was continued until disease progression or intolerable toxicity was observed. RESULTS: The baseline patient characteristics were rather favorable; only 3 of 16 patients had liver metastases and 7 patients had an Eastern Cooperative Oncology Group performance status of 0. Of these, response to TC therapy was achieved in 5 (31.3%), including 2 with complete and 3 with partial response. The median progression-free and overall survival times in the 16 patients were 7.9 and 17.3 months, respectively. CONCLUSIONS: TC therapy appeared to show modest activity with acceptable tolerability in patients refractory to GC therapy; therefore, TC chemotherapy might be considered as an alternative option as a second-line regimen for advanced urothelial carcinoma following GC therapy.
    2014, Urologia internationalis, 92(2) (2), 180 - 5, English, International magazine
    [Refereed]

  • Hideaki Miyake, Iori Sakai, Tomoaki Terakawa, Ken-ichi Harada, Masato Fujisawa
    OBJECTIVES: To retrospectively review the oncologic outcomes of docetaxel-based chemotherapy in Japanese men with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: This study included 257 consecutive Japanese patients with mCRPC who were treated with docetaxel-based chemotherapy between April 2007 and March 2010. The prognostic significance of several clinicopathologic factors in these patients was analyzed. RESULTS: In these 257 patients, the median age and serum value of prostate-specific antigen (PSA) prior to docetaxel-based chemotherapy were 72 years and 43.0 ng/ml, respectively. Of these patients, 64 (24.9%) and 193 (75.1%) received docetaxel as a weekly (30 mg/m(2)) and 3-weekly (70-75 mg/m(2)) regimen, respectively, and estramustine (EM) was administered in combination with docetaxel in 137 (53.3%). PSA decline was observed in 205 patients (79.8%), including 143 (55.6%) achieving PSA decline ≥ 50%. The median progression-free survival and overall survival (OS) were 4.3 and 25.4 months, respectively. Of several factors examined, univariate analysis identified performance status (PS), PSA value, significant clinical pain, bone metastasis, prior treatment with EM, treatment cycle, and PSA response as significant predictors of OS, of which only PS, significant clinical pain, prior treatment with EM, treatment cycle, and PSA response appeared to be independently related to OS on multivariate analysis. Furthermore, there were significant differences in OS according to positive numbers of these 5 independent risk factors. CONCLUSIONS: Oncologic outcomes in Japanese mCRPC patients receiving docetaxel-based chemotherapy is generally favorable, and the risk stratification presented in this study may contribute to precisely predicting the prognosis of such patients.
    Aug. 2013, Urologic oncology, 31(6) (6), 733 - 8, English, International magazine
    [Refereed]

  • Yuji Kusuda, Hideaki Miyake, Tomoaki Terakawa, Yutaka Kondo, Tetsuya Miura, Masato Fujisawa
    OBJECTIVES: To retrospectively assess the significance of gender as a predictor of intravesical recurrence following nephroureterectomy for urothelial carcinoma of the upper urinary tract (UC-UUT). MATERIALS AND METHODS: This study included 502 consecutive patients (360 male and 142 female) who were diagnosed as having clinically localized UC-UUT and underwent nephroureterectomy. Clinicopathologic outcomes of these patients were analyzed focusing on the impact of gender. RESULTS: The incidence of intravesical recurrence in male patients (41.9%) was significantly greater than that in female patients (27.5%). Despite the lack of significant differences in cancer-specific and overall survivals with respect to gender, the intravesical recurrence-free survival in male patients was significantly worse than that in female patients. Of several parameters examined, univariate analysis identified gender, tumor site, and tumor focality as significant predictors of intravesical recurrence following nephroureterectomy. Of these, only gender and tumor site appeared to be independently associated with intravesical recurrence-free survival on multivariate analysis. Furthermore, there was a significant difference in intravesical recurrence-free survival according to positive numbers of these two independent factors; that is, intravesical recurrence occurred in 12 of 55 patients who were negative for both risk factors (21.8%), 96 of 280 positive for a single risk factor (34.3%), and 82 of 167 positive for both risk factors (49.1%). CONCLUSIONS: The incidence of intravesical recurrence following nephroureterectomy for UC-UUT is comparatively high. Therefore, it would be potentially important to perform careful follow-up targeting intravesical recurrence for such patients, particularly for male patients and/or patients with tumor located at the ureter.
    Aug. 2013, Urologic oncology, 31(6) (6), 899 - 903, English, International magazine
    [Refereed]

  • Tomoaki Terakawa, Hideaki Miyake, Yuji Kusuda, Masato Fujisawa
    OBJECTIVES: To investigate the expression levels of multiple molecular markers in radical nephrectomy specimens from patients with metastatic renal cell carcinoma (RCC) treated with sunitinib in order to identify factors predicting susceptibility to this agent. MATERIALS AND METHODS: This study included a total of 40 consecutive patients undergoing radical nephrectomy, who were diagnosed as having metastatic RCC and subsequently treated with sunitinib. Expression levels of 10 molecular markers, including Bcl-2, Bcl-xL, Bax, phosphorylated Akt, p44/42 mitogen-activated protein kinase, and signal transducers and activation of transcription 3, vascular endothelial growth factor receptor (VEGFR)-1 and -2, and platelet-derived growth factor receptor-α and -β, in primary RCC specimens were assessed by immunohistochemical staining. RESULTS: Of several factors examined, tumor grade and the expression level of VEGFR-2 were shown to have significant impacts on response to sunitinib in these 40 patients. Progression-free survival (PFS) was significantly associated with the expression levels of VEGFR-2 in addition to tumor grade, performance status, Memorial Sloan-Kettering Cancer Center risk classification and pretreatment c-reactive protein level on univariate analysis. Of these significant factors, only VEGFR-2 expression appeared to be independently related to PFS on multivariate analysis. In fact, PFS in patients with strong expression of VEGFR-2 was significantly favorable compared with that in those with weak expression of VEGFR-2. CONCLUSIONS: Collectively, these findings suggest that it would be useful to consider expression levels of potential molecular markers, particularly VEGFR-2, as well as conventional clinical parameters to select metastatic RCC patients likely to benefit from treatment with sunitinib.
    May 2013, Urologic oncology, 31(4) (4), 493 - 8, English, International magazine
    [Refereed]

  • H. Miyake, T. Terakawa, J. Furukawa, M. Muramaki, M. Fujisawa
    Jul. 2012, EJSO, 38(7) (7), 630 - 636, English
    [Refereed]
    Scientific journal

  • 根治的腎摘除術を施行した静脈内腫瘍塞栓を伴う腎細胞癌症例の予後規定因子としての腫瘍塞栓進展レベルの意義
    Miyake Hideaki, Terakawa Tomoaki, Furukawa Jyunya, Muramaki Mototsugu, Fujisawa Masato
    Jun. 2012, 腎癌研究会会報, (42号) (42号), 47, Japanese
    Research society

  • Ken-Ichi Harada, Hideaki Miyake, Tomoaki Terakawa, Masato Fujisawa
    BACKGROUND: The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB). PATIENTS AND METHODS: This study included 48 patients with NMIUCB following complete transurethral resection who were randomly divided into 27 receiving UFT therapy (group A) and 21 without any adjuvant therapies (group B). Serum levels of GBL, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8 were measured. RESULTS: There was no significant difference in the intravesical recurrence-free survival between groups A and B. Despite the lack of significant differences in serum levels of vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8, serum GBL in group A was significantly greater than in group B. Multivariate analysis identified tumor size as an independent predictor of intravesical recurrence irrespective of the other factors examined. CONCLUSIONS: Despite the significant induction of GBL, adjuvant UFT therapy failed to show a preventive effect on intravesical recurrence of NMIUCB. Therefore, we should consider enhancing the anti-angiogenic effect of GBL using an alternative administration schedule of UFT.
    May 2012, Current urology, 6(1) (1), 27 - 32, English, International magazine
    [Refereed]

  • Mototsugu Muramaki, Hideaki Miyake, Tomoaki Terakawa, Masafumi Kumano, Iori Sakai, Masato Fujisawa
    Mar. 2012, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 30(2) (2), 161 - 166, English
    [Refereed]
    Scientific journal

  • Mototsugu Muramaki, Hideaki Miyake, Tomoaki Terakawa, Yuji Kusuda, Masato Fujisawa
    OBJECTIVE: To investigate the impact of the expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract (UC-UUT) on the probability of intra- and extravesical disease recurrence in patients undergoing nephroureterectomy. METHODS: This study included 59 consecutive patients diagnosed as having clinically localized UC-UUT who underwent nephroureterectomy. Expression levels of E-cadherin and N-cadherin in resected specimens from these patients were measured by immunohistochemical staining. RESULTS: In this series, intra- and extravesical recurrence occurred in 20 (33.9%) and 19 (32.2%) patients, respectively. Both intra- and extravesical recurrence-free survivals significantly favored patients with positive E-cadherin or negative N-cadherin expression compared with those of patients with reduced E-cadherin or positive N-cadherin expression, respectively. Univariate analysis identified pathologic T stage, multifocality, and N-cadherin expression as significant predictors of intravesical recurrence, of which multifocality and N-cadherin expression were independently related to intravesical recurrence-free survival on multivariate analysis. Furthermore, pathologic T stage, grade, lymph node metastasis, E-cadherin expression, and N-cadherin expression were significantly associated with extravesical recurrence-free survival on univariate analysis. Of these significant factors, pathologic T stage, grade, lymph node metastasis, and N-cadherin expression were shown to be independent predictors of extravesical recurrence on multivariate analysis. CONCLUSION: These findings suggest that expression profiles of E-cadherin and N-cadherin, particularly the gain of N-cadherin rather than loss of E-cadherin expression, in UC-UUT appeared to be significantly associated with disease recurrence after nephroureterectomy.
    Dec. 2011, Urology, 78(6) (6), 1443.e7-12, English, International magazine
    [Refereed]

  • Hideaki Miyake, Mototsugu Muramaki, Iori Sakai, Tomoaki Terakawa, Yuji Kusuda, Yuji Yamada, Kazuki Yamanaka, Masato Fujisawa
    Nov. 2011, Current Urology, 5(3) (3), 145 - 150, English
    [Refereed]
    Scientific journal

  • Atsushi Takenaka, Isao Hara, Hideo Soga, Iori Sakai, Tomoaki Terakawa, Mototsugu Muramaki, Hideaki Miyake, Kazushi Tanaka, Masato Fujisawa
    INTRODUCTION: We analyzed the general health QOL (GH-GOL), urinary QOL, and sexual QOL in patients with orthotopic neobladder who were followed for more than 5 years. MATERIALS AND METHODS: Eighty-six (male 78, female 8) patients who underwent orthotopic neobladder and followed for more than 5 years were enrolled in this study. QOL regarding general health and urinary function were surveyed by SF-36 and ICSmaleSF, respectively. Sexual function was assessed by International Index of Erectile Function (IIEF-5). Satisfaction with urinary and sexual function was evaluated by visual analogue scale (VAS). RESULTS: On overall analysis by SF-36, 2 categories (role-physical functioning and role-emotional functioning) showed significantly lower scores, although bodily pain showed a better than average score for Japanese people of the same age. While patients who required clean intermittent catheterizaion (CIC) or had daytime incontinence presented worse scores in several categories on SF-36, the presence of enuresis did not affect SF-36 score. ICSmaleSF survey showed that voiding symptoms significantly impaired QOL in patients who required CIC and incontinence symptoms significantly impaired QOL in patients who had daytime incontinence and enuresis. With regard to sexual function, most patients (88%) had lost sexual function. On VAS, satisfaction with urinary function was 5.63, and sexual function was only 0.98. CONCLUSIONS: Although GH-QOL was generally well maintained, the presence of CIC or daytime incontinence impaired GH-QOL. Most were not satisfied with their level of sexual function 5 years after orthotopic neobladder construction.
    Sep. 2011, International urology and nephrology, 43(3) (3), 749 - 54, English, International magazine
    [Refereed]
    Scientific journal

  • Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA.
    Tomoaki Terakawa, Hideaki Miyake, Masafumi Kumano, Masato Fujisawa
    The objective of this study was to investigate the inhibitory effects of Aurora-A expression on the growth and chemosensitivity of Caki-2 cells in human renal cell carcinoma (RCC). Caki-2 cells were established, in which an expression vector containing short hairpin RNA (shRNA) targeting Aurora-A was introduced (Caki-2/sh-A). The growth and sensitivity of chemotherapeutic agents in Caki-2/sh-A cells were compared to those in Caki-2 cells transfected with control vector alone (Caki-2/C). The expression levels of both Aurora-A mRNA and protein in Caki-2/sh-A cells were less than 10% of those in Caki-2/C cells. The in vitro growth of Caki-2/sh-A cells was significantly inferior to that of Caki-2/C cells, and the proportion of Caki-2/sh-A cells in the G2-M phase was significantly greater compared to that of Caki-2/C cells. In addition, the expression level of Bax in Caki-2/sh-A cells was significantly higher as compared to that in Caki-2/C cells, while phosphorylated Akt in Caki-2/sh-A cells was markedly down-regulated compared to that in Caki-2/C cells. Among several chemotherapeutic agents examined, the most significant difference between Caki-2/sh-A and Caki-2/C cells was observed in the sensitivity to docetaxel. Thus, the IC(50) value of docetaxel in Caki-2/sh-A cells was decreased by approximately 90% compared to that in Caki-2/C cells. Treatment of Caki-2/sh-A cells, but not Caki-2/C ones, with 5 nM docetaxel resulted in the induction of apoptotic cell death accompanying the induction of p53. The findings suggest that the suppression of Aurora-A expression using shRNA is a useful therapeutic strategy against RCC through growth inhibition as well as enhanced chemosensitivity.
    Jul. 2011, Oncology letters, 2(4) (4), 713 - 717, English, International magazine
    [Refereed]

  • [The efficacy of PSA related parameters].
    Tomoaki Terakawa, Hideaki Miyake, Masato Fujisawa
    Jun. 2011, Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 5, 250 - 3, Japanese, Domestic magazine
    [Refereed]

  • Iori Sakai, Hideaki Miyake, Tomoaki Terakawa, Masato Fujisawa
    The objective of the present study was to investigate the inhibitory effects of interleukin-6 (IL-6) secretion by androgen-independent human prostate cancer PC3 cells on their growth and chemosensitivity. In this study, we established PC3 in which the expression vector containing short hairpin RNA (shRNA) targeting IL-6 was introduced (PC3/sh-IL6). Changes in the growth and sensitivity to docetaxel in PC3/sh-IL6 were compared with those in PC3 transfected with control vector alone (PC3/Co). Concentration of IL-6 in the culture supernatant from PC3/sh-IL6 was approximately 20% of that from PC3/Co. Both in vitro and in vivo, the growth of PC3/sh-IL-6 was significantly inferior to that of PC3/Co, accompanying downregulation of Bcl-2, Bcl-xL, phosphorylated Akt, p44/42 mitogen-activated protein kinase, and signal transducers and activation of transcription 3 in PC3/sh-IL-6 compared with that in PC3/Co. Despite the higher sensitivity of PC3/sh-IL6 to docetaxel than that of PC3/Co, the secretion of IL-6 by both cell lines was increased after treatment with docetaxel due to the formation of positive autocrine loops between these cell lines and NFκB signaling pathways. Furthermore, combined treatment with the proteasome inhibitor bortezomib, which completely inhibited the docetaxel-induced IL-6 secretion via the inactivation of NFκB signaling, resulted in the marked sensitization of these cell lines to docetaxel both in vitro and in vivo. These findings suggest that suppressed IL-6 secretion using shRNA, either alone or in combination with docetaxel and bortezomib, could be a useful therapeutic strategy against androgen-independent prostate cancer.
    Apr. 2011, Cancer science, 102(4) (4), 769 - 75, English, International magazine
    [Refereed]

  • Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature.
    Yuji Kusuda, Hideaki Miyake, Tomoaki Terakawa, Junya Furukawa, Mototsugu Muramaki, Masato Fujisawa
    The present study reports our experience with five renal cell carcinoma (RCC) patients with brain metastases treated with sunitinib and radiotherapy. All patients had undergone radical nephrectomy. Before treatment with sunitinib, radiotherapy for brain metastases, either by gamma-knife surgery or whole brain radiation, was carried out. After treatment with sunitinib, shrinkage of brain metastases was achieved in all patients with complete response, partial response and stable disease in two, one and two patients, respectively. Although progression of brain metastases occurred in four of the five patients, additional gamma-knife surgery was effective in three patients. Over a 12.5-month follow up, four patients, including three who maintained their best response, remained alive. The remaining one patient died of disease progression. Despite the observation of several adverse events after treatment with sunitinib, there was no intracerebral hemorrhage in any patient. These findings suggest that sunitinib combined with radiation therapy can be safely carried out in RCC patients with brain metastases and provides a favorable prognosis in these cases. However, considering their frequent progression, it would be important to carry out careful follow up for these patients by focusing on the control of brain metastases.
    Apr. 2011, International journal of urology : official journal of the Japanese Urological Association, 18(4) (4), 326 - 9, English, International magazine
    [Refereed]

  • 酒井 伊織, 寺川 智章, 古川 順也, 原田 健一, 楠田 雄司, 村蒔 基次, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 348 - 348, Japanese

  • 三宅 秀明, 寺川 智章, 酒井 伊織, 古川 順也, 原田 健一, 楠田 雄司, 村蒔 基次, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 349 - 349, Japanese

  • 田中 一志, 中野 雄造, 山口 耕平, 寺川 智章, 酒井 伊織, 古川 順也, 楠田 雄司, 石村 武志, 村蒔 基次, 原口 貴裕, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 513 - 513, Japanese

  • 古川 順也, 寺川 智章, 酒井 伊織, 原田 健一, 楠田 雄司, 村蒔 基次, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 410 - 410, Japanese

  • 原田 健一, 寺川 智章, 酒井 伊織, 古川 順也, 楠田 雄司, 村蒔 基次, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 371 - 371, Japanese

  • 楠田 雄司, 寺川 智章, 酒井 伊織, 原田 健一, 古川 順也, 村蒔 基次, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 355 - 355, Japanese

  • 寺川 智章, 酒井 伊織, 古川 順也, 原田 健一, 楠田 雄司, 村蒔 基次, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 354 - 354, Japanese

  • 村蒔 基次, 寺川 智章, 酒井 伊織, 古川 順也, 原田 健一, 楠田 雄司, 三宅 秀明, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2011, 日本泌尿器科学会雑誌, 102(2) (2), 501 - 501, Japanese

  • Junya Furukawa, Hideaki Miyake, Tomoaki Terakawa, Iori Sakai, Mototsugu Muramaki, Atsushi Takenaka, Masato Fujisawa
    Dec. 2010, Current Urology, 4(4) (4), 188 - 192, English
    [Refereed]
    Scientific journal

  • The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
    Tomoaki Terakawa, Hideaki Miyake, Masafumi Kumano, Iori Sakai, Masato Fujisawa
    The objective of this study was to assess the effect of antiandrogen on the activation of mutated androgen receptor (AR) and its signaling pathway in prostate cancer. We transfected the AR gene with a point mutation at codon 741 (tryptophan to leucine; W741L) into human androgen-independent prostate cancer PC3 cells lacking the expression of AR, and established PC3 cells overexpressing mutant type AR (PC3/W741L). Changes in the phenotype in these cells were compared to those in PC3 cells transfected with wild- type AR (PC3/Wild) and control vector alone (PC3/Co). There was no significant differences in the growth among PC3/Co, PC3/Wild and PC3/W741L cells. A transactivation assay using these cells showed that bicalutamide activated W741L mutant type AR, but not wild-type AR, while hydroxyflutamide failed to activate either type of ARs. Treatment with specific inhibitors of the MAPK or STST3 pathway (UO126 or AG490, respectively), in contrast to treatment with the Akt pathway inhibitor LY294002, significantly inhibited the dihydrotestosterone-induced activation of both wild-type and mutant ARs; however, activation of W741L mutant AR by bicalutamide was significantly inhibited by treatment with UO126, in contrast to treatment with AG490 or LY294002. Furthermore, treatment of PC3/W741L with bicalutamide, in contrast to treatment with hydroxyflutamide, resulted in significant upregulation of phosphorylated p44/42 MAPK. These findings suggest that the MAPK pathway might be involved in the activation of the AR with a point mutation at codon 741 induced by treatment with the antiandrogen bicalutamide.
    Nov. 2010, Oncology reports, 24(5) (5), 1395 - 9, English, International magazine
    [Refereed]

  • Tomoaki Terakawa, Hideaki Miyake, Mototsugu Muramaki, Atsushi Takenaka, Masato Fujisawa
    The objective of the present study was to assess the use of salvage chemotherapy using methotrexate, etoposide and actinomycin D (MEA) in men with nonseminomatous germ cell tumor (NSGCT) with a choriocarcinoma component. Nine patients were included. They had initially received bleomycin, etoposide and cisplatin, and high-dose ifosfamide, carboplatin and etoposide as induction chemotherapies. However, they failed to achieve the normalization of ß-human chorionic gonadotropin (ß-HCG). Therefore, MEA therapy (methotrexate: 450 mg/body on day 1, actinomycin D: 0.5 mg/body on days 1–5, etoposide: 100 mg/body on days 1–5) was subsequently administered. After MEA therapy (median: 3 cycles), serum ß-HCG was normalized in five of the nine patients. Of these five, three achieved long-term disease-free survival and one died of disease unrelated to NSGCT, whereas the remaining patient developed disease recurrence and died of disease progression. All four patients who failed to achieve the normalization of ß-HCG died of disease progression. Although several severe toxicities greater than grade 3, which were mainly associated with bone marrow suppression, occurred in all patients, there was no treatment-related death. Considering the current outcomes, MEA regimen could be an attractive option as a salvage chemotherapy for metastatic NSGCT patients with a choriocarcinoma component showing resistance to intensive conventional chemotherapies.
    Oct. 2010, International journal of urology : official journal of the Japanese Urological Association, 17(10) (10), 881 - 5, English, International magazine
    [Refereed]

  • Iori Sakai, Hideaki Miyake, Tomoaki Terakawa, Mototsugu Muramaki, Atsushi Takenaka, Masato Fujisawa
    Sep. 2010, Current Urology, 4(3) (3), 125 - 130, English
    [Refereed]
    Scientific journal

  • Masafumi Kumano, Hideaki Miyake, Tomoaki Terakawa, Junya Furukawa, Masato Fujisawa
    OBJECTIVES: To investigate the inhibitory effects of Aurora-A expression in prostate cancer cells on their growth and chemosensitivity. PATIENTS AND METHODS: Aurora-A expression in radical prostatectomy specimens obtained from 193 patients were evaluated by immunohistochemical staining. We then established PC3 cells in which the expression vector containing short-hairpin RNA (shRNA) targeting Aurora-A was introduced (PC3/sh-A). The growth and the sensitivity to docetaxel in PC3/sh-A were compared with those in PC3 transfected with control vector alone (PC3/C). RESULTS: Immunohistochemistry showed that there were various levels of Aurora-A expression in most prostate cancer tissues, and the expression levels of Aurora-A in prostate cancer were significantly related to Gleason score. Expression levels of both Aurora-A mRNA and protein in PC3/sh-A were approximately 20% of those in PC3/C. In vitro growth of PC3/sh-A was significantly worse than that of PC3/C, and the proportion of PC3/sh-A in the G2-M phase was significantly greater than that of PC3/C. The 50% inhibitory concentration of docetaxel in PC3/sh-A decreased by 67% compared with that in PC3/C. Tumour volume in nude mice injected with PC3/sh-A was significantly smaller than that with PC3/C. Furthermore, treatment of nude mice bearing PC3/sh-A tumour with docetaxel (10 mg/kg, once weekly for 4 weeks) achieved a synergistic cytotoxic effect, despite the lack of an enhanced antitumour effect of docetaxel on PC3/C tumours. CONCLUSIONS: The suppression of Aurora-A using shRNA could be a useful therapeutic strategy against androgen-independent prostate cancer, through growth inhibition as well as enhanced chemosensitivity.
    Jul. 2010, BJU international, 106(1) (1), 121 - 7, English, International magazine
    [Refereed]

  • 楠田 雄司, 寺川 智章, 酒井 伊織, 村蒔 基次, 三宅 秀明, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 307 - 307, Japanese

  • 三宅 秀明, 寺川 智章, 酒井 伊織, 楠田 雄司, 村蒔 基次, 武中 篤, 近藤 有, 井上 隆朗, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 306 - 306, Japanese

  • 酒井 伊織, 寺川 智章, 楠田 雄司, 村蒔 基次, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 292 - 292, Japanese

  • 寺川 智章, 酒井 伊織, 楠田 雄司, 村蒔 基次, 三宅 秀明, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 291 - 291, Japanese

  • 田中 一志, 山口 耕平, 寺川 智章, 兵頭 洋二, 村蒔 基次, 石村 武志, 原口 貴裕, 中野 雄造, 三宅 秀明, 竹田 雅, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 352 - 352, Japanese

  • 村蒔 基次, 酒井 伊織, 寺川 智章, 楠田 雄司, 三宅 秀明, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 277 - 277, Japanese

  • 武中 篤, 小川 悟史, 寺川 智章, 酒井 伊織, 石村 武志, 村蒔 基次, 原口 貴裕, 三宅 秀明, 曽我 英雄, 田中 一志, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 165 - 165, Japanese

  • 武中 篤, 寺川 智章, 酒井 伊織, 楠田 雄司, 村蒔 基次, 三宅 秀明, 田中 一志, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 147 - 147, Japanese

  • T. Terakawa, H. Miyake, J. Furukawa, S. L. Ettinger, M. E. Gleave, M. Fujisawa
    Nov. 2009, BRITISH JOURNAL OF CANCER, 101(10) (10), 1731 - 1739, English
    [Refereed]
    Scientific journal

  • Atsushi Takenaka, Hideo Soga, Tomoaki Terakawa, Masafumi Kumano, Junya Furukawa, Mototsugu Muramaki, Toshifumi Kurahashi, Hideaki Miyake, Kazushi Tanaka, Nozomu Yamanaka, Masato Fujisawa
    OBJECTIVE: To compare the voiding status in elderly patients (aged >or=80 years) with that in younger patients undergoing orthotopic neobladder substitution during long-term survival. PATIENTS AND METHODS: The voiding status was assessed in 111 patients (ileal neobladder in 62, ascending colonic neobladder in 14, sigmoid colonic neobladder in 21 and ileocolonic neobladder in 14) who lived for >5 years after radical cystectomy with an orthotopic neobladder, using a self-completed questionnaire and uroflowmetry. According to the age at the time of these assessments, patients were divided into two groups (group 1, <80 years, 94; group 2, >or=80 years, 17). The voiding status was compared between the groups. RESULTS: In all, 78 patients (92%) in group 1 and 16 (94%) in group 2 were capable of spontaneous voiding. In group 1 and 2, respectively, daytime continence was achieved by 67 (74%) and 12 (75%) patients, but night-time continence was achieved by 54 (60%) and six (38%), although the difference was not statistically significant. In groups 1 and 2, respectively, the median maximum flow rate was 13.3 and 11.7 mL/s and the median postvoid residual urine volume was 19 and 18 mL. The only statistically significant difference was for voiding posture, assessed in men. CONCLUSIONS: There was no significant difference in voiding status of patients with orthotopic neobladders except for voiding posture between patients aged <80 or carefully selected elderly patients aged >or=80 years during long-term survival. However, night-time continence might be clinically worse in the elderly than in the younger group.
    Apr. 2009, BJU international, 103(7) (7), 927 - 30, English, International magazine
    [Refereed]

  • Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy.
    Tomoaki Terakawa, Hideaki Miyake, Toshifumi Kurahashi, Junya Furukawa, Atsushi Takenaka, Masato Fujisawa
    OBJECTIVE: To compare the usefulness between real-time reverse transcriptase polymerase chain reaction (RT-PCR) with that of conventional RT-PCR for detecting micrometastases in pelvic lymph nodes (PLN) dissected during radical prostatectomy (RP) for prostate cancer. PATIENTS AND METHODS: In all, 120 patients with clinically localized prostate cancer who underwent RP and pelvic lymphadenectomy were included. Expression of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in 2215 PLNs obtained from these 120 patients were assessed by fully quantitative real-time RT-PCR and as well as conventional RT-PCR. Specimens, in which either PSA or PSMA mRNA was positive, were regarded as showing the 'presence of micrometastasis'. RESULTS: Pathological examinations detected tumour cells in 29 PLNs from 11 patients, while real-time RT-PCR and conventional RT-PCR further identified micrometastasis in 143 and 81 PLNs from 32 and 19 patients, respectively, with no pathological evidence of nodal involvement; that is, the sensitivity of real-time RT-PCR for detecting micrometastases was significantly higher than that of conventional RT-PCR. In this series, biochemical recurrence occurred in 32 patients, and in both assays, there were significant differences in biochemical recurrence-free survival between patients with and with no micrometastases. However, despite the significant association of micrometastases detected by both assays with biochemical recurrence on univariate analysis, the presence of micrometastases detected by real-time RT-PCR but not that detected by conventional RT-PCR appeared to be useful as an independent predictor on multivariate analysis. CONCLUSION: Although micrometastatic tumour foci in PLNs that were missed by routine pathological examination could be diagnosed by both real-time RT-PCR and conventional RT-PCR assays, it would be strongly recommended to use real-time RT-PCR to detect micrometastases considering its high sensitivity and the close association between the outcome of this assay and the probability of biochemical recurrence.
    Apr. 2009, BJU international, 103(8) (8), 1074 - 8, English, International magazine
    [Refereed]

  • 倉橋 俊史, 酒井 伊織, 寺川 智章, 村蒔 基次, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 283 - 283, Japanese

  • 酒井 伊織, 寺川 智章, 村蒔 基次, 倉橋 俊史, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 219 - 219, Japanese

  • 寺川 智章, 酒井 伊織, 村蒔 基次, 倉橋 俊史, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 220 - 220, Japanese

  • 村蒔 基次, 酒井 伊織, 寺川 智章, 倉橋 俊史, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2009, 日本泌尿器科学会雑誌, 100(2) (2), 470 - 470, Japanese

  • Tomoaki Terakawa, Hideaki Miyake, Naoki Kanomata, Masafumi Kumano, Atsushi Takenaka, Masato Fujisawao
    OBJECTIVES: To investigate the effect of the presence of histologic inflammation in needle biopsy specimens on the detection of prostate cancer (PCa) in men with a high serum prostate-specific antigen (PSA) level. METHODS: This study included 143 consecutive patients with serum a PSA level of 10-50 ng/mL who had undergone initial needle biopsies of the prostate. We defined moderate or severe inflammation in the biopsy specimens, according to De Marzo et al., as the presence of histologic inflammation. RESULTS: Of the 143 patients, 86 and 57 were diagnosed with PCa (PCa group) or benign prostatic disease (BPD group), respectively. The prostate volume and transition zone volume in the PCa group were significantly smaller than those in the BPD group, and the serum PSA level, PSA density (PSAD), and PSAD in the transition zone were significantly greater than those in the BPD group. A significant difference was found in the incidence of histologic inflammation between the PCa (40.7%) and BPD (73.7%) groups. Among the factors examined, the PSAD and the presence of histologic inflammation appeared to be independently associated with the detection of PCa. Furthermore, the combined consideration of these 2 independent factors could differentiate PCa from BPD in the biopsy specimens with a sensitivity, specificity, positive predictive value, and negative predictive value of 87.2%, 63.2%, 78.1%, and 76.6%, respectively. CONCLUSIONS: It seems possible to avoid unnecessary repeat biopsy using the PSAD and the presence of histologic inflammation in biopsy specimens in patients with continuously elevated serum PSA levels after the initial biopsy.
    Dec. 2008, Urology, 72(6) (6), 1194 - 7, English, International magazine
    [Refereed]

  • Tomoaki Terakawa, Hideaki Miyake, Kazushi Tanaka, Atsushi Takenaka, Taka-aki Inoue, Masato Fujisawa
    OBJECTIVES: To compare the surgical margin (SM) status between open and laparoscopic radical prostatectomy (RRP and LRP, respectively) specimens. METHODS: Surgical specimens from 137 patients undergoing LRP and 220 patients undergoing RRP for clinically localized prostate cancer were included in the analysis. SM status in each resected specimen, including the number of positive SM as well as their location, was examined. RESULTS: The incidence of positive SM in the LRP group was significantly greater than that in the RRP group. Despite the lack of significant difference in the proportion of solitary positive SM between these two groups, the proportion of multiple positive SM in the LRP group was significantly greater than that in the RRP group. There was no significant difference in the incidence of anterior positive SM between the two groups, while the incidences of positive SM at the apex, posterior site and bladder neck in the LRP group were significantly greater than those in the RRP group. Furthermore, there were no significant preoperative parameters predicting positive SM in the LRP group. On the other hand, the biopsy Gleason score and clinical T stage were identified as significant predictors of positive SM in the RRP group, of which the biopsy Gleason score was independently related to the presence of positive SM. CONCLUSIONS: Clinical T stage and Gleason score could be useful predictors of SM status following RRP, while positive SM in LRP specimens were detected irrespective of preoperative parameters, suggesting the need for an effort for further refining the LRP procedure.
    Aug. 2008, International journal of urology : official journal of the Japanese Urological Association, 15(8) (8), 704 - 7, English, International magazine
    [Refereed]

  • Tomoaki Terakawa, Hideaki Miyake, Isao Hara, Atsushi Takenaka, Masato Fujisawa
    PURPOSE: To compare the outcomes of retroperitoneoscopic nephroureterectomy (RNU) with those of open retroperitoneal nephroureterectomy (ORNU) for upper urinary tract cancer. PATIENTS AND METHODS: This study included 240 consecutive patients who received a clinical diagnosis of localized upper urinary tract cancer and underwent nephroureterectomy by a retroperitoneal approach. Of these, 120 patients underwent RNU and 120 patients underwent ORNU. RESULTS: The mean operative time for RNU (346 min) was significantly longer than that for ONU (209 min), despite the lack of a significant difference in the estimated blood loss between these two groups. Significant differences were observed in parameters related to postoperative recovery between the groups, including the time to walk (1.8 versus 2.3 days), the time to oral intake (1.8 versus 2.7 days), and the time until permission for discharge (9.9 versus 13.4 days). There were no significant differences in the major pathologic factors between the groups. Furthermore, the incidences of intravesical as well as extravesical recurrence between the RNU and ORNU groups were similar, and there were no significant differences in cause-specific and overall survivals between the groups. Among patients with grade 3 disease, cause-specific survivals in patients undergoing RNU were significantly poorer than those in patients undergoing ORNU, while there was no significant difference in the overall survival between the groups. Multivariate analysis, however, indicated that the surgical procedure (RNU versus ORNU) could not be an independent predictor of both overall and cancer-specific survivals irrespective of tumor grade. CONCLUSIONS: RNU represents an effective, safe, and less invasive management option for upper urinary tract cancer and achieves a cancer control rate similar to that of ORNU; however, it is necessary to perform further investigations to determine the optimal indications for RNU for patients with high-grade disease.
    Aug. 2008, Journal of endourology, 22(8) (8), 1693 - 9, English, International magazine
    [Refereed]

  • 倉橋 俊史, 寺川 智章, 熊野 晶文, 村蒔 基次, 曽我 英雄, 三宅 秀明, 田中 一志, 武中 篤, 田中 宏和, 井上 隆朗, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2008, 日本泌尿器科学会雑誌, 99(2) (2), 302 - 302, Japanese

  • 村蒔 基次, 寺川 智章, 熊野 晶文, 倉橋 俊史, 曽我 英雄, 三宅 秀明, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2008, 日本泌尿器科学会雑誌, 99(2) (2), 395 - 395, Japanese

  • 寺川 智章, 古川 順也, 熊野 晶文, 村蒔 基次, 倉橋 俊史, 三宅 秀明, 曽我 英雄, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2008, 日本泌尿器科学会雑誌, 99(2) (2), 353 - 353, Japanese

  • 熊野 晶文, 寺川 智章, 倉橋 俊史, 村蒔 基次, 曽我 英雄, 三宅 秀明, 田中 一志, 武中 篤, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2008, 日本泌尿器科学会雑誌, 99(2) (2), 353 - 353, Japanese

  • 曽我 英雄, 武中 篤, 寺川 智章, 熊野 晶文, 村蒔 基次, 倉橋 俊文, 三宅 秀明, 田中 一志, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2008, 日本泌尿器科学会雑誌, 99(2) (2), 341 - 341, Japanese

  • Tomoaki Terakawa, Hideaki Miyake, Mototsugu Muramaki, Atushi Takenaka, Isao Hara, Masato Fujisawa
    OBJECTIVES: To identify risk factors for developing subsequent bladder cancer in patients undergoing surgical management of transitional cell carcinoma (TCC) of the upper urinary tract. METHODS: This study included 177 patients who were diagnosed as having clinically localized upper urinary tract TCC and thereafter underwent nephroureterectomy after exclusion of those with a previous and/or concurrent history of bladder cancer. Univariate and multivariate analyses using both the logistic regression model and the Cox proportional hazards model were carried out in these 177 patients to determine the risk factors for intravesical recurrence after nephroureterectomy. RESULTS: Of the 177 patients, 63 (35.6%) developed recurrent bladder cancer after a median interval of 7.5 months. Intravesical recurrence-free survival rates for these 177 patients at 1, 3, and 5 years were 75.7%, 63.7%, and 54.1%, respectively. Univariate analyses showed that patients with low-stage tumors and those with multifocal tumors were likely to undergo subsequent intravesical recurrence; however, there was no significant impact of other factors on subsequent intravesical recurrence, including age, tumor side, tumor location, surgical modality, operation time, management of the distal ureter, tumor grade, lymph node metastasis, microvascular invasion, lymphatic invasion, and margin status. Furthermore, pathologic stage and tumor multifocality were identified as independent predictors for the development of recurrent bladder cancer by multivariate analyses. CONCLUSIONS: The incidence of intravesical recurrence after nephroureterectomy for upper urinary tract TCC is comparatively high. It could be important to perform careful follow-up targeting intravesical recurrence for such patients after nephroureterectomy, particularly those with low-stage tumors and/or multifocal tumors.
    Jan. 2008, Urology, 71(1) (1), 123 - 7, English, International magazine
    [Refereed]

  • Prostatic ductal adenocarcinoma successfully treated with endocrine therapy: A case report
    Isao Taguchi, Tomoaki Terakawa, Hiroyuki Tunemori, Osamu Imanishi, Nozomu Yamanaka, Rieko Itoh
    Nov. 2007, Nishinihon Journal of Urology, 69(11) (11), 647 - 650, Japanese
    Scientific journal

  • [Renal parencymal malacoplakia successfully treated with conservative therapy; a case report].
    Isao Taguchi, Tomoaki Terakawa, Hiroyuki Tsunemori, Osamu Imanishi, Nozomu Yamanaka, Takeshi Kondo, Rieko Ito
    Malacoplakia is a relatively rare form of chronic granulomatous inflammation. Which occurs most frequently in the genito-urinary system, but renal parenchymal involvement is rare. We present a case of malacoplakia of the renal parenchyma. A 69-year-old woman with left renal mass was referred to our department. Abdominal enhanced CT scan revealed heterogeneous mass in the left kidney (50 x 45 mm). CT-guided percutaneous left renal needle biopsy confirmed the diagnosis of renal malakoplakia. We successfully treated her with oral levofloxacin. The lesion resolved after the 4-months-therapy, and there has been no recurrence for 22 months since the treatment.
    Nov. 2007, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 98(7) (7), 839 - 42, Japanese, Domestic magazine
    [Refereed]

  • 下大静脈内腫瘍塞栓を認めたベリニ管癌の1例
    磯谷 周治, 寺川 智章, 山田 裕二, 田中 一志, 武中 篤, 原 勲, 藤澤 正人
    泌尿器科紀要刊行会, Oct. 2007, 泌尿器科紀要, 53(10) (10), 745 - 745, Japanese

  • Transurethral drainage for prostatic abscess in a patient with metastatic testicular cancer undergoing systemic chemotherapy.
    Tomoaki Terakawa, Hideaki Miyake, Yuzo Nakano, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Masato Fujisawa
    We report a case of prostatic abscess in a 22-year-old man with metastatic testicular cancer being treated by BEP (bleomycin, etoposide and cisplatin) chemotherapy. This abscess was successfully treated by surgical drainage with transurethral resection of the prostate (TURP) under the guidance of transrectal ultrasound, allowing the patient to continue be receiving BEP without significant interruption. Drainage TURP is suggested to be a useful strategy for prostate abscess, when prompt control of symptoms caused by prostatic abscess is required.
    Oct. 2007, Hinyokika kiyo. Acta urologica Japonica, 53(10) (10), 725 - 8, English, Domestic magazine
    [Refereed]

  • Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava.
    Tomoaki Terakawa, Hideaki Miyake, Atsushi Takenaka, Isao Hara, Masato Fujisawa
    BACKGROUND: The objective of this study was to evaluate the clinical outcome after surgical management of renal cell carcinoma (RCC) extending to the inferior vena cava (IVC). METHODS: This study included a total of 55 patients (41 men and 14 women; mean age, 59.3 years) with RCC (39 right- and 16 left-sided tumors) involving the IVC, who underwent radical nephrectomy and tumor thrombectomy between 1983 and 2005 at a single institution in Japan. The level of thrombus was classified as follows: level I, infrahepatic; level II, intrahepatic; level III, suprahepatic; and level IV, extending to the atrium. Clinicopathological data from these patients were retrospectively reviewed to identify factors associated with survival. RESULTS: There were 11 and 18 patients who were diagnosed as having lymph node and distant metastases, respectively. Twenty-two patients had tumor thrombus in level I, 20 in level II, 10 in level III, and 3 in level IV. Pathological examinations demonstrated that 34 and 21 patients had clear cell carcinoma and non-clear cell carcinoma, respectively, 42, 9 and 4 were pT3b, pT3c and pT4, respectively, and 6, 35 and 14 were Grades 1, 2 and 3, respectively. Cancer-specific 1-, 3- and 5-year survival rates of these 55 patients were 74.5%, 51.4% and 30.3%, respectively. Among several factors examined, clinical stage (P = 0.047), lymph node metastasis (P = 0.016), histological subtype (P = 0.034) and tumor grade (P < 0.001) were significantly associated with cancer-specific survival by univariate analysis. Furthermore, multivariate analysis demonstrated clinical stage (P = 0.037) and tumor grade (P < 0.001) as independent predictors of cancer-specific survival irrespective of other significant factors identified by univariate analysis. CONCLUSIONS: In patients with RCC involving the IVC, biological aggressiveness characterized by tumor grade rather than tumor extension would have more potential prognostic importance; therefore, more intensive multimodal therapy should be considered in patients with high grade RCC with tumor thrombus extending into the IVC.
    Sep. 2007, International journal of urology : official journal of the Japanese Urological Association, 14(9) (9), 781 - 4, English, International magazine
    [Refereed]

  • 曽我 英雄, 武中 篤, 寺川 智章, 熊野 晶文, 古川 順也, 倉橋 俊史, 三宅 秀明, 田中 一志, 原 勲, 村上 弦, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 504 - 504, Japanese

  • 田中 一志, 寺川 智章, 熊野 晶文, 古川 順也, 中野 雄造, 三宅 秀明, 武中 篤, 原 勲, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 322 - 322, Japanese

  • 寺川 智章, 熊野 晶文, 古川 順也, 倉橋 俊史, 三宅 秀明, 田中 一志, 武中 篤, 原 勲, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 351 - 351, Japanese

  • 古川 順也, 山田 裕二, 寺川 智章, 熊野 晶文, 倉橋 俊史, 田中 一志, 三宅 秀明, 武中 篤, 原 勲, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 443 - 443, Japanese

  • 三浦 徹也, 中野 雄造, 田中 一志, 熊野 晶文, 寺川 智章, 古川 順也, 倉橋 俊史, 三宅 秀明, 武中 篤, 荒川 創一, 原 勲, 藤澤 正人
    一般社団法人 日本泌尿器科学会, 2007, 日本泌尿器科学会雑誌, 98(2) (2), 279 - 279, Japanese

  • 田口 功, 寺川 智章, 常森 寛行, 今西 治, 山中 望
    一般社団法人 日本泌尿器科学会, 2006, 日本泌尿器科学会雑誌, 97(2) (2), 290 - 290, Japanese

  • [Modifications in the technique for apical dissection of radical retropubic prostatectomy to improve urinary incontinence].
    Tomoaki Terakawa, Atushi Takenaka, Hiroyuki Tunemori, Isao Taguchi, Osamu Imanishi, Nozomu Yamanaka
    PURPOSE: To evaluate urinary continence after modified radical retropubic prostatectomy. MATERIAL AND METHODS: From March 1999 to May 2004, 110 patients with prostate cancer underwent radical retropubic prostatectomy. In all patients, the fascia of the levator ani was preserved, and the plane between the prostate and rectum was dissected prior to cutting the urethra. A modification to the technique of apical dissection was introduced in May 2002. The modified method included cutting the urethra along a precise line between the prostate and urethra following the shape of the prostatic apex. The grade of early urinary incontinence was analyzed by using the incontinence rate (urinary incontinence volume (ml)/total urinary volume x 100 (%)). The incontinence rate was compared between the conventional and modified surgical techniques. Several other risk factors were also examined in these patients. Continence rates were analyzed among the patients over a one-year postoperative course. RESULTS: The incontinence rate on the day, the next day and 5-7 days after the removal of the urethral catheter were 18.1%, 11.2%, 6.0% in the modified group, and 36.6%, 22.5%, 12.6% in the conventional group, respectively. With the introduction of this modified method, the incontinence rate was significantly decreased (P<0.005). Complete continence rates 3 and 12 months after the operation were 81.3% and 98.3% in the modified and 60.0% and 97.8% in the conventional group. The time to regain complete continence in the modified was earlier than that in the conventional. After one-year, the rate of complete continence was similar and a satisfactory average in each group. Except for surgical techniques, no other factors were associated with a risk of incontinence statistically. CONCLUSIONS: We recommend modified apical dissection to preserve the urethral striated sphincter, which can be useful in improving the early incontinence rate and the recovery of continence.
    Jan. 2006, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 97(1) (1), 1 - 9, Japanese, Domestic magazine
    [Refereed]

  • [A case of retroperitoneal liposarcoma arising from the renal capsule].
    Tomoaki Terakawa, Isao Taguchi, Osamu Imanishi, Nozomu Yamanaka
    We treated a case of retroperitoneal liposarcoma arising from the renal capsule by operation and adjuvant radiation. A 61-year-old woman was referred to our department for treatment of a right renal tumor revealed by computed tomography (CT). CT, magnetic resonance imaging and angiography demonstrated a large renal tumor with fat tissue, fed from the renal capsular artery. Right radical nephrectomy was performed on February 4, 2003. The tumor was diagnosed histopathologically as well differentiated liposarcoma arising from the renal capsule. The surgical margin was positive. Therefore, the patient was given 50 Gy of radiation postoperatively. There have been only 18 reports of liposarcoma arising from the renal capsule in Japan.
    Mar. 2005, Hinyokika kiyo. Acta urologica Japonica, 51(3) (3), 171 - 3, Japanese, Domestic magazine
    [Refereed]

  • 田口 功, 寺川 智章, 今西 治, 山中 望
    一般社団法人 日本泌尿器科学会, 2005, 日本泌尿器科学会雑誌, 96(2) (2), 339 - 339, Japanese

  • 寺川 智章, 田口 功, 今西 治, 山中 望
    一般社団法人 日本泌尿器科学会, 2005, 日本泌尿器科学会雑誌, 96(2) (2), 231 - 231, Japanese

  • 外傷後の腎盂尿管移行部狭窄症に対し腹腔鏡下腎盂形成術を施行した1例
    寺川智章, 石田敏郎, 土橋正樹, 原章二, TANAKA, Kazushi, HARA, Isao, KAWABATA,Gaku, ARAKAWA, Souichi, KAMIDONO,Sadao, SOGA, Hideo, 山崎浩, FUJISAWA, Masato
    Feb. 2004, 泌尿器科紀要, 50巻, 2号, pp. 139-139, Japanese
    International conference proceedings

  • Solitary fibrous tumor in the pelvic space.
    Tomomoto Ishikawa, Gaku Kawabata, Tomoaki Terakawa, Sadao Kamidono, Masato Fujisawa
    A case of a solitary fibrous tumor (SFT) of the pelvic space in a 64-year-old man is reported herein. Computed tomography (CT) of the pelvis showed a large mass enhanced heterogeneously left paracentral and posterior to the bladder and intimately associated with prostate. The site of origin of the mass could not be defined on CT because margins blended with the bladder, prostate, and rectum. A tumorectomy was performed and has remained well with no evidence of recurrence during the last 3 months. The tumor was 12.5 x 9.5 x 8.3 cm in size, solid with a fibromuscular capsule, and gray-tan in color. Histologically, the neoplasms were well circumscribed and composed of short spindle cells arranged without an obvious pattern. Immunohistochemically, these cells were strongly positive for CD 34 and negative for S-100, alpha SMA, and AE1/AE3.
    Feb. 2004, Urological research, 32(1) (1), 49 - 50, English, International magazine
    [Refereed]

  • 今西 治, 寺川 智章, 田口 功, 山中 望, 武中 篤
    一般社団法人 日本泌尿器科学会, 2004, 日本泌尿器科学会雑誌, 95(2) (2), 419 - 419, Japanese

  • 田口 功, 寺川 智章, 今西 治, 山中 望, 畠中 真帆, 久保田 晋, 武中 篤
    一般社団法人 日本泌尿器科学会, 2004, 日本泌尿器科学会雑誌, 95(2) (2), 380 - 380, Japanese

  • [Laparoscopic pyeloplasty for a secondary ureteropelvic junction obstruction after renal trauma: a case report].
    Tomoaki Terakawa, Kazushi Tanaka, Toshiro Ishida, Masaki Dobashi, Syoji Hara, Isao Hara, Gaku Kawabata, Hiroshi Okada, Sadao Kamidono, Hideo Soga, Hiroshi Yamazaki, Masato Fujisawa
    We report a case of secondary ureteropelvic junction obstruction due to renal trauma treated by laparoscopic pyeloplasty. A 25-year-old man, who had renal trauma due to a traffic accident, complained of left lumbago and was diagnosed with left ureteropelvic junction obstruction. Endoscopic balloon dilation was performed twice, but the hydronephrosis did not change. Subsequently, laparoscopic pyeloplasty was performed with no complications. After operation, lumbago disappeared and hydronephrosis and renal function improved. Secondary ureteropelvic junction obstruction is rare, and this case seems to be the first case managed by laparoscopy in Japan.
    Nov. 2003, Hinyokika kiyo. Acta urologica Japonica, 49(11) (11), 663 - 5, Japanese, Domestic magazine
    [Refereed]

■ MISC
  • Clinical outcome of EP therapy (VP16+CDDP)in 10 prostate cancer patients with neuroendocrine differentiation
    Tomoaki Terakawa, Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Oct. 2020, INTERNATIONAL JOURNAL OF UROLOGY, 27, 74 - 75, English
    Summary international conference

  • PREDICTIVE EFFICACYOF SERUMSOLUBLE PD-L1ONPATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB
    Yukari Bando, Nobuyuki Hinata, Yusuke Shiraishi, Naoto Wakita, Mariko Sakamoto, Yasuyoshi Okamura, Kotaro Yuzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Apr. 2020, JOURNAL OF UROLOGY, 203, E239 - E240, English
    Summary international conference

  • 当院における腎癌患者のニボルマブとイピリムマブ併用療法の治療成績
    原琢人, 白石祐介, 脇田直人, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    2020, 西日本泌尿器科, 82

  • 寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 173 - 173, Japanese

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌10例の臨床的検討
    寺川 智章, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人, 神保 直江
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P103 - 7, English

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌7例の臨床的検討
    寺川 智章, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 石村 武志, 重村 克己, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 270, Japanese

  • NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Yukari Bando, Mariko Sakamoto, Yasuyoshi Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    Apr. 2019, JOURNAL OF UROLOGY, 201(4) (4), E344 - E345, English
    Summary international conference

  • APPLICATION OF HYALURONIC ACID/CARBOXYMETHYL CELLULOSE MEMBRANE FOR EARLY CONTINENCE AFTER NERVE-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY
    Nobuyuki Hinata, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa
    Apr. 2019, JOURNAL OF UROLOGY, 201(4) (4), E572 - E573, English
    Summary international conference

  • ニボルマブ関連内分泌異常に対する当科での取り組み
    原 琢人, 坂本 茉莉子, 坂東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 148, Japanese

  • 淡明細胞型腎細胞癌に対するfirst-line Sunitinibの治療成績
    古川 順也, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 141, Japanese

  • 神戸大学における進行性腎癌に対する2nd lineアキシチニブの治療成績
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 146, Japanese

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌7例の臨床的検討
    寺川 智章, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 石村 武志, 重村 克己, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 270, Japanese

  • 神戸大学における進行性腎癌に対するニボルマブの臨床的検討
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 459, Japanese

  • ハイリスク前立腺癌に対するロボット根治的前立腺全摘除術の治療成績
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP2 - 097, Japanese

  • 転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の臨床的検討
    坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 069, Japanese

  • 腎癌下大静脈腫瘍塞栓を有する患者に対して術前分子標的薬投与を行った際の手術成績の比較検討
    岡村 泰義, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 185, Japanese

  • 腎癌のtotal management:機能温存手術から薬物療法まで
    古川順也, 寺川智章, 原田健一, 日向信之, 中野雄造, 藤澤正人
    2019, 泌尿器科再建再生研究会プログラム・抄録集, 16th

  • 腎盂尿管移行部狭窄症に対するロボット支援腹腔鏡下腎盂形成術の初期経験
    寺川智章, 千葉公嗣, 古川順也, 原田健一, 石村武志, 重村克己, 山口雷蔵, 日向信之, 中野雄造, 藤澤正人
    2019, 日本泌尿器内視鏡学会(Web), 33rd

  • 膀胱ヘルニアを合併した前立腺癌に対しロボット支援下前立腺全摘除術を施行した1例
    寺川 智章, 千葉 公嗣, 原田 健一, 重村 克己, 石村 武志, 日向 信之, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2018, 日本内視鏡外科学会雑誌, 23(7) (7), DP137 - 8, Japanese

  • 膀胱ヘルニアを合併した前立腺がんに対しロボット支援腹腔鏡下前立腺全摘除術を施行した一例
    山下遥介, 寺川智章, 古川順也, 原田健一, 松下経, 石村武志, 重村克巳, 日向信之, 中野雄造, 藤澤正人
    西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 197 - 197, Japanese

  • 転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
    古川順也, 坂本茉莉子, 岡村泰義, 坂東由加里, 鈴木光太郎, 原琢人, 寺川智章, 重村克巳, 原田健一, 日向信之, 石村武志, 中野雄造, 藤澤正人
    西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese

  • 当院における尿路上皮癌に対するペムブロリズマブの初期使用経験
    安野恭平, 古川順也, 原琢人, 鈴木光太郎, 寺川智章, 千葉公嗣, 原田健一, 松下経, 石村武志, 重村克巳, 日向信之, 中野雄造, 藤澤正人
    西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 212 - 212, Japanese

  • 神戸大学における転移性腎癌に対するニボルマブの成績
    原田健一, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 原琢人, 寺川智章, 古川順也, 重村克巳, 石村武志, 日向信之, 中野雄造, 藤澤正人
    西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese

  • 神戸大学における転移性腎癌に対するニボルマブの成績
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 重村 克巳, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese

  • 転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
    古川 順也, 坂本 茉莉子, 岡村 泰義, 坂東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 重村 克巳, 原田 健一, 日向 信之, 石村 武志, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese

  • 山下 遥介, 寺川 智章, 古川 順也, 原田 健一, 松下 経, 石村 武志, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 197 - 197, Japanese

  • 安野 恭平, 古川 順也, 原 琢人, 鈴木 光太郎, 寺川 智章, 千葉 公嗣, 原田 健一, 松下 経, 石村 武志, 重村 克巳, 日向 信之, 中野 雄造, 藤澤 正人
    西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 212 - 212, Japanese

  • 進行腎癌に対するニボルマブの効果予測因子の検討
    原田 健一, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P32 - 2, English

  • 去勢抵抗性前立腺癌患者におけるアビラテロン効果予測因子としての血清DHEAS値の検討
    坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 板東 由加里, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P43 - 6, English

  • 当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療経験
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P44 - 8, English

  • 下大静脈塞栓を有する腎癌患者に対する術前補助化学療法としてのパゾパニブの使用経験
    寺川 智章, 坂本 茉莉子, 板東 由加里, 岡村 泰義, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 4, English

  • 転移性腎細胞癌に対するパゾパニブの治療成績
    鈴木 光太郎, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 6, English

  • パゾパニブ使用した進行腎癌症例の無増悪生存、および肝障害ノモグラムの有用性の検討
    岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 7, English

  • 当院における切除不能腎癌に対するnivolumabの治療成績
    原 琢人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P100 - 3, English

  • 神戸大学におけるロボット支援根治的膀胱全摘除術の初期成績
    日向 信之, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 寺川 智章, 古川 順也, 原田 健一, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P101 - 4, English

  • パラガングリオーマと原発性アルドステロン症を合併した1例
    芳村 魁, 福岡 秀規, 志智 大城, 小松 正人, 神澤 真紀, 寺川 智章, 重村 克己, 岡田 裕子, 廣田 勇士, 井口 元三, 藤澤 正人, 小川 渉, 高橋 裕
    (一社)日本内分泌学会, Sep. 2018, 日本内分泌学会雑誌, 94(2) (2), 704 - 704, Japanese

  • 播種性骨髄癌症を伴った前立腺癌の1例
    白石祐介, 寺川智章, 古川順也, 重村克巳, 原田健一, 松下経, 石村武志, 日向信之, 中野雄造, 藤澤正人
    泌尿器科紀要刊行会, 30 Jun. 2018, 泌尿器科紀要, 64(6) (6), 289 - 289, Japanese

  • ロボット支援腹腔鏡下前立腺全摘時に使用したヘモロックが膀胱に迷入した1例
    河村駿, 寺川智章, 古川順也, 重村克己, 原田健一, 松下経, 石村武志, 日向信之, 中野雄造, 藤澤正人
    泌尿器科紀要刊行会, 30 Jun. 2018, 泌尿器科紀要, 64(6) (6), 290‐291 - 291, Japanese

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    原田 健一, 坂本 茉莉子, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, 寺川 智章, 古川 順也, 重村 克己, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    泌尿器科紀要刊行会, May 2018, 泌尿器科紀要, 64(5) (5), 237 - 237, Japanese

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    原田健一, 坂本茉莉子, 板東由加里, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.OP‐184 (WEB ONLY) - 184, Japanese

  • Presurgical therapyとしてTyrosine Kinase Inhibitors(TKIs)を使用した腎細胞癌症例の検討
    坂本茉莉子, 岡村泰義, 鈴木光太郎, 板東由加里, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.PP1‐183 (WEB ONLY) - 183, Japanese

  • ロボット支援腎部分切除術におけるTrifecta達成に関する要因の検討
    古川順也, 日向信之, 小川悟史, 岡田圭輔, 寺川智章, 千葉公嗣, 重村克巳, 原田健一, 松下経, 石村武志, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.OP‐345 (WEB ONLY) - 345, Japanese

  • 根治的膀胱全摘除術における非禁制型尿路変向術の術後腎機能に与える影響の検討
    鈴木光太郎, 岡村泰義, 板東由加里, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.OP‐581 (WEB ONLY) - 581, Japanese

  • 神戸大学病院における転移性腎癌に対する分子標的薬の治療成績についての臨床的検討
    桃園宏之, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 原琢人, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.PP1‐179 (WEB ONLY) - 179, Japanese

  • PD‐L1発現を低下させた腎癌細胞を接腫したマウスにおけるsunitinibの抗腫瘍効果についての検討
    原琢人, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 三宅秀明, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.PP2‐011 (WEB ONLY) - 011, Japanese

  • 当院で施行したロボット支援根治的前立腺全摘除術におけるpT3症例の生物学的再発予測因子
    板東由加里, 坂本茉莉子, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会(Web), 106th, ROMBUNNO.PP2‐139 (WEB ONLY) - 139, Japanese

  • 術前にパゾパニブを投与した下大静脈腫瘍塞栓を伴う右腎癌の1例
    前田光毅, 寺川智章, 古川順也, 重村克巳, 原田健一, 日向信之, 石村武志, 中野雄造, 藤澤正人
    泌尿器科紀要刊行会, 31 Mar. 2018, 泌尿器科紀要, 64(3) (3), 136 - 136, Japanese

  • 神戸大学病院におけるカバジタキセルの治療成績と高齢者に生じる有害事象の検討
    桃園宏之, 岡村泰義, 原琢人, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    日本老年泌尿器科学会, 05 Mar. 2018, 日本老年泌尿器科学会誌, 30, 106 - 106, Japanese

  • 当院における副腎腫瘍マネージメントにおける術後多科合同カンファレンスについて
    重村克巳, 重村克巳, 寺川智章, 千葉公嗣, 古川順也, 原田健一, 日向信之, 福岡秀規, 高橋裕, 中野雄造, 藤澤正人
    2018, Japanese Journal of Endourology, 31(3 (Web)) (3 (Web))

  • 当院におけるロボット支援根治的前立腺全摘除術における拡大リンパ節郭清の検討
    板東由加里, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤倉航平, 上野嘉子, 藤澤正人
    2018, Japanese Journal of Endourology, 31(3 (Web)) (3 (Web))

  • 前立腺癌合同カンファレンスを通じたロボット支援根治的前立腺全摘除術術後尿禁制改善の試み
    板東由加里, 坂本茉莉子, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    2018, 泌尿器科再建再生研究会プログラム・抄録集, 15th, 28, Japanese

  • 低侵襲手術に対応する病期診断
    高橋哲, 上野嘉子, 古川順也, 日向信之, 寺川智章, 藤澤正人, 村上卓道
    2018, 泌尿器画像診断・治療技術研究会プログラム・抄録, 6th, 27, Japanese

  • 下大静脈腫瘍塞栓を伴う腎癌症例におけるcine MRIの有用性
    田寛之, 寺川智章, 上野嘉子, 高橋哲, 古川順也, 原田健一, 重村克巳, 日向信之, 中野雄造, 藤澤正人
    2018, 泌尿器画像診断・治療技術研究会プログラム・抄録, 6th, 45, Japanese

  • 当院で経験した膀胱異物の3例
    高瀬雄太, 小田晃廉, 寺川智章, 古川順也, 原田健一, 松下経, 石村武志, 重村克巳, 日向信之, 中野雄造, 藤澤正人
    2018, 日本泌尿器科学会中部総会プログラム・抄録集, 68th, 227, Japanese

  • 80歳以上の高齢者における膀胱全摘後の腎機能変化や術後合併症についての検討
    原琢人, 岡村泰義, 板東由加里, 鈴木光太郎, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    2018, 日本老年泌尿器科学会プログラム・抄録集, 31st, 167, Japanese

  • 腎腫瘍のFDG‐PET:画像と病理所見の対比
    上野嘉子, 野上宗伸, 高橋哲, 高橋哲, 山崎隆, 山崎隆, 寺川智章, 日向信之, 田中宇多留, 藤澤正人, 伊藤智雄, 村上卓道
    2018, 泌尿器画像診断・治療技術研究会プログラム・抄録, 6th, 51, Japanese

  • ロボット支援腹腔鏡下前立腺全摘除術後の性機能に関する検討
    中野雄造, 寺川智章, 古川順也, 重村克巳, 原田健一, 日向信之, 石村武志, 藤澤正人
    (一社)日本泌尿器内視鏡学会, Nov. 2017, Japanese Journal of Endourology, 30(3) (3), 208 - 208, Japanese

  • ロボット支援腹腔鏡下前立腺全摘除術後の性機能に関する検討
    中野 雄造, 寺川 智章, 古川 順也, 重村 克巳, 原田 健一, 日向 信之, 石村 武志, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2017, Japanese Journal of Endourology, 30(3) (3), 208 - 208, Japanese

  • 神戸大学におけるロボット支援根治的膀胱全摘除術の初期経験
    日向信之, 寺川智章, 千葉公嗣, 松下経, 古川順也, 原田健一, 石村武志, 中野雄造, 藤澤正人
    日本外科系連合学会, 30 Oct. 2017, 日本外科系連合学会誌, 42(5) (5), 897 - 897, Japanese

  • 精巣癌の検査・診断 リスク分類と予後因子
    寺川智章, 日向信之, 藤澤正人
    20 Oct. 2017, 日本臨床, 75, 397‐401, Japanese

  • 根治的前立腺全摘除術Gleason Score8‐10症例の臨床的検討
    古川順也, 坂東由加里, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 今井聡士, 宮崎彰, 寺川智章, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本癌治療学会, Oct. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.OP05‐6 (WEB ONLY) - 6, Japanese

  • ロボット支援腹腔鏡下前立腺全摘除術における拡大リンパ節郭清の成績
    板東由加里, 坂本茉莉子, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P89‐4 (WEB ONLY) - 4, Japanese

  • ロボット支援腎部分切除術におけるRENAL nephrometry scoreと手術成績に関する検討
    古川順也, 岡村泰義, 坂東由加里, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P9‐4 (WEB ONLY) - 4, Japanese

  • 当院における進行性腎細胞癌に対するパゾパニブの治療成績
    鈴木光太郎, 岡村泰義, 板東由加里, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P27‐7 (WEB ONLY) - 7, Japanese

  • 下大静脈塞栓を有する腎癌患者に対する術前補助化学療法としてのパゾパニブの使用経験
    原琢人, 坂東由加里, 岡村泰義, 鈴木光太郎, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P27‐6 (WEB ONLY) - 6, Japanese

  • ロボット支援腹腔鏡下前立腺全摘除術における拡大リンパ節郭清の成績
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P89 - 4, Japanese

  • 根治的前立腺全摘除術Gleason Score 8-10症例の臨床的検討
    岡村 泰義, 古川 順也, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 寺川 智章, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P96 - 6, Japanese

  • 神戸大学におけるロボット支援根治的膀胱全摘除術の初期経験
    日向 信之, 寺川 智章, 千葉 公嗣, 松下 経, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    日本外科系連合学会, Oct. 2017, 日本外科系連合学会誌, 42(5) (5), 897 - 897, Japanese

  • 腎Solitary fibrous tumorの1例
    植木秀登, 寺川智章, 古川順也, 原田健一, 日向信之, 石村武志, 中野雄造, 藤澤正人
    泌尿器科紀要刊行会, 31 May 2017, 泌尿器科紀要, 63(5) (5), 217 - 217, Japanese

  • ロボット支援根治的前立腺全摘除術における解剖学的根拠に基づいた膀胱頸部離断法
    日向 信之, 板東 由加里, 鈴木 光太郎, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, AVP2 - 06, Japanese

  • 当院におけるロボット支援前立腺全摘術に併施する拡大リンパ節郭清の工夫
    板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, VP04 - 4, Japanese

  • 神戸大学における転移性腎癌に対する1st lineスニチニブ-2nd lineアキシチニブの検討
    原田 健一, 板東 由香里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, OP15 - 3, Japanese

  • 神戸大学におけるTSC‐AMLに対するエベロリムスの治療成績と診療連携の重要性
    原田健一, 板東由香里, 鈴木光太郎, 原琢人, 桃園宏之, 今井聡士, 宮崎彰, 寺川智章, 古川順也, 重村克己, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.OP19‐6 (WEB ONLY) - 6, Japanese

  • 根治的前立腺全摘除術Gleason Score8‐10症例の臨床的検討
    岡村泰義, 古川順也, 板東由加里, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P96‐6 (WEB ONLY) - 6, Japanese

  • 神戸大学における開腹腎部分切除術と腹腔鏡下腎部分切除術の検討
    宮崎 彰, 原 琢人, 今井 聡士, 桃園 宏之, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, PP08 - 05, Japanese

  • 前立腺癌患者における癌検出ウィルスマーカーOBP-1101を用いた血中循環癌細胞の検出
    日向 信之, 鈴木 光太郎, 板東 由加里, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 浦田 泰生, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, PP17 - 04, Japanese

  • 当院における進行性腎癌に対するパゾパニブ投与23例の初期治療成績
    今井聡士, 鈴木光太郎, 板東由加里, 原琢人, 桃園宏之, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP07‐03 (WEB ONLY) - 03, Japanese

  • 当院における去勢抵抗性前立腺癌に対する抗アンドロゲン薬交替療法の成績
    鈴木光太郎, 坂東由加里, 原琢人, 桃園宏之, 今井聡士, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP18‐11 (WEB ONLY) - 11, Japanese

  • 当院における前立腺癌合同カンファレンスの意義
    板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人, 高橋 哲
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, PP86 - 11, Japanese

  • 当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療経験
    日向 信之, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, PP89 - 01, Japanese

  • 当院および関連施設における去勢抵抗性前立腺癌に対するアビラテロンの治療成績についての検討
    桃園宏之, 岡村泰義, 坂東由加里, 鈴木光太郎, 原琢人, 今井聡士, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP52‐09 (WEB ONLY) - 09, Japanese

  • 去勢抵抗性前立腺癌に対するエンザルタミドの治療成績について検討
    原琢人, 坂東由加里, 鈴木光太郎, 桃園宏之, 今井聡, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP51‐10 (WEB ONLY) - 10, Japanese

  • 転移性腎細胞癌に対する3rdライン分子標的治療としてのテムシロリムスの治療成績
    宮崎彰, 原琢人, 今井聡士, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP42‐09 (WEB ONLY) - 09, Japanese

  • 術前にパゾパニブ投与を行った下大静脈腫瘍塞栓を伴う転移性腎癌の2例
    寺川智章, 板東由加里, 鈴木光太郎, 原琢人, 桃園宏之, 今井聡士, 宮崎彰, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP77‐01 (WEB ONLY) - 01, Japanese

  • 神経温存ロボット支援根治的前立腺全摘除術後の摘出床へのHA‐CM貼付が術後尿禁制に及ぼす影響
    日向信之, 板東由加里, 鈴木光太郎, 桃園宏之, 今井聡士, 宮崎彰, 寺川智章, 千葉公嗣, 古川順也, 原田健一, 石村武志, 中野雄造, 藤澤正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会(Web), 105th, ROMBUNNO.PP95‐10 (WEB ONLY) - 10, Japanese

  • Solitary fibrous tumor of the kidney; A case report
    植木秀登, 寺川智章, 古川順也, 重村克巳, 原田健一, 日向信之, 石村武志, 中野雄造, 藤澤正人
    医学図書出版(株), 15 Jan. 2017, 泌尿器外科, 30(1) (1), 79‐83 - 83, Japanese

  • 神戸大学病院におけるカバジタキセルの治療成績と高齢者に生じる有害事象の検討
    桃園宏之, 岡村泰義, 原琢人, 宮崎彰, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    2017, 日本老年泌尿器科学会プログラム・抄録集, 30th, 145, Japanese

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    原田健一, 坂本茉莉子, 板東由加里, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 重村克己, 石村武志, 日向信之, 中野雄造, 藤澤正人
    2017, 日本泌尿器科学会中部総会プログラム・抄録集, 67th, 213, Japanese

  • 合同カンファレンスを通じたロボット支援腹腔鏡下前立腺全摘除術成績改善の試み
    板東由加里, 坂本茉莉子, 岡村泰義, 鈴木光太郎, 原琢人, 桃園宏之, 寺川智章, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人, 高橋晢
    2017, 泌尿器画像診断・治療技術研究会プログラム・抄録, 5th, 41, Japanese

  • ロボット支援根治的前立腺全摘除術における拡大切除および拡大リンパ節廓清の手技と短期成績
    日向 信之, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2016, 日本内視鏡外科学会雑誌, 21(7) (7), OS61 - 3, Japanese

  • 神戸大学における開腹腎部分切除術と腹腔鏡下腎部分切除術の検討
    宮崎 彰, 寺川 智章, 重村 克己, 石村 武志, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2016, 日本内視鏡外科学会雑誌, 21(7) (7), OS196 - 2, Japanese

  • 日向 信之, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2016, Japanese Journal of Endourology, 29(3) (3), 187 - 187, Japanese

  • 古川 順也, 寺川 智章, 千葉 公嗣, 松下 経, 重村 克巳, 原田 健一, 石村 武志, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2016, Japanese Journal of Endourology, 29(3) (3), 243 - 243, Japanese

  • 原田 健一, 日向 信之, 宮崎 彰, 寺川 智章, 古川 順也, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2016, Japanese Journal of Endourology, 29(3) (3), 254 - 254, Japanese

  • 寺川 智章, 日向 信之, 宮崎 彰, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2016, Japanese Journal of Endourology, 29(3) (3), 254 - 254, Japanese

  • 中野 雄造, 寺川 智章, 古川 順也, 重村 克巳, 原田 健一, 日向 信之, 石村 武志, 藤澤 正人
    (一社)日本泌尿器内視鏡学会, Nov. 2016, Japanese Journal of Endourology, 29(3) (3), 313 - 313, Japanese

  • 術前の尿道線維化および炎症所見がロボット支援根治的前立腺全摘術後の短期尿禁制に及ぼす影響
    日向 信之, 桃園 宏之, 板東 由加里, 原 琢人, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 中野 雄造, 藤澤 正人
    日本外科系連合学会, Oct. 2016, 日本外科系連合学会誌, 41(5) (5), 889 - 889, Japanese

  • 腎癌細胞株に対するclusterinを標的としたアンチセンスオリゴによるAxitinibの効果増強
    今井 聡士, 原 琢人, 桃園 宏之, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 三宅 秀明, 藤澤 正人
    日本癌学会, Oct. 2016, 日本癌学会総会記事, 75回, P - 2369, English

  • 前立腺 骨転移・他 血清DHEA-Sが去勢抵抗性前立腺癌に対するアビラテロンの効果予測因子になるかの検討
    寺川 智章, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, WS6 - 4, Japanese

  • 膀胱 筋層非浸潤膀胱がんの治療 当科における膀胱尿路上皮癌に対する再発予防BCG維持療法の成績
    板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, WS65 - 1, Japanese

  • 転移性腎細胞癌に対する3rdライン分子標的治療としてのテムシロリムスの治療成績
    宮崎 彰, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P44 - 2, Japanese

  • 当院における進行性腎癌に対するパゾパニブ投与11例の初期治療成績
    今井 聡士, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P44 - 8, Japanese

  • 術前の尿道線維化・炎症とロボット支援腹腔鏡下前立腺全摘(RARP)術後尿禁制との検討
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P52 - 4, Japanese

  • 前立腺癌患者における癌検出ウイルスマーカーOBP-1101を用いた血中循環癌細胞の検出
    日向 信之, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 浦田 泰生, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P54 - 8, Japanese

  • 神戸大学における去勢抵抗性前立腺癌に対するカバジタキセルの治療経験
    日向 信之, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 石村 武志, 中野 雄造, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P57 - 1, Japanese

  • 去勢抵抗性前立腺癌に対する新規ホルモン療法後のドセタキセル+プレドニゾン療法
    鈴木 光太郎, 坂東 由加里, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P58 - 2, Japanese

  • ドセタキセル投与前の去勢抵抗性前立腺癌に対するエンザルタミドの治療成績
    原 琢人, 鈴木 光太郎, 桃園 宏之, 今井 聡志, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 藤澤 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, P59 - 4, Japanese

  • 原田 健一, 原 琢人, 今井 聡士, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 日向 信之, 藤澤 正人
    日本老年泌尿器科学会, Oct. 2016, 日本老年泌尿器科学会誌, 29, 82 - 82, Japanese

  • 術前の尿道線維化および炎症所見がロボット支援根治的前立腺全摘術後の短期尿禁制に及ぼす影響
    日向 信之, 桃園 宏之, 板東 由加里, 原 琢人, 今井 聡士, 宮崎 彰, 寺川 智章, 古川 順也, 原田 健一, 中野 雄造, 藤澤 正人
    日本外科系連合学会, Oct. 2016, 日本外科系連合学会誌, 41(5) (5), 889 - 889, Japanese

  • 転移性腎細胞癌に対する分子標的薬療法の治療成績
    今井 聡士, 原 琢人, 桃園 宏之, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 日向 信之, 原田 健一, 村蒔 基次, 三宅 秀明, 藤澤 正人
    泌尿器科紀要刊行会, Apr. 2016, 泌尿器科紀要, 62(4) (4), 220 - 220, Japanese

  • 腎癌細胞株に対するclusterinを標的としたアンチセンスオリゴによるAxitinibの効果増強
    今井 聡士, 原 琢人, 桃園 宏之, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 日向 信之, 原田 健一, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP1 - 017, Japanese

  • 腎門部腫瘍に対するロボット支援腎部分切除術の成績
    古川 順也, 西川 昌友, 寺川 智章, 千葉 公嗣, 重村 克巳, 松下 経, 日向 信之, 原田 健一, 石村 武志, 村蒔 基次, 三宅 秀明, 田中 一志, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP2 - 243, Japanese

  • 結節性硬化症に伴う腎血管筋脂肪腫に対するエベロリムスの使用経験
    原田 健一, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 鄭 裕元, 西川 昌友, 寺川 智章, 古川 順也, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP3 - 029, Japanese

  • 腎癌細胞株に対するclusterinを標的としたアンチセンスオリゴによるAxitinibの効果増強
    今井 聡士, 原 琢人, 桃園 宏之, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 日向 信之, 原田 健一, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP1 - 017, Japanese

  • 腎門部腫瘍に対するロボット支援腎部分切除術の成績
    古川 順也, 西川 昌友, 寺川 智章, 千葉 公嗣, 重村 克巳, 松下 経, 日向 信之, 原田 健一, 石村 武志, 村蒔 基次, 三宅 秀明, 田中 一志, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP2 - 243, Japanese

  • 結節性硬化症に伴う腎血管筋脂肪腫に対するエベロリムスの使用経験
    原田 健一, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, 鄭 裕元, 西川 昌友, 寺川 智章, 古川 順也, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本泌尿器科学会総会事務局, Apr. 2016, 日本泌尿器科学会総会, 104回, PP3 - 029, Japanese

  • 当科における技術認定者育成の取り組み 自治体との連係を通じて
    田中 一志, 重村 克巳, 寺川 智章, 日向 信之, 石村 武志, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本内視鏡外科学会, Dec. 2015, 日本内視鏡外科学会雑誌, 20(7) (7), OS33 - 3, Japanese

  • 寺川 智章, 宮崎 彰, 西川 昌友, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 田中 一志, 藤澤 正人
    日本泌尿器内視鏡学会, Nov. 2015, Japanese Journal of Endourology, 28(3) (3), 222 - 222, Japanese

  • 筋層非浸潤性膀胱癌に対するピラルビシン術直後単回膀胱内注入療法による再発予防効果
    村蒔 基次, 日向 信之, 寺川 智章, 古川 順也, 原田 健一, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1935 - 1935, Japanese

  • 進行前立腺癌に対する抗アンドロゲン剤除去及び抗アンドロゲン剤交替療法の臨床的検討
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 771 - 771, Japanese

  • 神戸大学におけるロボット支援腹腔鏡下前立腺全摘除術後のQOLに関する検討
    宮崎 彰, 原 琢人, 桃園 宏之, 今井 聡士, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 782 - 782, Japanese

  • 去勢抵抗性前立腺癌に対する新規ホルモン製剤の使用経験
    寺川 智章, 桃園 宏之, 今井 聡士, 宮崎 彰, 鄭 裕元, 西川 昌友, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 803 - 803, Japanese

  • 泌尿器 精巣胚細胞腫瘍の治療 難治性胚細胞腫瘍患者に対する救済化学療法としてのirinotecan・nedaplatin併用療法
    西川 昌友, 桃園 宏之, 今井 聡志, 宮崎 彰, 鄭 裕元, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1439 - 1439, Japanese

  • 腎細胞癌におけるGeriatric Nutritional Risk Index(GNRI)の予後予測因子としての意義
    原 琢人, 桃園 宏之, 今井 聡志, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1842 - 1842, Japanese

  • 高齢者の転移性腎癌に対する分子標的治療の臨床的検討
    原田 健一, 原 琢人, 桃園 宏之, 今井 聡志, 宮崎 彰, 西川 昌友, 寺川 智章, 古川 順也, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1893 - 1893, Japanese

  • MVAC抵抗性尿路上皮癌に対するgemcitabine/carboplatin療法の成績
    今井 聡士, 原 琢人, 桃園 宏之, 宮崎 彰, 西川 昌友, 鄭 裕元, 寺川 智章, 古川 順也, 原田 健一, 日向 信之, 村蒔 基次, 三宅 秀明, 藤澤 正人
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 1990 - 1990, Japanese

  • INVERSE ASSOCIATION BETWEEN THE PRESENCE OF HISTOLOGICAL INFLAMMATION IN NEEDLE BIOPSY SPECIMENS AND THE POSITIVE BIOPSY FINDINGS FOR PROSTATE CANCER IN MEN WITH SERUM PROSTATE-SPECIFIC ANTIGEN LEVEL OF 10-50 NG/ML
    Tomoaki Terakawa, Hideaki Miyake, Iori Sakai, Masato Fujisawa
    Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E833 - E833, English
    Summary international conference

  • Yuji Kusuda, Hideaki Miyake, Tomoaki Terakawa, Junya Furukawa, Mototsugu Muramaki, Masato Fujisawa
    Apr. 2011, INTERNATIONAL JOURNAL OF UROLOGY, 18(4) (4), 326 - 329, English
    Book review

  • EXPRESSION PROFILE OF MOLECULAR MARKERS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION IN RENAL CELL CARCINOMA
    Mototsugu Muramaki, Hideaki Miyake, Tomoaki Terakawa, Yuuji Kusuda, Masato Fujisawa
    Apr. 2011, JOURNAL OF UROLOGY, 185(4) (4), E50 - E50, English
    Summary international conference

  • THREE-DIMENSIONAL (3D) VISION: DOES IT IMPROVE ASSISTANT SKILLS DURING ROBOTIC SURGERY? AN ASSESSMENT OF A 3D SYSTEM USING A FLAT HIGH-QUALITY 3D SCREEN AND POLARIZED GLASSES
    Kazushi Tanaka, Minori Matsumoto, Tomihiko Yasufuku, Katsumi Shigemura, Kohei Yamaguchi, Tomoaki Terakawa, Takeshi Ishimura, Mototsugu Muramaki, Takahiro Haraguchi, Junya Furukawa, Yuzo Nakano, Hideaki Miyake, Masato Fujisawa
    Apr. 2011, JOURNAL OF UROLOGY, 185(4) (4), E600 - E600, English
    Summary international conference

  • SURGICAL TREATMENT FOR INVASIVE BLADDER CANCER IN ELDERLY PATIENTS AGED 80 YEARS OR OLDER
    TAKENAKA ATSUSHI, SAKAI IORI, TERAKAWA TOMOAKI, FURUKAWA JUNYA, MURAMAKI MOTOTSUGU, MIYAKE HIDEAKI, TANAKA KAZUSHI, FUJISAWA MASATO, YAMANAKA KAZUKI, INOUE TAKA-AKI
    日本泌尿器科学会西日本支部, 20 Jul. 2010, The Nishinihon journal of urology, 72(7) (7), 376 - 383, Japanese

  • GROWTH INHIBITION AND ENHANCED CHEMOSENSITIVITY BY DOWNREGULATION OF AURORA-A IN HUMAN RENAL CELL CARCINOMA CAKI-2 CELLS USING SHORT HAIRPIN RNA
    Tomoaki Terakawa, Hideaki Miyake, Toshifumi Kurahashi, Masato Fujisawa
    Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E31 - E31, English
    Summary international conference

  • ENHANCED SENSITIVITY TO ANDROGEN WITHDRAWAL DUE TO OVEREXPRESSION OF INTERLEUKIN-6 IN ANDROGEN-DEPENDENT HUMAN PROSTATE CANCER LNCAP CELLS
    Tomoaki Terakawa, Hideaki Miyake, Junya Furukawa, Martin Gleave, Masato Fujisawa
    Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E88 - E89, English
    Summary international conference

  • ANTIANDROGEN BICALUTAMIDE ACTIVATES ANDROGEN RECEPTOR WITH A MUTATION IN CODON 741 THROUGH MITOGEN ACTIVATED PROTEIN KINASE PATHWAY
    Tomoaki Terakawa, Hideaki Miyake, Junya Furukawa, Masato Fujisawa
    Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E89 - E89, English
    Summary international conference

  • CHEMOSENSITIZATION AND INHIBITION OF TUMOR GROWTH BY SHORT HAIRPIN RNA TARGETING INTERLEUKIN-6 IN ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCER PC3 CELLS
    Iori Sakai, Hideaki Miyake, Tomoaki Terakawa, Masato Fujisawa
    Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E88 - E88, English
    Summary international conference

  • ESTABLISHMENT OF SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA ACHN CELLS AND CHARCTERIZATION OF THEIR ACQUIRED RESISTANT MECHANISM
    Iori Sakai, Hideaki Miyake, Tomoaki Terakawa, Masato Fujisawa
    Apr. 2010, JOURNAL OF UROLOGY, 183(4) (4), E31 - E31, English
    Summary international conference

  • ASSESSMENT OF VOIDING FUNCTION OF ORTHOTOPIC NEOBLADDERS IN ELDERLY PATIENTS WITH LONG-TERM SURVIVAL
    Atsushi Takenaka, Tomoaki Terakawa, Masafumi Kumano, Iori Sakai, Mototsugu Muramaki, Toshifumi Kurahashi, Hideaki Miyake, Hideo Soga, Kazushi Tanaka, Masato Fujisawa
    Apr. 2009, JOURNAL OF UROLOGY, 181(4) (4), 269 - 269, English
    Summary international conference

  • ENHANCED SENSITIVITY TO ANDROGEN WITHDRAWAL BY OVEREXPRESSION OF INTERLEUKIN-6 IN HUMAN ANDROGEN-DEPENDENT PROSTATE CANCER LNCAP CELLS
    Tomoaki Terakawa, Hideaki Miyake, Junya Furukawa, Atsushi Takenaka, Masato Fujisawa
    Apr. 2009, JOURNAL OF UROLOGY, 181(4) (4), 480 - 480, English
    Summary international conference

  • EFFICACY OF COMBINATION SALVAGE CHEMOTHERAPY WITH METHOTREXATE, ACTINOMYCIN D AND ETOPOSIDE FOR ADVACED GERM CELL TUMOR PATIENTS WITH CHORIOCARCINOMA COMPONENT
    Tomoaki Terakawa, Hideaki Miyake, Atsushi Takenaka, Masato Fujisawa
    Apr. 2009, JOURNAL OF UROLOGY, 181(4) (4), 198 - 199, English
    Summary international conference

  • Risk factors for intravesical recurrence following surgical management of transitional cell carcinoma of the upper urinary tract
    Tomoaki Terakawa, Hideaki Miyake, Atsushi Takenaka, Sadao Kamidono, Masato Fujisawa
    Apr. 2008, JOURNAL OF UROLOGY, 179(4) (4), 292 - 292, English
    Summary international conference

  • Imroved sensitivity to detect micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer who underwent radical prostatectomy
    Tomoaki Terakawa, Hideaki Miyake, Atsushi Takenaka, Sadao Kamidono, Masato Fujisawa
    Apr. 2008, JOURNAL OF UROLOGY, 179(4) (4), 50 - 50, English
    Summary international conference

  • 保存的治療にて軽快した腎マラコプラキアの1例
    田口 功, 寺川 智章, 常森 寛行, 今西 治, 山中 望, 近藤 武史, 伊藤 利江子
    (一社)日本泌尿器科学会, Nov. 2007, 日本泌尿器科学会雑誌, 98(7) (7), 839 - 842, Japanese

  • 内分泌療法が奏効した前立腺導管癌の1例
    田口 功, 寺川 智章, 常森 寛行, 今西 治, 山中 望, 伊藤 利江子
    西日本泌尿器科学会, Nov. 2007, 西日本泌尿器科, 69(11) (11), 647 - 650, Japanese

  • MOFを併発した前立腺膿瘍、精巣上体膿瘍、精巣膿瘍の1例
    福本 亮, 寺川 智章, 常森 寛行, 田口 功, 今西 治, 山中 望
    泌尿器科紀要刊行会, Oct. 2007, 泌尿器科紀要, 53(10) (10), 741 - 741, Japanese

  • 術中電気刺激による陰茎海綿体神経の同定および神経温存判定 : 腹腔鏡下前立腺全摘除術での検討
    曽我 英雄, 武中 篤, 寺川 智章, 熊野 晶文, 古川 順也, 石村 武志, 村蒔 基次, 倉橋 俊史, 三宅 秀明, 竹田 雅, 田中 一志, 藤澤 正人
    10 Aug. 2007, 日本性機能学会雑誌 = The japanese journal of Impotence Research, 22(2) (2), 241 - 242, Japanese

  • Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: A comparative study with conventional open retroperitoneal nephroureterectomy
    Tomoaki Terakawa, Hideaki Miyake, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Masato Fujisawa
    Apr. 2007, JOURNAL OF UROLOGY, 177(4) (4), 138 - 138, English
    Summary international conference

  • 尿管子宮内膜症の1例
    常森 寛行, 寺川 智章, 田口 功, 今西 治, 山中 望
    泌尿器科紀要刊行会, Sep. 2006, 泌尿器科紀要, 52(9) (9), 750 - 750, Japanese

  • 視力低下および視野障害を呈した前立腺癌の1例
    今西 治, 寺川 智章, 常森 寛行, 野瀬 隆一郎, 田口 功, 山中 望
    泌尿器科紀要刊行会, Sep. 2006, 泌尿器科紀要, 52(9) (9), 749 - 749, Japanese

  • 鼠径ヘルニア術後に発生した膀胱周囲肉芽腫の1例
    寺川 智章, 常森 寛行, 田口 功, 今西 治, 山中 望, 伊藤 利江子, 近藤 武史
    泌尿器科紀要刊行会, Jul. 2006, 泌尿器科紀要, 52(7) (7), 595 - 595, Japanese

  • 急激な転帰をたどった両側上部尿路腫瘍の1例
    寺川 智章, 常森 寛行, 田口 功, 今西 治, 山中 望, 伊藤 利江子, 近藤 武史
    泌尿器科紀要刊行会, Jul. 2006, 泌尿器科紀要, 52(7) (7), 585 - 585, Japanese

  • 膀胱褐色細胞腫の1例
    今西 治, 寺川 智章, 常森 寛行, 田口 功, 山中 望, 伊藤 江利子, 近藤 武史
    泌尿器科紀要刊行会, Jul. 2006, 泌尿器科紀要, 52(7) (7), 596 - 596, Japanese

  • 根治的前立腺全摘除術後の補助放射線療法に関する臨床的検討
    田口 功, 寺川 智章, 常森 寛行, 今西 治, 山中 望, 畠中 真帆, 藤代 早月, 本山 新, 小久保 雅樹
    泌尿器科紀要刊行会, May 2006, 泌尿器科紀要, 52(5) (5), 396 - 396, Japanese

  • 膀胱癌治療後に発生した腎盂尿管癌の臨床的検討
    寺川 智章, 常森 寛行, 田口 功, 今西 治, 山中 望
    泌尿器科紀要刊行会, May 2006, 泌尿器科紀要, 52(5) (5), 398 - 398, Japanese

  • 常森 寛行, 寺川 智章, 田口 功, 今西 治, 坂野 茂, 山中 望
    (一社)日本泌尿器科学会, Mar. 2006, 日本泌尿器科学会雑誌, 97(2) (2), 363 - 363, Japanese

  • 下部尿管再建術の臨床的検討
    今西 治, 寺川 智章, 常森 寛行, 田口 功, 山中 望
    (一社)日本泌尿器科学会, Mar. 2006, 日本泌尿器科学会雑誌, 97(2) (2), 292 - 292, Japanese

  • 前立腺全摘除術における尖部処理の改良と術後尿禁制
    寺川 智章, 武中 篤, 常森 寛行, 田口 功, 今西 治, 山中 望
    (一社)日本泌尿器科学会, Jan. 2006, 日本泌尿器科学会雑誌, 97(1) (1), 1 - 9, Japanese

■ Lectures, oral presentations, etc.
  • Treatment outcomes of non-metastatic castration-resistant prostate cancer
    寺川智章, 脇田直人, 白石祐介, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 原琢人, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    第108回 日本泌尿器科学会総会, Dec. 2020

  • Clinical outcome of EP therapy (VP16+CDDP）in 12 prostate cancer patients with neuroendocrine differentiation
    寺川智章, 脇田直人, 白石祐介, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 原琢人, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    第108回 日本泌尿器科学会総会, Dec. 2020

  • Presurgical therapyによって腎静脈内まで腫瘍塞栓が縮小し腹腔鏡下に摘除し得た腎癌下大静脈腫瘍塞栓の1例
    寺川智章, 前田光毅, 脇田直人, 白石祐介, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 原琢人, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    第70回 日本泌尿器科学会中部総会, Dec. 2020

  • Clinical outcome of EP therapy (VP16+CDDP）in 10 prostate cancer patients with neuroendocrine differentiation
    寺川智章, 板東由加里, 鈴木光太郎, 原琢人, 古川順也, 原田健一, 日向信之, 中野雄造, 藤澤正人
    日本泌尿器腫瘍学会第6回学術集会, Oct. 2020

  • 腎盂尿管移行部狭窄症に対するロボット支援腹腔鏡下腎盂形成術の初期経験
    寺川智章, 坂本茉莉子、岡村泰義、板東由加里、鈴木光太郎、原琢人、古川順也、原田健一、石村武志、重村克己、日向信之、中野雄造、藤澤正人
    第33回日本泌尿器内視鏡学会, Nov. 2019
    Oral presentation

  • 膀胱ヘルニアを合併した前立腺癌に対しロボット支援下前立腺全摘除術を施行した1例
    TERAKAWA TOMOAKI, CHIBA KOJI, HARADA KENICHI, SHIGEMURA KATSUMI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第31回日本内視鏡外科学会学術総会, Dec. 2018, Japanese, 福岡, Domestic conference
    Poster presentation

  • 原発性アルドステロン症に対する腹腔鏡下手術の手術成績と臨床的アウトカムの検討
    坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第31回日本内視鏡外科学会学術総会, Dec. 2018, Japanese, 福岡, Domestic conference
    Poster presentation

  • ロボット支援根治的前立腺全摘除術における断端陽性症例の生物学的再発予測因子についての検討
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第34回前立腺シンポジウム, Dec. 2018, Japanese, 東京, Domestic conference
    Poster presentation

  • 当院におけるロボット支援根治的前立腺全摘除術における拡大リンパ節郭清の検討
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第32回日本泌尿器内視鏡学会総会, Nov. 2018, Japanese, 仙台, Domestic conference
    Poster presentation

  • カバジタキセルの使用経験
    HINATA NOBUYUKI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, FUJISAWA MASATO
    第3回近畿CRPC講演会, Nov. 2018, Japanese, 大阪, Domestic conference
    Poster presentation

  • 膀胱ヘルニアを合併した前立腺がんに対し ロボット支援腹腔鏡下前立腺全摘術を施行した一例
    山下 遥介, TERAKAWA TOMOAKI, SHIGEMURA KATSUMI, HARADA KENICHI, HINATA NOBUYUKI, ISHIMURA TAKESHI, NAKANO YUZO, FUJISAWA MASATO
    第70回西日本泌尿器科学会総会, Oct. 2018, Japanese, 長崎, Domestic conference
    Oral presentation

  • 当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療経験
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, Japanese, 横浜, Domestic conference
    Oral presentation

  • 転移性副腎腫瘍に対する副腎摘除術の臨床的検討
    坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第4回 日本泌尿器腫瘍学会, Oct. 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
    FURUKAWA JYUNYA, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, SHIGEMURA KATSUMI, HARADA KENICHI, HINATA NOBUYUKI, ISHIMURA TAKESHI, NAKANO YUZO, FUJISAWA MASATO
    第70回西日本泌尿器科学会総会, Oct. 2018, Japanese, 長崎, Domestic conference
    Oral presentation

  • 転移性腎癌に対する2nd lineの治療選択 ～アキシチニブ推奨の立場から～
    HARADA KENICHI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, SHIGEMURA KATSUMI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第68回日本泌尿器科学会中部総会, Oct. 2018, Japanese, 名古屋, Domestic conference
    Poster presentation

  • 淡明細胞型腎細胞癌に対するfirst-line Sunitinibの治療成績
    FURUKAWA JYUNYA, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第4回 日本泌尿器腫瘍学会, Oct. 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    HARADA KENICHI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, SHIGEMURA KATSUMI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第70回西日本泌尿器科学会総会, Oct. 2018, Japanese, 長崎, Domestic conference
    Oral presentation

  • 神戸大学におけるロボット支援根治的膀胱全摘除術の初期成績
    HINATA NOBUYUKI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, Japanese, 横浜, Domestic conference
    Oral presentation

  • 使用した腎細胞癌症例の検討
    坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • The efficacy of Nivolumab in advanced Renal Cell Carcinoma
    原 琢人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, English, 横浜, Domestic conference
    Poster presentation

  • Presurgical therapyにて病理学的に完全奏功を得た腎癌下大静脈腫瘍栓の1例
    戸邉 泰将, TERAKAWA TOMOAKI, MATSUSHITA KEI, FURUKAWA JYUNYA, HARADA KENICHI, ISHIMURA TAKESHI, SHIGEMURA KATSUMI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第239回日本泌尿器科学会関西地方会, Oct. 2018, Japanese, 滋賀, Domestic conference
    Oral presentation

  • Presurgical Pazopanib for Renal Cell Carcinoma with High Level Inferior Vena Caval Thrombus: Single Institutional Study
    Tomoaki Terakawa, Mariko Sakamoto, Yukari Bando, Yasuyoshi Okamura, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Masato Fujisawa
    第56回日本癌治療学会学術集会, Oct. 2018, English, 横浜, Domestic conference
    Poster presentation

  • Neutrophil-to-lymphocyte ratio as predictive biomarkers for response to nivolumab in patients with advanced renal cell carcinoma
    HARADA KENICHI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, SHIGEMURA KATSUMI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, English, 横浜, Domestic conference
    Poster presentation

  • Clinical outcomes of patients with metastatic renal cell carcinoma treated with pazopanib
    鈴木 光太郎, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第56回日本癌治療学会学術集会, Oct. 2018, English, 横浜, Domestic conference
    Poster presentation

  • 当院における排尿ケアチームの取り組み
    FUKUDA TERUO, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, SHIGEMURA KATSUMI, HARADA KENICHI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第25回日本排尿機能学会, Sep. 2018, Japanese, 名古屋, Domestic conference
    Oral presentation

  • 転移性副腎腫瘍に対する開腹手術、腹腔鏡下手術の検討
    岡村 泰義, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第31回近畿内視鏡外科研究会, Sep. 2018, Japanese, 神戸, Domestic conference
    Oral presentation

  • Knockdown of PD-L1 in Mouse Renal Cell Carcinoma Inhibits Tumor Growth and Improve the Anti-tumor effect of Sunitinib.
    原 琢人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第77回日本癌学会学術総会, Sep. 2018, English, 大阪, Domestic conference
    Poster presentation

  • High Expression of SLCO2B1 in Prostate Cancer is Associated with worse disease-free survival after Radical Prostatectomy
    Tomoaki Terakawa, Eriko Katsuta, Yukari Bando, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Masato Fujisawa, Khurshid A. Guru, Kazuaki Takabe
    第77回日本癌学会学術総会, Sep. 2018, English, 大阪, Domestic conference
    Poster presentation

  • 前立腺癌合同カンファレンスを通じたロボット支援根治的前立腺全摘除術術後尿禁制改善の試み
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第15回泌尿器科再建再生研究会, Jun. 2018, Japanese, 沖縄, Domestic conference
    Poster presentation

  • SLCO2B1 high expressed tumor in high Gleason score prostate cancer patients recur earlier after Radical Prostatectomy
    Tomoaki Terakawa, Eriko Katsuta, Khurshid Guru, Kazuaki Takabe
    The 113th American Urological Association, May 2018, English, San Francisco, International conference
    Poster presentation

  • Interposition of novel nerve-regeneration conduit after wide excision of the neurovascular bundle during radical prostatectomy did not improve postoperative erectile function
    Nobuyuki Hinata, Tomoaki Terakawa, Koji Chiba, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    AUA annual meeting 2018, May 2018, English, San Francisco, International conference
    Poster presentation

  • Accuracy of ACS NSQIP Universal Surgical Risk Calculator in Predicting Complications Following Robot-Assisted Radical Cystectomy at a National Comprehensive Cancer Center
    Tomoaki Terakawa, Ahmed A. Hussein, Youssef E. Ahmed, Paul R. May, Austin Miller, Zhe Jing, Nunez Bragayrac LA, Cohen Jared, Hijab Khan, Adam Cole, Omer Rana, Michelle Whittum, Renuka Kanapan, Christian Prechtl, Terrell Johnson, Qiang Li, Khurshid A. Guru
    The 113th American Urological Association, May 2018, English, San Francisco, International conference
    Oral presentation

  • 当院で施行したロボット支援根治的前立腺全摘除術におけるpT3症例の生物学的再発予測因子
    板東 由加里, 坂本 茉莉子, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference
    Poster presentation

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    HARADA KENICHI, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, SHIGEMURA KATSUMI, ISHIMURA TAKESHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference
    Oral presentation

  • 根治的膀胱全摘除術における 非禁制型尿路変向術の 術後腎機能に与える影響の検討
    鈴木 光太郎, 岡村 泰義, 板東 由加里, 原 琢人, 桃園 宏之, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference
    Poster presentation

  • Presurgical therapy としてTyrosine Kinase Inhibitors (TKIs) を使用した腎細胞癌症例の検討
    坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, FUJISAWA MASATO
    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference
    Poster presentation

  • PD-L1発現を低下させた腎癌細胞のマウスモデルにおけるsunitinibの抗腫瘍効果についての検討
    原 琢人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, TERAKAWA TOMOAKI, FURUKAWA JYUNYA, HARADA KENICHI, HINATA NOBUYUKI, NAKANO YUZO, 三宅 秀明, FUJISAWA MASATO
    第106回日本泌尿器科学会総会, Apr. 2018, Japanese, 京都, Domestic conference
    Poster presentation

  • High Expression of SLCO2B1 is Associated with Prostate Cancer Recurrence after Radical Prostatectomy
    Tomoaki Terakawa, Eriko Katsuta, Kazuaki Takabe, Yukari Bando, Takuto Hara, Koutarou Suzuki, Hiroyuki Momozono, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
    第106回日本泌尿器科学会総会 16th Urological Association of Asia (UAA) Congress 2018, Apr. 2018, English, 京都, International conference
    Oral presentation

  • 神戸大学における転移性腎癌に対するニボルマブの初期経験
    Harada Kenichi, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第67回 日本泌尿器科学会中部総会, Nov. 2017, Japanese, 日本泌尿器科学会, 大阪, Domestic conference
    Oral presentation

  • 神戸大学におけるTSC-AMLに対するエベロリムスの治療成績
    Harada Kenichi, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Shigemura Katsumi, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第69回 西日本泌尿器科学会総会, Nov. 2017, Japanese, 日本泌尿器科学会, 大分, Domestic conference
    Oral presentation

  • 当院における進行性腎細胞癌に対するパゾパニブの治療成績
    鈴木 光太郎, 岡村 泰義, 板東 由加里, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第55回 日本癌治療学会学術集会, Oct. 2017, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 当院におけるニボルマブの初期使用経験
    原 琢人, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第3回 日本泌尿器腫瘍学会学術集会, Oct. 2017, Japanese, 泌尿器腫瘍学会, 横浜, Domestic conference
    Poster presentation

  • 腎静脈塞栓を有する腎細胞癌患者に対する術前補助化学療法としてのパゾパニブの使用経験
    原 琢人, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第55回 日本癌治療学会学術集会, Oct. 2017, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 根治的前立腺全摘除術Gleason Score 8-10症例の臨床的検討
    岡村 泰義, Furukawa Jyunya, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第55回 日本癌治療学会学術集会, Oct. 2017, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • ロボット支援腎部分切除術におけるRENAL NEPHROMETRY SCORと手術成績に関する検討
    Furukawa Jyunya, 坂本 茉利子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Harada Kenichi, Hinata Nobuyuki, Fujisawa Masato
    第55回 日本癌治療学会学術集会, Oct. 2017, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 前立腺癌患者におけるデガレリクスと下部尿路症状の関連性
    Terakawa Tomoaki, Nakano Yuzo, Fujisawa Masato
    第24回 日本排尿機能学会総会, Sep. 2017, Japanese, 日本排尿機能学会, 有明, Domestic conference
    Poster presentation

  • 神戸大学における開腹腎部分切除術と腹腔鏡下腎部分切除術の検討
    角井 健太, Harada Kenichi, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Shigemura Katsumi, Ishimura Takeshi, Matsushita Kei, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第30回 近畿内視鏡外科研究会, Sep. 2017, Japanese, 近畿内視鏡外科研究会, 大阪, Domestic conference
    Oral presentation

  • 当院における単孔式腹腔鏡下ドナー腎採取術の成績
    横山 直己, Ishimura Takeshi, Terakawa Tomoaki, Furukawa Jyunya, Shigemura Katsumi, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    6th Reduced Port Surgery Forum 2017 in Oita, Aug. 2017, Japanese, 単孔式内視鏡手術研究会, 大分, Domestic conference
    Oral presentation

  • 播種性骨髄癌症を伴った前立腺癌の1例
    白石 祐介, Terakawa Tomoaki, Furukawa Jyunya, Shigemura Katsumi, Harada Kenichi, Matsushita Kei, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第235回 日本泌尿器科学会関西地方会, Jun. 2017, Japanese, 日本泌尿器科学会, 大阪, Domestic conference
    Oral presentation

  • ロボット支援腹腔鏡下前立腺全摘時に使用したヘモロックが膀胱に迷入した1例
    河村 駿, Terakawa Tomoaki, Furukawa Jyunya, Shigemura Katsumi, Harada Kenichi, Matsushita Kei, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第235回 日本泌尿器科学会関西地方会, Jun. 2017, Japanese, 日本泌尿器科学会, 大阪, Domestic conference
    Oral presentation

  • The nerves in the glans penis: anatomical and histological study
    Hinata Nobuyuki, Ahmed Aly Hussein, Terakawa Tomoaki, Yukari Bando, Gen Murakami, Khurshid Guru, Fujisawa Masato
    AUA Annual Meeting 2017, May 2017, English, American Urological Association, Boston, U.S.A, International conference
    Poster presentation

  • Hiatal Smooth Muscles: a Novel Anatomical Landmark for Female Nerve-Sparing Radical Cystectomy
    Hinata Nobuyuki, Ahmed Aly Hussein, Terakawa Tomoaki, Yukari Bando, Gen Murakami, Khurshid Guru, Fujisawa Masato
    AUA Annual Meeting 2017, May 2017, English, American Urological Association, Boston, U.S.A, International conference
    Poster presentation

  • Detection of circulating tumor cell in the patients with prostate cancer using novel viral marker OBP-1101
    Hinata Nobuyuki, Yukari Bando, Akira Miyazaki, Terakawa Tomoaki, Junya Furukawa, Harada Kenichi, Fujisawa Masato
    AUA Annual Meeting 2017, May 2017, English, American Urological Association, Boston, U.S.A, International conference
    Oral presentation

  • 当院における去勢抵抗性前立腺癌に対する抗アンドロゲン薬交替療法の成績
    鈴木 光太郎, 岡村 泰義, 板東 由加里, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 当院および関連施設における去勢抵抗性前立腺癌に対するアビラテロン治療成績についての検討
    桃園 宏之, 鈴木 光太郎, 原 琢人, 今井 聡士, 宮崎 彰, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 前立腺癌患者における癌検出ウィルスマーカーOBP-1101を用いた血中循環癌細胞の検出
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 神戸大学における転移性腎癌に対する1st lineスニチニブ-2nd lineアキシチニブの検討
    Harada Kenichi, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Shigemura Katsumi, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Oral presentation

  • 神戸大学におけるTSC-AMLに対するエベロリムスの治療成績と診療連携の重要性
    Harada Kenichi, 坂本 茉莉子, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Shigemura Katsumi, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Oral presentation

  • 神経温存ロボット支援根治的前立腺全摘除術後の摘出床へのHA-CM貼付が術後尿禁制に及ぼす影響
    Hinata Nobuyuki, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 術前にパゾパニブ投与を行った下大静脈腫瘍塞栓を伴う転移性腎癌の2例
    Terakawa Tomoaki, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 根治的前立腺全摘除術Gleason Score 8-10症例の 臨床的検討
    Furukawa Jyunya, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 去勢抵抗性前立腺癌に対するエンザルタミドの治療成績
    原 琢人, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • ロボット支援根治的前立腺全摘除術における解剖学的根拠に基づいた膀胱頸部離断法
    Hinata Nobuyuki, 板東 由加里, 岡村 泰義, 鈴木 光太郎, 原 琢人, 桃園 宏之, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Oral presentation

  • ドセタキセル抵抗性去勢抵抗性前立腺癌に対するカバジタキセルの初期治療経験
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第105回 日本泌尿器科学会総会, Apr. 2017, Japanese, 日本泌尿器科学会, 鹿児島, Domestic conference
    Poster presentation

  • 術前にパゾパニブを投与した下大静脈腫瘍塞栓を伴う右腎癌の一例
    前田 光毅, Miyazaki Akira, Enatsu Noritoshi, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Shigemura Katsumi, Harada Kenichi, Hinata Nobuyuki, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第234回 日本泌尿器科学会関西地方会, Jan. 2017, Japanese, 日本泌尿器科学会, 京都, Domestic conference
    Oral presentation

  • 当科における膀胱尿路上皮癌に対するBCG維持療法の成績
    Harada Kenichi, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, 重村 克己, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第9回 BCG注入療法研究会, Dec. 2016, Japanese, BCG注入療法研究会, 東京, Domestic conference
    Oral presentation

  • 神戸大学における開腹部分切除術と腹腔鏡下部分切除術の検討
    Miyazaki Akira, Furukawa Jyunya, Terakawa Tomoaki, Chiba Koji, 重村 克己, Ishimura Takeshi, Matsushita Kei, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第29回 日本内視鏡外科学会, Dec. 2016, Japanese, 日本内視鏡外科学会, 横浜, Domestic conference
    Oral presentation

  • 血清DHEA-Sが去勢抵抗性前立腺癌に対するアビラテロンの効果予測因子になるかの検討
    Terakawa Tomoaki, 鈴木 光太郎, 板東 由加里, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第33回 前立腺シンポジウム, Dec. 2016, Japanese, 前立腺研究財団, 東京, Domestic conference
    Poster presentation

  • ロボット支援根治的前立腺全摘除術における拡大切除および拡大リンパ節廓清の手技と短期成績
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第29回 日本内視鏡外科学会, Dec. 2016, Japanese, 日本内視鏡外科学会, 横浜, Domestic conference
    Oral presentation

  • Efficacy and safety of tyrosine kinase inhibitors as first-line therapy for elderly patients with metastatic renal cell carcinoma
    Harada Kenichi, Satoshi Imai, Terakawa Tomoaki, Hideaki Miyake, Fujisawa Masato
    The 36th Societe International Urology Congress (SIU), Dec. 2016, English, Societe International Urology, Buenos Aires, Argentina, International conference
    Poster presentation

  • 神戸大学におけるTSC-AMLに対するエベロリムスの治療成績
    Harada Kenichi, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, 重村 克己, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第4回 日本結節性硬化症学会学術総会, Nov. 2016, Japanese, 日本結節性硬化症学会, 大阪, Domestic conference
    Oral presentation

  • 神経非温存ロボット支援根治的前立腺全摘除の際の神経再生誘導チューブ架橋留置が術後短期男性機能に及ぼす影響
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第30回 日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, 日本泌尿器内視鏡学会, 大阪, Domestic conference
    Oral presentation

  • 神経温存ロボット支援根治的前立腺全摘除術後の摘出床へのHA-CM貼付が術後尿禁制に及ぼす影響
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第30回 日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, 日本泌尿器内視鏡学会, 大阪, Domestic conference
    Oral presentation

  • 後腹膜アプローチによるロボット支援腎部分切除術の成績
    Furukawa Jyunya, Terakawa Tomoaki, Chiba Koji, Matsushita Kei, Shigemura Katsumi, Harada Kenichi, Ishimura Takeshi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第30回 日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, 日本泌尿器内視鏡学会, 大阪, Domestic conference
    Oral presentation

  • ロボット支援前立腺全摘における神経再生誘導チューブが術後短期男性機能に及ぼす影響
    Terakawa Tomoaki, Hinata Nobuyuki, Miyazaki Akira, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第30回 日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, 日本泌尿器内視鏡学会, 大阪, Domestic conference
    Oral presentation

  • ロボット支援根治的前立腺全摘除術の際の拡大切除および拡大リンパ節廓清の手技と初期成績
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Chiba Koji, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第30回 日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, 日本泌尿器内視鏡学会, 大阪, Domestic conference
    Oral presentation

  • 当科における膀胱尿路上皮癌に対するBCG維持療法の成績
    板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 当院における進行性腎癌に対するPazopanib投与16例の初期治療成績
    今井 聡士, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 転移性腎細胞癌に対する3rdライン分子標的治療としてのテムシロリムスの治療成績
    Miyazaki Akira, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 前立腺癌患者における癌検出ウイルスマーカーOBP-1101を用いた血中循環癌細胞の検出
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, 浦田 泰生, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Oral presentation

  • 術前の尿道線維化および炎症が ロボット支援下前立腺全摘（RARP）術後尿禁制に及ぼす影響についての検討
    桃園 宏之, 鈴木 光太郎, 原 琢人, 今井 聡士, Miyazaki Akira, 西川 昌友, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, 三宅 秀明, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • 血清DHEA-Sが去勢抵抗性前立腺癌に対するアビラテロンの効果予測因子になるかの検討
    Terakawa Tomoaki, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Oral presentation

  • 結節性硬化症に伴う腎血管筋脂肪腫に対するエベロリムスの使用経験
    Harada Kenichi, 鈴木 光太郎, 板東 由加里, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Hinata Nobuyuki, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第66回 日本泌尿器科学会中部総会, Oct. 2016, Japanese, 日本泌尿器科学会, 四日市, Domestic conference
    Oral presentation

  • 去勢抵抗性前立腺癌に対する新規ホルモン療法後のドセタキセル+プレドニゾン療法
    鈴木 光太郎, 坂東 由加里, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • ドセタキセル投与前の去勢抵抗性前立腺癌に対するエンザルタミドの治療成績
    原 琢人, 鈴木 光太郎, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Poster presentation

  • ドセタキセル抵抗性去勢抵抗性前立腺癌に対するカバジタキセルの初期治療経験
    Hinata Nobuyuki, 板東 由加里, 鈴木 光太郎, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第54回 日本癌治療学会学術集会, Oct. 2016, Japanese, 日本癌治療学会, 横浜, Domestic conference
    Oral presentation

  • The effects of Paclitaxel and Carboplatin as a second-line chemotherapy against advanced urothelial carcinoma after failure of first-line Gemcitabine and Cisplatin therapy
    Terakawa Tomoaki, Hiroyuki Momozono, Satoshi Imai, Miyazaki Akira, Masayuki Nishikawa, Junya Furukawa, Harada Kenichi, Hinata Nobuyuki, Takaaki Inoue, Yuzou Nakano, Fujisawa Masato
    14th Urological Association of Asia Congress, Jul. 2016, English, Urological Association of Asia Congress, Singapore , Singapore, International conference
    Oral presentation

  • 腎Solitary fibrous tumorの1例
    植木 秀登, Terakawa Tomoaki, Furukawa Jyunya, Shigemura Katsumi, Harada Kenichi, Hinata Nobuyuki, Ishimura Takeshi, Nakano Yuzo, Fujisawa Masato
    第232回 日本泌尿器科学会関西地方会, May 2016, Japanese, 日本泌尿器科学会, 和歌山, Domestic conference
    Oral presentation

  • 術前の尿道線維化および炎症所見がロボット支援根治的前立腺全摘術後の短期尿禁制に及ぼす影響
    Hinata Nobuyuki, 桃園 宏之, 板東 由加里, 原 琢人, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Nakano Yuzo, Fujisawa Masato
    第26回 骨盤外科機能温存研究会, May 2016, Japanese, 骨盤外科機能温存研究会, 東京, Domestic conference
    Oral presentation

  • 高齢者の転移性腎癌に対する1st line分子標的治療チロシンキナーゼ阻害剤の効果および安全性の検討
    Harada Kenichi, 原 琢人, 今井 聡士, Miyazaki Akira, 西川昌友, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Hinata Nobuyuki, Fujisawa Masato
    第29回 日本老年泌尿器科学会, May 2016, Japanese, 日本老年泌尿器科学会, 福岡, Domestic conference
    Oral presentation

  • Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies
    Hiroyuki Momozono, Kotaro Suzuki, Takuto Hara, Satoshi Imai, Miyazaki Akira, Masatomo Nishikawa, Terakawa Tomoaki, Junya Furukawa, Harada Kenichi, Hinata Nobuyuki, Nakano Yuzo, Hideaki Miyake, Fujisawa Masato
    American Urological Association 2016 Annual Meeting, May 2016, English, American Urological Association, San Diego, USA, International conference
    Poster presentation

  • Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of Axitinib in a human renal cell carcinoma model
    Satoshi Imai, Takuto Hara, Hiroyuki Momozono, Miyazaki Akira, Terakawa Tomoaki, Junya Furukawa, Harada Kenichi, Hinata Nobuyuki, Hideaki Miyake, Martin Gleave, Fujisawa Masato
    American Urological Association 2016 Annual Meeting L74:AA74+Z87F87L86:X87L86:AC87L86:AA87, May 2016, English, American Urological Association, San Diego, USA, International conference
    Poster presentation

  • 腎門部腫瘍に対するロボット支援腎部分切除術の成績
    Furukawa Jyunya, 西川 昌友, Terakawa Tomoaki, Chiba Koji, Shigemura Katsumi, Matsushita Kei, Hinata Nobuyuki, Harada Kenichi, Ishimura Takeshi, 三宅 秀明, 田中 一志, Fujisawa Masato
    第104回 日本泌尿器科学会総会, Apr. 2016, Japanese, 日本泌尿器科学会, 宮城, Domestic conference
    Poster presentation

  • 腎癌細胞株に対するclusterinを標的としたアンチセンスオリゴによるAxitinibの効果増強
    今井 聡士, 原 琢人, 桃園 宏之, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, 三宅 秀明, Fujisawa Masato
    第104回 日本泌尿器科学会総会, Apr. 2016, Japanese, 日本泌尿器科学会, 宮城, Domestic conference
    Poster presentation

  • 去勢抵抗性前立腺癌に対するアビラテロンの使用経験
    Terakawa Tomoaki, 原 琢人, 桃園 宏之, 今井 聡士, Miyazaki Akira, 鄭 裕元, 西川 昌友, Furukawa Jyunya, Harada Kenichi, 田中 一志, 三宅 秀明, Fujisawa Masato
    第104回 日本泌尿器科学会総会, Apr. 2016, Japanese, 日本泌尿器科学会, 宮城, Domestic conference
    Poster presentation

  • ドセタキセル耐性前立腺癌に対するカバジタキセルの抗腫瘍効果発現機序の解析
    Miyazaki Akira, 原 琢人, 桃園 宏之, 今井 聡士, 西川 昌友, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, 村蒔 基次, 三宅 秀明, Fujisawa Masato
    第104回 日本泌尿器科学会総会, Apr. 2016, Japanese, 日本泌尿器科学会, 宮城, Domestic conference
    Poster presentation

  • First line TKI治療を行った腎癌患者と免疫チェックポイントの関連ついての検討
    原 琢人, 鈴木 光太郎, 坂東 由加里, 桃園 宏之, 今井 聡士, Miyazaki Akira, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Fujisawa Masato
    第104回 日本泌尿器科学会総会, Apr. 2016, Japanese, 日本泌尿器科学会, 宮城, Domestic conference
    Poster presentation

  • 神戸大学におけるロボット支援腹腔鏡下前立腺全摘除術後のQOLに関する検討
    Terakawa Tomoaki, 宮崎 彰, Nishikawa Masatomo, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Tanaka Kazushi, Fujisawa Masato
    第29回 日本泌尿器内視鏡学会総会, Nov. 2015, Japanese, 日本泌尿器内視鏡学会, 東京, Domestic conference
    Poster presentation

  • 進行性前立腺がんに対する抗アンドロゲン剤除去および抗アンドロゲン剤交替療法についての臨床的検討
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Miyake Hideaki, Fujisawa Masato
    第53回 日本癌治療学会学術集会, Oct. 2015, Japanese, 日本癌治療学会, 京都, Domestic conference
    Poster presentation

  • 高齢者の転移性腎癌に対する分子標的治療の臨床的検討
    Harada Kenichi, 原 琢人, 桃園 宏之, 宮崎 彰, Nishikawa Masatomo, Terakawa Tomoaki, Furukawa Jyunya, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    第53回 日本癌治療学会学術集会, Oct. 2015, Japanese, 日本癌治療学会, 京都, Domestic conference
    Poster presentation

  • 去勢抵抗性前立腺癌に対する新規ホルモン製剤の使用経験
    Terakawa Tomoaki, 桃園 宏之, 今井 聡士, 宮崎 彰, 鄭 裕元, Nishikawa Masatomo, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    第53回 日本癌治療学会学術集会, Oct. 2015, Japanese, 日本癌治療学会, 京都, Domestic conference
    Poster presentation

  • Targeting clusterin using OGX-011 synergistically enhances antitumor activity of temsirolimus in a human renal cell carcinoma model
    Nishikawa Masatomo, Akira Miyazaki, Hiromoto Tei, Terakawa Tomoaki, Junya Furukawa, Ken-ichi Harada, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    第74回 日本癌学会学術総会, Oct. 2015, English, 日本癌学会, 名古屋, Domestic conference
    Poster presentation

  • Accelerated cell proliferation and enhanced resistance to docetaxel by inhibition of 4E-binding protein 1 expression in human castration-resistant prostate cancer PC3 cells
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Miyake Hideaki, Fujisawa Masato
    第74回 日本癌学会学術総会, Oct. 2015, English, 日本癌学会, 名古屋, Domestic conference
    Poster presentation

  • Significance of urethral fibrosis evaluated by preoperative magnetic resonance imaging as a predictor of continence status after RARP
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Miyake Hideaki, Fujisawa Masato
    European Cancer Congress2015, Sep. 2015, English, EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, ウィーン, オーストリア, International conference
    Poster presentation

  • Efficacy and safety of tyrosine kinase inhibitors as first-line therapy for elderly patients with metastatic renal cell carcinoma
    Terakawa Tomoaki, Harada Kenichi, H Momozono, S Imai, A Miyazaki, Nishikawa Masatomo, H Tei, Furukawa Jyunya, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    13th Congress of the Urological Association of Asia, Sep. 2015, English, Ｔhe Urological Association of Asia, 上海, 中国, International conference
    Oral presentation

  • 腎細胞癌における Geriatric Nutritional Risk Index（GNRI）の 予後予測因子としての意義
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Miyake Hideaki, Fujisawa Masato
    第46回 腎癌研究会, Jul. 2015, Japanese, 腎癌研究会, 東京, Domestic conference
    Oral presentation

  • Accelerated cell proliferation and enhanced resistance to docetaxel by inhibition of 4E-binding protein 1 expression in human castration-resistant prostate cancer PC3 cells
    桃園 宏之, 原 琢人, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Miyake Hideaki, Fujisawa Masato
    AUA2015 Annual Meeting, May 2015, English, American Urological Association, ニューオリンズ, アメリカ, International conference
    Poster presentation

  • 翻訳抑制因子4E-BP1発現抑制が腎細胞癌の形質変化に及ぼす影響
    宮崎 彰, 原 琢人, 桃園 宏之, 今井 聡士, Nishikawa Masatomo, 鄭 裕元, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    第103回日本泌尿器科学会総会, Apr. 2015, Japanese, 日本泌尿器科学会, 金沢, Domestic conference
    Poster presentation

  • 前立腺癌細胞における翻訳抑制因子4E-BP1の役割
    鄭 裕元, 原 琢人, 桃園 宏之, 今井 聡士, 宮崎 彰, Nishikawa Masatomo, Terakawa Tomoaki, Furukawa Jyunya, Harada Kenichi, Hinata Nobuyuki, Muramaki Mototsugu, Miyake Hideaki, Fujisawa Masato
    第103回日本泌尿器科学会総会, Apr. 2015, Japanese, 日本泌尿器科学会, 金沢, Domestic conference
    Poster presentation

  • 原発性女子尿道癌の6例
    横山 直己, 桃園 宏之, Terakawa Tomoaki, 田中 浩之, 井上 隆朗
    第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会, 神戸, Domestic conference
    Poster presentation

  • Gemcitabine, Cisplatin併用療法抵抗性の進行性尿路上皮癌に対するsecond-line chemotherapyとしてのPaclitaxel, Carboplatin併用療法の検討
    Terakawa Tomoaki, 横山 直己, 桃園 宏之, 田中 浩之, 井上 隆朗
    第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会, 神戸, Domestic conference
    Poster presentation

  • 絨毛癌成分を含む難治性精巣腫瘍に対する救済化学療法としてのMEA療法の有用性
    Terakawa Tomoaki, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第58回日本泌尿器科学会中部総会, Nov. 2008, Japanese, 日本泌尿器学会中部総会, 滋賀, Domestic conference
    Poster presentation

  • 腹腔鏡下根治的前立腺全摘除術
    Terakawa Tomoaki, Muramaki Mototsugu, Kurahashi Toshifumi, Takenaka Atsushi, Nakano Yuzo, Miyake Hideaki, Soga Hideo, Tanaka Kazushi, Fujisawa Masato
    第58回日本泌尿器科学会中部総会, Nov. 2008, Japanese, 日本泌尿器学会中部総会, 滋賀, Domestic conference
    Others

  • ホルモン療法抵抗性前立腺癌に対するDocetaxel/Estramustine（DE)併用療法の成績
    Kurahashi Toshifumi, Terakawa Tomoaki, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第58回日本泌尿器科学会中部総会, Nov. 2008, Japanese, 日本泌尿器学会中部総会, 滋賀, Domestic conference
    Poster presentation

  • 膀胱全摘除術および新膀胱造設術を施行した女性浸潤性膀胱癌症例の臨床成績
    Miyake Hideaki, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference
    Oral presentation

  • 表在性膀胱癌におけるRandom biopsyの有用性
    Kumano Masafumi, Terakawa Tomoaki, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference
    Oral presentation

  • 前立腺全摘除標本グリソンソコアと術前PSA 値に関する臨床的検討
    Muramaki Mototsugu, Terakawa Tomoaki, Kumano Masafumi, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference
    Oral presentation

  • 前立腺癌の新規診断マーカーとしてのRelaxinの有用性
    Kurahashi Toshifumi, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • 前立腺癌の局所診断におけるMRIの意義
    Terakawa Tomoaki, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference
    Oral presentation

  • 根治的腎摘除術を施行した腎細胞癌症例における分子マーカー発現の意義
    Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • 血清clsterin値測定による前立腺癌診断の試み
    Miyake Hideaki, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • アンドロゲン依存性前立腺癌細胞株LNCaPおけるIL－６高発現の意義
    Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • T1c前立腺癌の臨床病理学的特徴
    Terakawa Tomoaki, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第46回日本癌治療学会, Oct. 2008, Japanese, 日本癌治療学会, 名古屋, Domestic conference
    Oral presentation

  • E-CadherinからN－Cadherinへの移行は表在性膀胱癌の再発を予測する因子である
    Muramaki Mototsugu, Terakawa Tomoaki, Kumano Masafumi, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • Aurora－Aを標的としたSmall interfering RNAによるヒト前立腺癌細胞株PC3の進展抑制および抗癌剤感受性の亢進
    Kumano Masafumi, Terakawa Tomoaki, Kurahashi Toshifumi, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第67回日本癌学会, Oct. 2008, Japanese, 日本癌学会, 名古屋, Domestic conference
    Oral presentation

  • 下大静脈腫瘍塞栓症に対する外科的治療戦略 下大静脈腫瘍塞栓を有する腎細胞癌に対する外科的治療
    Takenaka Atsushi, Terakawa Tomoaki, Hyodo Yoji, Muramaki Mototsugu, Ishimura Takeshi, Kurahashi Toshifumi, Soga Hideo, Takeda Masashi, Miyake Hideaki, Tanaka Kazushi, Fujisawa Masato
    第24回腎移植・血管外科研究会, Jul. 2008, Japanese, 腎移植・血管外科研究会, 神戸, Domestic conference
    Others

  • 腹腔鏡下前立腺全摘除術における術中電気生理学的判定と術後勃起能回復に関する検討
    Soga Hideo, Takenaka Atsushi, Terakawa Tomoaki, Kumano Masafumi, Yanagiuchi Akihiro, Ishimura Takeshi, Muramaki Mototsugu, Kurahashi Toshifumi, Nakano Yuzo, Miyake Hideaki, Takeda Masashi, Tanaka Kazushi, Fujisawa Masato
    第5回泌尿器科再建再生研究会, Jun. 2008, Japanese, 泌尿器科再建再生研究会, 仙台, Domestic conference
    Oral presentation

  • 長期観察が可能であった自排尿型代用膀胱の排尿状態に関する検討；８０歳以上の高齢者と若年者の比較
    Soga Hideo, Takenaka Atsushi, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Nakano Yuzo, Miyake Hideaki, Tanaka Kazushi, Fujisawa Masato
    第21回日本老年日尿器科学会, May 2008, Japanese, 日本老年日尿器科学会, 小倉, Domestic conference
    Oral presentation

  • Risk factors for intravesical recurrence following surgical management of transitional cell carcinoma of the upper urinary tract.
    Terakawa Tomoaki, Miyake Hideaki, Muramaki Mototsugu, Takenaka Atsushi, Kamidono Sadao, Fujisawa Masato
    第103回ＡＵＡ（American Urological Association）ａｎｎｕａｌ ｍｅｅｔｉｎｇ, May 2008, English, 米国泌尿器科学会, オーランド, アメリカ, International conference
    Poster presentation

  • Imroved sensitivity to detect micrometastases in pelvic lymph nodes by real-time Reverse Transcriptase Polymerase Chain Reaction(RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer who underwent radical prostate
    Terakawa Tomoaki, Miyake Hideaki, Takenaka Atsushi, Kamidono Sadao, Fujisawa Masato
    第103回ＡＵＡ（American Urological Association）ａｎｎｕａｌ ｍｅｅｔｉｎｇ, May 2008, English, 米国泌尿器科学会, オーランド, アメリカ, International conference
    Poster presentation

  • 前立腺癌の前立腺内進展様式に関する臨床的検討
    Muramaki Mototsugu, Terakawa Tomoaki, Kumano Masafumi, Kurahashi Toshifumi, Soga Hideo, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference
    Poster presentation

  • 根治的前立腺全摘除術施行症例におけるQOL評価に関する検討
    Kurahashi Toshifumi, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Soga Hideo, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference
    Oral presentation

  • ヒト前立腺癌細胞株PC3におけるSmall interfering RNA(siRNA)発現ベクターを用いたAurora-A発現抑制の意義
    Kumano Masafumi, Terakawa Tomoaki, Kurahashi Toshifumi, Muramaki Mototsugu, Soga Hideo, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference
    Oral presentation

  • アンドロゲン依存性前立腺癌細胞株LNCaPにおけるIL-6高発現の意義
    Terakawa Tomoaki, Furukawa Jyunya, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Soga Hideo, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference
    Oral presentation

  • 80歳以上の高齢者における、自排尿型代用膀胱機能に関する検討
    Soga Hideo, Takenaka Atsushi, Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Fujisawa Masato
    第96回日本泌尿器科学会, Apr. 2008, Japanese, 日本泌尿器科学会, 横浜, Domestic conference
    Oral presentation

  • 腎下垂をともなう腎盂尿管移行部狭窄症に対する腹腔鏡下腎盂形成および腎固定術の検討
    Tanaka Kazushi, Yamaguchi Kohei, Terakawa Tomoaki, Nakano Yuzo, Takeda Masashi, Takenaka Atsushi, Hara Isao, Fujisawa Masato, Kawabata Gaku
    第57回日本泌尿器科学会中部総会, Nov. 2007, Japanese, 日本泌尿器科学会中部総会, 奈良, Domestic conference
    Oral presentation

  • 経皮道的ドレナージを行った前立腺膿瘍の1例
    Terakawa Tomoaki, Nakano Yuzo, Tanaka Kazushi, Takenaka Atsushi, Arakawa Soichi, Hara Isao, Fujisawa Masato
    第18回尿路感染症研究会, Nov. 2007, Japanese, 尿路感染症研究会, 仙台, Domestic conference
    Oral presentation

  • 「腎細胞癌：外科治療の最前線」下大静脈腫瘍塞栓を有する腎細胞癌に対する手術療法
    Takenaka Atsushi, Terakawa Tomoaki, Miyake Hideaki, Fujisawa Masato
    第57回日本泌尿器科学会中部総会, Nov. 2007, Japanese, 日本泌尿器科学会中部総会, 奈良, Domestic conference
    Others

  • PSA高値に対する初回前立腺生検における非癌検出例の検討
    Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Soga Hideo, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第57回日本泌尿器科学会中部総会, Nov. 2007, Japanese, 日本泌尿器科学会, 奈良, Domestic conference
    Oral presentation

  • Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens)
    Kurahashi Toshifumi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • 腹腔鏡下前立腺全摘除標本における切除断端陽性部位が生化学的再発に及ぼす影響
    Kumano Masafumi, Terakawa Tomoaki, Furukawa Jyunya, Kurahashi Toshifumi, Muramaki Mototsugu, Soga Hideo, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • 腹腔鏡下および恥骨後式前立腺全摘除術における術後早期尿禁制回復に関する検討
    Soga Hideo, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • Expression of molecular markers in prostate cancer: correlation with clinicopathological outcomes
    Miyake Hideaki, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, English, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • Expression of urokinae plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes
    Kumano Masafumi, Terakawa Tomoaki, Furukawa Jyunya, Kurahashi Toshifumi, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • 浸潤性膀胱癌に対する膀胱全摘除術後アジュバント化学療法の効果と予後規定因子
    Muramaki Mototsugu, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Soga Hideo, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • 浸潤性膀胱癌に対する膀胱全摘除術および新膀胱造設術の中長期成績
    Miyake Hideaki, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Soga Hideo, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • 上部尿路上皮癌に対する腎尿管全摘除術後の膀胱再発の検討
    Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Soga Hideo, Tanaka Kazushi, Takenaka Atsushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • 骨盤内臓神経の温存を目指した手術術式 鏡視下前立腺全摘における神経温存および神経再建に関する新しい試み
    Takenaka Atsushi, Kumano Masafumi, Terakawa Tomoaki, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Soga Hideo, Tanaka Kazushi, Fujisawa Masato
    第45回日本癌治療学会総会, Oct. 2007, Japanese, 日本癌治療学会, 京都, Domestic conference
    Oral presentation

  • Anticancer Drug Resistance CHEMOSENSITIZATION OF GEMCITAB1NE-RESISTANT BLADDER CANCER CELLS USING ANTISENSE OLIGONUCLEOTIDE TARGETTING CLUSTERIN
    Muramaki Mototsugu, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • Improved sensitivity in detecting lymph node micrometastasis in patients with prostate cancer by real-time RT-PCR)
    Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • Improved sensitivity in detecting lymph node micrometastasis in patients with prostate cancer by real-time RT-PCR
    Terakawa Tomoaki, Kumano Masafumi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from patients with bladder cancer
    Kurahashi Toshifumi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    第66回日本癌学会総会, Oct. 2007, Japanese, 日本癌学会, 横浜, Domestic conference
    Oral presentation

  • 術中電気刺激による陰茎海綿体神経の同定および電気生理学的神経温存判定 腹腔鏡下前立腺全摘除術における経験
    Takenaka Atsushi, Soga Hideo, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Ishimura Takeshi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Hara Isao, Fujisawa Masato
    第18回日本性機能学会, Sep. 2007, Japanese, 日本性機能学会, 岡山, Domestic conference
    Oral presentation

  • 術中電気刺激による陰茎海綿体神経の同定および神経温存判定 腹腔鏡下前立腺全摘除術での検討
    Soga Hideo, Takenaka Atsushi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Ishimura Takeshi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Takeda Masashi, Tanaka Kazushi, Fujisawa Masato
    第18回日本性機能学会, Sep. 2007, Japanese, 日本性機能学会, 岡山, Domestic conference
    Oral presentation

  • Improved sensitivity in detecting lymph node micrometastasis in patients with prostate cancer by real-time RT-PCR
    Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Fujisawa Masato
    102ndAmericanUrologicalAssociation, Jun. 2007, English, American Urological Association, アナハイム, アメリカ, International conference
    Poster presentation

  • Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy
    Terakawa Tomoaki, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Fujisawa Masato
    102ndAmericanUrologicalAssociation, May 2007, English, American Urological Association, アナハイム, アメリカ, International conference
    Poster presentation

  • Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from patients with bladder cancer
    Kurahashi Toshifumi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Muramaki Mototsugu, Miyake Hideaki, Takenaka Atsushi, Fujisawa Masato
    102ndAmericanUrologicalAssociation, May 2007, English, American Urological Association, アナハイム, アメリカ, International conference
    Oral presentation

  • 泌尿器癌に対する腹腔鏡手術の治療成績
    Tanaka Kazushi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Nakano Yuzo, Miyake Hideaki, Takenaka Atsushi, Hara Isao, Fujisawa Masato
    第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference
    Oral presentation

  • 男性会陰部における直腸尿道筋およびPerineal bodyの組織学的検討
    Soga Hideo, Takenaka Atsushi, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Hara Isao, Fujisawa Masato
    第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference
    Oral presentation

  • 腎盂尿管腫瘍に対する体腔鏡下腎尿管全摘除術の検討
    Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Takenaka Atsushi, Hara Isao, Fujisawa Masato
    第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference
    Oral presentation

  • 進行性精巣腫瘍に対する末梢血幹細胞移植併用超大量化学療法施行時の発熱性好中球減少症における感染症診断マーカーとしての血清プロカルシトニンの有用性
    Nakano Yuzo, Tanaka Kazushi, Kumano Masafumi, Terakawa Tomoaki, Furukawa Jyunya, Kurahashi Toshifumi, Miyake Hideaki, Takenaka Atsushi, Arakawa Soichi, Hara Isao, Fujisawa Masato
    第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference
    Oral presentation

  • リンパ節転移を有する浸潤性膀胱癌に対する膀胱全摘および骨盤内リンパ節郭清術の治療成績
    Furukawa Jyunya, Yamada Yuji, Terakawa Tomoaki, Kumano Masafumi, Kurahashi Toshifumi, Tanaka Kazushi, Miyake Hideaki, Takenaka Atsushi, Hara Isao, Fujisawa Masato
    第95回日本泌尿器科学会総会, Apr. 2007, Japanese, 日本泌尿器科学会総会, 神戸, Domestic conference
    Oral presentation

  • 術中電気刺激による陰茎海綿体神経の同定および電気生理学的神経温存判定 -腹腔鏡下前立腺全摘除術における経験-
    Takenaka Atsushi, Soga Hideo, Terakawa Tomoaki, Kumano Masafumi, Furukawa Jyunya, Ishimura Takeshi, Muramaki Mototsugu, Kurahashi Toshifumi, Miyake Hideaki, Tanaka Kazushi, Hara Isao, Fujisawa Masato
    第17回日本性機能学会東部総会, Feb. 2007, Japanese, 日本性機能学会東部総会, 横浜, Domestic conference
    Oral presentation

■ Research Themes
TOP